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Abstract 
Longitudinal Cerebrospinal Fluid Biomarkers of Alzheimer Disease: Movement Toward the 
Diagnosis, Prognosis and Staging of Disease 
by 
Courtney Sutphen 
Doctor of Philosophy in Biology and Biomedical Sciences 
Neurosciences 
Washington University in St. Louis, 2017 
John Cirrito, Chair 
Alzheimer’s disease (AD) is a devastating neurodegenerative disease that slowly claims the 
memories and experiences that comprise the life experiences of individuals that suffer from the 
disease. Despite a continually accelerating pace of research and discovery, a viable therapeutic 
intervention for AD has yet to be realized. There are a multitude of factors that may contribute to 
this difficulty including the challenge of separating the overall disease of Alzheimer’s from the 
clinically recognizable memory loss that occurs in what is now known to be the end-stage of the 
disease. Efforts to treat AD have increasingly turned toward very early disease states, before 
clinical signs and symptoms become apparent, as a number of clinical trials have failed to meet 
cognitive endpoints over the last 5-10 years – potentially due to the sole recruitment of 
individuals already experiencing significant cognitive decline.  
One important aspect of AD treatment is identification. It is now recognized that the disease 
begins more than a decade before the signature symptoms of cognitive impairment become 
apparent. Identifying individuals in this “preclinical” disease state has become a primary focus of 
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many investigators who believe that AD must be targeted and fought well before the clinical 
manifestations of memory impairment appear.  
Biomarkers, indicators of normal biological or pathological processes that may be studied as a 
means to give individuals a disease diagnosis, prognosis, or theragnosis – provided a treatment is 
available for the disease in question – are of paramount importance in many diseases. AD has 
proved a difficult target to nail down reliable, sensitive, and specific biomarkers. This is in part 
due to analytical difficulties in major, core biomarkers of disease and in part due to setbacks in 
clinical trials of promising therapeutic candidates.  
The current work begins with an overview of biomarker modalities used in AD; however, the 
primary focus is on protein biomarkers in cerebrospinal fluid (CSF). CSF provides an intimate 
window to the central nervous system that, in the case of AD, has shown the ability to identify 
and monitor disease progress over time in cohorts of cognitively normal and demented 
individuals. In an effort to pinpoint AD before clinical signs and symptoms manifest, biomarker 
research in preclinical AD has become a robust area of investigation. CSF biomarkers of amyloid 
pathology, neuronal damage, and neuroinflammation are discussed in two independent cohorts: 
the Adult Children Study (ACS) from Washington University in St. Louis and the Alzheimer’s 
Disease Neuroimaging Initiative.  
The ACS cohort is comprised of middle-aged, cognitively normal individuals recruited on a 
volunteer basis from community dwelling participants with and without a family history of AD. 
The ADNI cohort is comprised of older individuals also recruited on a volunteer basis from 
community dwelling participants, though participants are recruited with respect to clinical status 
and include cognitively normal individuals, individuals with mild cognitive impairment, and 
individuals with AD, in addition to being older than the ACS cohort. 
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In both cohorts, it was found that CSF markers of amyloid plaques – one of two required 
pathological hallmarks that indicate AD – changed earlier than those of tau tangles, the second 
required pathological hallmark.  
Currently, examining biomarkers on a group-wide basis is the best way to get an accurate picture 
of biomarkers at baseline and followup lumbar punctures (LPs). As the goal is to be able to give 
individual people a diagnosis and prognosis of their disease, the behavior of biomarkers is 
particularly interesting because studies have found that CSF Aβ42 changes up to 15 or more 
years before cognitive signs and symptoms become apparent and, hopefully, beginning treatment 
in this period will be helpful not only for diagnosing for individuals with AD dementia, but also 
for individuals with very early disease.
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Chapter 1: Introduction 
Portions of this chapter were published in the April 2014 issue of Biological Psychiatry1. 
1.1 Background 
Alzheimer disease (AD) is a chronic, progressive neurodegenerative disease that slowly strips 
individuals of their memories and other cognitive functions. In the United States alone, an 
estimated 5.5 million people are living with AD in 2017, and an estimated 253 billion dollars 
will be spent caring for individuals with AD or other dementias, with both estimates predicted to 
rise substantially as the population ages2. Unlike diseases such as heart disease or stroke, deaths 
from AD increased more than 89% between the year 2000 and 2014 - making development an 
intervention to slow or halt the disease has a paramount focus2. As AD research moves forward, 
recent proposals from some leaders in the field have trended toward defining AD on a continuum 
as the disease is multifactorial, quite variable between individuals, and a large body of research 
is still needed to fully define AD from onset to end of life3, though AD is currently diagnosed in 
clinical stages4. These stages fit in to the proposed view of a continuum; preclinical AD is 
defined by the absence of clinical signs or symptoms but evidence of pathological amyloid and 
tau accumulation in the brain, mild cognitive impairment (MCI) (or prodromal AD) is defined by 
the addition of mild clinical symptoms such as a consistent inability to remember appointments, 
and mild, moderate, and severe dementia are marked by further dramatic cognitive impairment 
ultimately resulting in complete dependence on caregivers for all daily activities. Instead of 
strictly defining each stage, research has begun to indicate – particularly in preclinical disease – 
that stages may not be clearly demarcated, and some lenience when making diagnostic, 
prognostic, and eventually theragnostic judgments may be needed3.         
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Currently, a definitive diagnosis of AD still requires postmortem identification of the 
pathological hallmarks of the disease: extracellular amyloid plaques composed mainly of 
aggregated amyloid-β (Aβ) peptides and neurofibrillary tangles composed mainly of 
hyperphosphorylated forms of the microtubule associated protein, tau (P-tau)4. Clinical diagnosis 
of AD is based on guidelines established by the National Institute of Neurological Disorders and 
Stroke–Alzheimer’s Disease and Related Disorders Association (NINDS-ADRDA), although the 
sensitivity and specificity of such a diagnosis is lower than desirable5. The addition of 
biomarkers to the diagnostic criteria for AD may increase the sensitivity and specificity of both 
the diagnostic and prognostic capabilities currently available through clinical and cognitive 
assessment. One goal of studying biomarkers is to reliably identify those with AD pathological 
changes (preclinical AD), as well as predict the odds that such individuals will clinically 
progress and at what rate.  
Intensive research has propelled the field closer to finding a disease-modifying therapy, but 
setbacks in clinical trials and inherent difficulties in successfully tracking disease progress pre-
mortem continue to be major roadblocks. The most promising clinical trials to date have focused 
on anti-Aβ antibodies that bind either aggregated or soluble forms of Aβ and encourage the 
removal or neutralization of these species from the brain. Phase III trials of the anti-Aβ 
antibodies bapineuzumab and solanezumab in mild to moderate dementia believed to be due to 
AD ended in late 2012. Two bapineuzumab trials showed no effect on the primary outcomes, the 
Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) or Disability 
Assessment for Dementia (DAD), either in carriers of the Apolipoprotein ε4 (APOE ε4) allele or 
in noncarriers, but did show encouraging changes in two disease biomarkers in the APOE ε4 
carrier group compared with placebo6. Two additional trials were halted early due to these  
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negative results and did not show the same changes in disease biomarkers7. Two trials involving 
solanezumab also failed to show efficacy in the primary outcome of ADAS-Cog and 
Alzheimer’s Disease Cooperative Study – Activities of Daily Living (ADCS-ADL) scale, but did 
show changes in blood and cerebrospinal fluid (CSF) amyloid levels, as expected based on the 
application of an anti-amyloid antibody8.  
In part because clinical trials have been unsuccessful in reversing, halting, or slowing cognitive 
decline, the investigation of AD biomarkers has been propelled forward. A widely held belief is 
that some of this failure is due to the exclusive enrollment of individuals who already exhibit 
mild or moderate dementia, stages of AD that are accompanied by robust neuronal cell death. At 
even earlier stages of the disease (very mild dementia and MCI due to AD), neuron loss in 
certain critical brain regions is already significant9. Thus, it is important to diagnose individuals 
at the preclinical and MCI disease stages - and enroll them in clinical trials - in order to identify 
and apply therapies that have the best chance of preserving normal cognitive function.  
A key roadblock is the development of robust, reliable biomarkers: as in many other medical 
conditions, the primary aim of biomarker development is to provide a diagnosis or prognosis to 
individuals with a disease or to track disease progress or severity. These are of particular 
importance because the underlying causative pathology of AD begins as many as 15-20 years 
before the appearance of cognitive symptoms10, meaning the identification of disease must take 
place when there are no clinically identifiable signs of impairment. In AD, biomarkers are most 
widely used in research – focusing on identification of individuals with preclinical disease, in 
differential diagnosis with other dementias, and perhaps most interestingly to provide a 
downstream indicator of treatment efficacy in disease-modifying agents. 
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As the AD community moves toward a treatment, it seems certain that biomarkers will play a 
key role in the process. It is the goal of investigators to determine the most effective combination 
of biomarkers to enable identification, differentiation, and treatment of the disease in question. 
Cognitive measures can serve as a biomarker of disease; however, CSF biomarkers as measures 
of underlying pathology and disease progression are the focus of this work, along with relevant 
investigations in imaging biomarkers (magnetic resonance imaging [MRI] and positron emission 
tomography [PET]). Each modality presents its own challenges for identifying and/or developing 
viable markers from assay validation, intra- and inter-lab consistency in measurement to accurate 
identification of when and how biomarkers change during disease, and these challenges add to 
those in the overarching field of biomarker usage in the clinical diagnosis of AD such as how to 
best use biomarkers in regular clinical practice. 
Nevertheless, within the last five years, groundbreaking clinical trials such as the Dominantly 
Inherited Alzheimer Network – Trials Unit (DIAN-TU)11, the Anti-Amyloid Treatment in 
Asymptomatic Alzheimer’s Disease (A4) trial12, and others have begun enrolling preclinical 
individuals, as identified by genetic testing or biomarker status, and will use various biomarkers 
to track drug target engagement and/or as endpoint measures of drug efficacy. The DIAN-TU 
will hopefully be particularly informative as to the temporal ordering and efficacy of several 
multimodal biomarkers in a genetically defined population. The comparison of biomarkers in the 
DIAN-TU population vs. sporadic, or late onset, AD could eventually allow the identification of 
the optimal window for therapeutic intervention the sporadic population. A number of caveats 
apply, particularly the development of an efficacious AD intervention, but one of the primary 
underpinnings of this theory is that ADAD and sporadic AD are the same disease; therefore 
investigations concerning biomarker trajectories of all modalities are of paramount importance. 
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1.2 Biomarker Modalities 
As outlined above, this work pertains largely to CSF biomarkers of AD, with relevant imaging 
biomarkers included as ancillary analyses. However, it is necessary to consider all biomarker 
modalities when attempting to identify a progression of disease indicators. Section 1.2 is 
dedicated to a brief literature review of current fluid (CSF, plasma, serum), imaging (MRI, PET), 
and cognitive biomarkers that aid investigators in better defining the spectrum of AD from 
preclinical through mild cognitive impairment and ultimate dementia. A brief summary of 
biomarkers covered in Chapter 1.2 can be found in Table 1.1. 
1.2.1 Core CSF Biomarkers 
CSF is considered a prime source for AD biomarkers because many proteins and metabolites in 
CSF directly reflect the internal milieu of the brain. A lumbar puncture (LP) is necessary for the 
collection of CSF which makes it somewhat more invasive than a blood draw. However, 
complications stemming from LP are not frequent13,14, and when the procedure is performed by 
experienced clinicians, it is usually not painful.  
Three proteins are typically considered the gold standard for AD CSF biomarkers – Aβ42, total 
tau (Tau) and tau phosphorylated at threonine 181 (P-tau). Aβ and tau proteins are the most 
abundant components of amyloid plaques and neurofibrillary tangles, respectively. Each of these 
analytes has been extensively studied and validated in a variety of cohorts world-wide and, while 
absolute concentrations of each marker may vary, similar results have been reported in multiple 
studies. 
Amyloid β42 
Aβ42 is a 42 amino acid peptide created from the processing of the amyloid precursor protein 
(APP). There are multiple lengths of Aβ peptides; the 42 amino acid form is the most abundant 
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in amyloid plaques. Significantly reduced levels of CSF Aβ42 in individuals diagnosed with AD, 
compared to cognitively normal, age-matched individuals, is one signature of amyloid plaques15. 
Studies have shown that CSF Aβ42 levels correlate inversely with amyloid plaque load in the 
brain as determined by postmortem histology16 and concomitant in vivo plaque measurement 
using amyloid imaging, regardless of clinical status17–23. CSF Aβ42 is likely low in the presence 
of amyloid deposition due to its sequestration in plaques24. Continued investigation on the link 
between CSF and imaging Aβ levels indicates that CSF Aβ42 begins changing prior to amyloid 
imaging25,26, which replicates changes seen in autosomal dominant AD (ADAD)27. Low CSF 
Aβ42 is useful as a marker that predicts future clinical disease progression and rate of cognitive 
decline, especially in the early clinical stages of the disease28–30. Most recently, longitudinal 
studies of AD biomarkers have shown CSF Aβ42 is perhaps the most reliable indicator of 
preclinical AD31–33. Aβ42 alone is not a sufficient biomarker for AD diagnosis and prognosis34,35, 
nor does it mark the presence of other AD pathologies, however, more recent recommendations 
do support the use of CSF Aβ42 to supplement clinical evaluation for differential diagnosis or to 
aid judgment in atypical or unclear cases36,37.  
Tau 
Tau is a microtubule associated protein that, when quantified in the CSF, is considered to be a 
biomarker of neuronal injury in AD. High levels of tau in the CSF may reflect neuronal damage, 
as is suggested by increases in tau after acute neuronal injury such as stroke, traumatic brain 
injuries, and Creutzfeld-Jakob disease (CJD)38,39. Phospho-tau levels correlate with total tau and 
also correlate closely with neurofibrillary tangle load in AD40. Tau is normally released by 
neurons in the absence of cell death. Evidence from wild type and transgenic mice expressing 
mutant human Tau (P301S) suggests tau is continuously secreted from healthy neurons into the 
brain interstitial fluid space41. In addition, both soluble and aggregated forms of tau have been 
7 
 
shown to be secreted by cultured cells42. CSF tau and P-tau are significantly increased in AD and 
Mild Cognitive Impairment (MCI)29(p200),40,43. More recent studies indicate levels of both tau and 
P-tau are also increased in preclinical AD, though likely after Aβ42 levels have already 
dropped44, which mirrors changes seen in ADAD27. Similar to CSF Aβ42 versus PET Aβ42, CSF 
Tau may also begin to increase prior to tangles being visualized with Tau PET imaging45. Levels 
of P-tau in CSF are also associated with disease progression in AD cases46 and may aid in 
differential diagnosis between AD and other dementias47. Some longitudinal studies have also 
indicated that tau and P-tau change after indicators of amyloid abnormality31. Tau and P-tau are 
similar to Aβ42 in diagnostic and prognostic performance but are not sufficient biomarkers on 
their own.  
Tau or Ptau181 to Aβ42 Ratios 
The Tau/Aβ42 ratio, when analyzed, has a history of good performance in identifying individuals 
with AD. The Geneva Task Force for the Roadmap of Alzheimer’s Biomarker report on the 
clinical validity of CSF biomarkers in AD states that the ratio of Tau or Ptau to Aβ42 often is 
superior to Aβ42 alone when predicting AD in individuals with MCI48. This was seen both in 
biomarker meta-analysis reports as well as primary research reports, however, the Task Force 
recommended against the use of such ratios because they may be abnormal in individuals where 
CSF Tau alone increases (such as in CJD).   
1.2.2 Non-Core CSF Biomarkers 
Because it is likely that no single biomarker will perform satisfactorily on its own, identification 
and development of additional CSF biomarkers that do not directly reflect AD pathology 
(plaques and tangles), but instead reflect more general processes such as neurodegeneration and 
inflammation might be very useful. Unbiased approaches such as proteomics and multi-analyte 
profiling have been used to identify novel fluid biomarkers. A unique challenge presented by 
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these unbiased approaches, however, has been identifying biomarkers that have high enough 
sensitivity and specificity to warrant investigation in large cohorts. Five CSF proteins have 
proved useful in differentiating AD from cognitively normal individuals in large, independent 
cohorts: visinin-like protein 1 (VILIP-1); Neurogranin (Ng); synaptosomal associated protein 25 
(SNAP-25); chitinase-3-like protein 1 (YKL-40); and neurofilament light (NfL).  
Amyloid β40 and Aβ42 to Aβ40 Ratio 
Aβ40 is the most abundant isoform of Aβ in the CSF at roughly ten times the concentration of 
CSF Aβ42, but relatively less reported in studies of AD biomarkers. One large meta-analysis in 
2011 did not report on Aβ40 as a CSF biomarker49, while a more recent meta-analysis from 2016 
reported that levels of CSF Aβ40 did not differ significantly between individuals with MCI due 
to AD and MCI, but did report a “significant but minor” average effect size in distinguishing AD 
from control individuals, with Aβ40 levels being slightly lower in AD50. However, unlike CSF 
Aβ42 and the Tau(s), this result was not wholly consistent across all 25 papers analyzed; 7 of 25 
studies showed almost no difference between AD and control individuals and one study showed 
higher levels. These meta-analyses reflect an interesting attitude in the research community of 
Aβ40 perhaps being less important than Aβ42 as a diagnostic or prognostic tool. A more recent 
study does report lower levels of CSF Aβ40 in individuals with preclinical AD as defined by low 
CSF Aβ42 levels and no cognitive impairment44. Reported in Chapter 2 of the current work, it 
was found that levels of Aβ40 decreased over time in middle-aged cognitively normal 
individuals, but findings were inconsistent between two assay platforms31. These inconsistencies 
likely contribute heavily to the relative dis-use of CSF Aβ40 as a common biomarker for AD. 
Despite CSF Aβ40 not performing as well as CSF Aβ42 as a biomarker of AD, the Aβ42 to 
Aβ40 ratio has nonetheless been proposed as a useful CSF biomarker because, while CSF Aβ42 
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levels may also be reduced in individuals with subcortical white matter lesions, CSF Aβ40 is 
unaffected51, resulting in better performance of the Aβ42 to Aβ40 ratio than Aβ42 alone in 
detecting amyloid pathology in MCI and AD. These and other studies indicate that the ratio may 
be a better predictor of AD pathology by adjusting for differences in overall amyloid production 
between individuals48, which becomes particularly evident when investigating CSF amyloid 
compared with amyloid PET measures. In this case, when assessing both CSF and PET amyloid, 
the concordance between CSF Aβ42 alone and amyloid PET is improved by substituting the CSF 
Aβ42 to Aβ40 ratio51–54. 
VILIP-1 
VILIP-1 is a neuron-specific intracellular calcium sensor protein. Particularly expressed in 
cortical and hippocampal neurons, VILIP-1 is found at high levels in the dendritic compartment 
mainly associated with cell membranes55.  Levels of CSF VILIP-1 have been shown to be 
elevated in stroke56. Immunohistochemical and cell culture studies on VILIP-1 localization in 
AD revealed an association with dystrophic neurites as well as amyloid plaques and tau 
tangles57,58. Increases in CSF VILIP-1 have been observed in AD compared with cognitively 
normal controls as well as individuals with MCI59,60. Elevated VILIP-1 levels also perform as a 
strong predictor of future cognitive decline in individuals with MCI/very mild dementia and in 
cognitively normal controls61–63. Longitudinal studies on VILIP-1 have not yet been widely 
executed, though VILIP-1 and Tau correlate very well in the CSF, suggesting that VILIP-1 may 
increase after amyloid changes are evident in preclinical disease31, and in ADAD may begin to 
decline after incipient cognitive impairment64. VILIP-1 may also aid in the differentiation 
between AD and other dementias such as Dementia with Lewy Bodies (DLB)65,66. When studied 
in conjunction with CSF Aβ42, Tau and P-Tau, VILIP-1 performs similarly to the Tau(s), 
indicating that it will not be a sufficient biomarker on its own. 
10 
 
Ng 
Neurogranin is a postsynaptic calmodulin-binding protein expressed largely in neuronal 
dendrites that seems necessary for sensing calcium concentration and calmodulin activity, thus 
strengthening synapses67. In AD, Ng is elevated in the CSF compared to cognitively normal 
individuals and provides diagnostic and prognostic utility similar to that of the core AD CSF 
biomarkers68,69. In preclinical AD, Ng is also elevated and predicts cognitive decline70,71, 
indicating it may be a useful biomarker across multiple disease stages. Longitudinally, levels of 
Ng in CSF increased in cognitively normal individuals at risk of developing dementia though did 
not change over time in individuals with MCI or AD72. Studies assessing Ng for differential 
diagnosis provided evidence that elevated Ng may aid in differentiation AD from behavioral 
variant frontotemporal dementia (bvFTD), LBD, Parkinson Disease (PD), progressive 
supranuclear palsy, and multiple system atrophy73,74, and major depressive disorder75. In many of 
the studies cited above, other CSF proteins such as Tau were measured, with Ng correlating with 
Tau and P-Tau. Further longitudinal research is necessary to determine where and how Ng best 
fits in the staging, diagnosis, or prognosis of AD. 
SNAP-25 
SNAP-25 is a presynaptic t-SNARE protein involved in regulating neurotransmitter release 
through facilitation of synaptic vesicle release at presynaptic terminals76. Much of the work on 
SNAP-25 pertaining to AD has been done in postmortem tissue, where decreases in SNAP-25 
protein levels are seen in AD, and other dementias, compared with control individuals77–79. Few 
studies in the CSF of demented compared with cognitively normal individuals have been 
reported. The first showed higher levels of SNAP-25 fragments in AD and prodromal AD 
compared with cognitively normal individuals80; the second showed increased levels of SNAP-
25 in the CSF of individuals with advanced PD81. Much work remains to determine the temporal 
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ordering of changes in SNAP-25 compared with other CSF proteins in AD, including 
longitudinal cohort studies. 
NfL 
Neurofilament Light is the lowest weight member of the neurofilament family found in neurons. 
Heavily involved in axonal structure, NfL levels in CSF have been studied in a wide variety of 
neurodegenerative disorders and are considered a marker of white matter lesions82,83. In 
amyotrophic lateral sclerosis (ALS)84, FTD85,CJD86, and Parkinson’s Disease Dementia (PDD)87, 
as well as vascular dementia (VaD)88, CSF NfL is elevated compared with normal controls. A 
particular focus has been the differential diagnosis of AD and FTD using CSF NfL, in which 
consistently higher levels of NfL were seen in FTD compared to AD89–91. As with other non-core 
markers, significant work remains to determine the usefulness of NfL for differential diagnosis 
among neurodegenerative diseases92,93. In AD, NfL levels are increased at the MCI and dementia 
stages of clinical impairment and may indicate disease progression94,95 but are not elevated in 
preclinical disease44,96, suggesting a later stage of NfL involvement, though further research is 
needed. 
YKL-40 
YKL-40 is the one of two non-neuronal associated proteins to show promise as a CSF AD 
biomarker; it is an astrocytic protein upregulated in a variety of neuroinflammatory conditions97–
99, however, despite being a chitinase, YKL-40 has no chitinase activity and its exact function 
remains to be elucidated. Early reports on YKL-40 in CSF showed elevations in AD vs. control 
individuals, with diagnostic and prognostic performance on par with the core CSF 
biomarkers100,101, though results were not universally replicated102.  More recent studies, 
including longitudinal analyses, have shown that YKL-40 levels increase with advancing age 
which may complicate its analysis in older cohorts31,103. However, there is evidence that YKL-40 
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could be useful to differentiate between AD and other dementias such as VaD104, DLB and 
PDD103, but not FTD105,106. YKL-40 needs more research, particularly longitudinally, to 
determine its best application as a biomarker of neuroinflammation in AD. 
TREM2 
The other non-neuronal protein is soluble Triggering Receptor Expressed on Myeloid Cells 2 
(sTREM2), associated primarily with microglia in the brain. Studies in DIAN and a LOAD 
cohort showed increases in sTREM2 in MCI and AD compared with control individuals107,108, 
but a third study showed only an association with sTREM2 and age109. Though promising, 
TREM2 is in very early stages of investigation as an AD CSF biomarker. 
1.2.3 Blood Biomarkers 
Identification of blood biomarkers (plasma and serum) for AD has proved particularly 
challenging. Possible contributing factors include low expression of target biomarker proteins in 
the periphery that could make quantification of central nervous system (CNS)-derived analytes 
difficult, as well as the relatively higher levels of total protein in plasma and serum compared 
with CSF which could interfere with analyte detection. 
Core and Novel Analytes in Blood Serum and Plasma 
Findings from studies exploring blood-based biomarkers in AD have been largely inconclusive. 
The core biomarker Aβ42, as well as the non-core Aβ40, alone have historically shown no utility 
in differentiating AD from control individuals or assessing prognosis110,111, though differences 
have been found between APOE ε4 carriers versus noncarriers110,112.However, one study did 
report reductions in the plasma Aβ42/Aβ40 ratio in individuals with MCI and in those who 
transitioned from cognitively normal to MCI113. Two recent studies also found a predictive 
association between (1) the plasma Aβ42/Aβ40 ratio and cortical amyloid burden measure by 
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PET114 and (2) the plasma Aβ42/Aβ40 an amyloid positivity defined by PET or mass 
spectrometry, in this case with high accuracy and precision115.  
Studies assessing plasma tau are at a similar uncertain stage due to the recent development of 
Tau PET agents116,117, though one study states that plasma tau and NfL levels may aid in 
identifying or ruling out neurodegeneration in rapidly progressive neurological syndromes118 and 
another identified elevated plasma Ptau181 in AD and Down Syndrome (DS) compared to control 
individuals119. The non-core analyte NfL has had some success in plasma120,121 and serum122 in 
differentiating MCI and AD individuals from control individuals. Plasma Ng, however, was not 
able to differentiate MCI or AD from control individuals123.  
Much of the focus in blood-based fluid biomarkers has involved novel multi-analyte panels124–
127. While results from these studies generally show efficacy in differentiating AD from control 
individuals, in some cases even longitudinally128, there are important factors to consider: often 
the cohort size or composition makes it difficult to translate results to other cohorts; these studies 
are often very recent and therefore not replicated in additional cohorts; the use of general multi-
analyte panels may result in lower success rates in differential diagnosis between AD and other 
dementias.  
Overall, the state of blood biomarkers in AD has been held in its infancy for a number of years. 
Largely, this status hinges upon a lack of reproducibility and an unclear path to clinical 
utilization129. As these are very early stage, many manuscripts cited above use assays developed 
“in-house” and are different from cohort to cohort. Lessons learned from studying CSF 
biomarkers indicate that a common technique or assay would likely be beneficial to more clearly 
outlining biomarker proteins in blood. 
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1.2.4 Imaging Biomarkers 
Imaging biomarkers capture a broad range of AD-associated processes, from brain size and 
structure to the presence of protein aggregates. Imaging biomarkers can be non-invasive or 
moderately invasive based on the modality used (ie, MRI vs. PET with radioactivity). One 
particular advantage for imaging biomarkers is the ability to image and track special patterns 
(e.g. regional atrophy, binding of PET tracers in regions with pathology). As with fluid 
biomarkers, inter-lab standardization is paramount but can be quite difficult due to the use of 
different makes and models of scanners, each with their own idiosyncrasies130.  
MRI Biomarkers 
Volumetric MRI is one of the most studied imaging biomarkers. The measurement of the size of 
a brain region at a single time point and within individuals longitudinally allows for detection of 
atrophy in either whole brain or targeted areas131–133. In many studies, a marked decrease in 
volume is observed in AD – this is seen both in normalized whole brain volume and in specific 
areas such as the hippocampus and entorhinal cortex134,135. Volumetric MRI performs as well as 
the CSF gold standard biomarkers for diagnosis and prognosis, from preclinical through 
advanced disease states, and has a rich history of investigation using both single timepoint and 
longitudinal data136–140. What remains to solidify MRI volumetric biomarkers for clinical use is 
similar to CSF biomarkers141 – reproducibility in large, independent cohorts; standardization of 
both imaging and image analysis throughout the field; longitudinal analysis; and identification of 
the most accurate and clinically useful brain regions for AD diagnosis and prognosis, particularly 
as regions such as caudate nucleus or hippocampus have not differentiated between AD and 
other dementias142,143. 
Both task-based and resting state functional MRI (fMRI) are promising imaging biomarkers for 
AD144. The difference in magnetization between oxygen-rich and oxygen-poor blood can be 
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measured using fMRI to detect changes in connectivity between areas of the brain while an 
individual is performing a task or resting. Some studies have shown fMRI differences between 
individuals with MCI vs. controls on task-based assessments145. Of particular interest in resting 
state fMRI assessments is the default mode network (DMN), a network of brain regions that is 
most active when a person is not engaged in a specific cognitive task and is deactivated when an 
individual is externally stimulated or is engaged in a specific task. One recent, large study of 500 
individuals showed progressive decline in resting state functional connectivity across multiple 
networks with disease progression146. Whether fMRI will prove useful in differential diagnosis, 
prognosis, or in clinical trials awaits further studies, though it has shown promise in recent 
preclinical and longitudinal studies147,148. 
PET Biomarkers 
PET biomarkers rely on radionuclide tracers specific to a molecule of interest within the body. 
Three radioligands are used regularly in AD research and, with amyloid PET, in clinical practice 
to aid in differential diagnosis of difficult or uncertain dementia cases149; 18Fluorodeoxyglucose, 
or FDG PET; amyloid PET; and tau PET. FDG PET is a highly studied radioligand that acts as 
an indicator of glucose metabolism and, by proxy, neuronal activity. A number of studies have 
shown prognostic value for FDG PET150 in identifying individuals who will progress from MCI 
to AD, but the usefulness of FDG PET as a diagnostic in differentiating cognitively normal from 
AD individuals is relatively less151. Studies using smaller cohorts have also reported longitudinal 
changes in FDG PET in individuals with MCI152,153(p3).  
Specific to amyloid-aggregating diseases, the use of amyloid PET has increased dramatically 
since the development of Pittsburgh Compound B (PiB), the first radioligand specific to fibrillar 
Aβ154. There are now 3 FDA approved amyloid-imaging agents, with evidence pointing to 
16 
 
efficacy in diagnosis in both research and clinical settings150, though extensive work remains to 
determine the relationship between amyloid PET and prognosis. Similar to CSF analytes, 
standardization of amyloid PET is a major point of concern155, including for longitudinal 
study156.  
Tau imaging remains in the early stages of development but there are indications it may be useful 
in assessing the extent of tau pathology present in individuals with AD, as well as potentially 
aiding in differential diagnosis between AD and other tauopathies such as progressive 
supranuclear palsy (PSP)157,158. One very early longitudinal report indicates Tau PET may have 
prognostic value in MCI and AD159, and yet another indicates it may have value in identifying 
high tau aggregation levels in preclinical AD160. 
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Table 1.1 Summary of Biomarker Modalities and Characteristics 
Biomarker Changes Observed 
in AD vs Cognitively 
Normal Individuals 
Disease Stage when 
Reported 
Longitudinal 
Data 
Available 
Major Obstacles to Validation as an AD Biomarker 
CSF 
Aβ42 Decreased Preclinical, MCI, Dementia Yes Assay validation, reduction in intra- and inter-lab variability 
Aβ40 Small 
Decrease/Unclear 
Preclinical, MCI, Dementia Yes May not be robust enough on its own 
Aβ42/Aβ40 Decreased Preclinical, MCI, Dementia Yes Validated assays, continued investigation in large, varied cohorts 
Tau Elevated Preclinical, MCI, Dementia Yes Must be used in combination with other biomarkers 
P-tau Elevated Preclinical, MCI, Dementia Yes Must be used in combination with other biomarkers 
Tau/Aβ42 Elevated Preclinical, MCI, Dementia Yes While reliable, Tau and Aβ42 may be better applied individually 
VILIP-1 Elevated Preclinical, MCI, Dementia Yes Continued investigation in large, varied cohorts 
SNAP-25 Elevated MCI, Dementia No Continued investigation in large, varied cohorts 
Ng Elevated Preclinical, MCI, Dementia Yes Continued investigation in large, varied cohorts 
NfL Elevated Preclinical, MCI, Dementia No Continued investigation in large, varied cohorts 
YKL-40 Elevated/Unclear Preclinical, MCI Dementia Yes May not be as robust as, e.g. sTREM2 due to age-associated elevation 
sTREM2 Elevated MCI, Dementia No Continued investigation in large, varied cohorts 
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Blood-Based Biomarkers  
Single 
Analyte 
(Aβ(s), 
Tau(s), NfL,) 
Variable Preclinical, MCI, Dementia Yes Continued investigation in large, varied cohorts 
Multi-
Analyte 
Panels 
Variable Dementia Yes May continue to have limited viability, though multi-analyte approaches 
may be useful in identifying novel single analytes 
Imaging Biomarkers 
MRI Increase in Atrophy Preclinical, MCI, Dementia Yes Must be used in combination with other biomarkers 
fMRI Change in Connected 
Regions 
Preclinical, MCI, Dementia Yes Must be used in combination with other biomarkers 
FDG PET Elevated Preclinical, MCI, Dementia Yes Must be used in combination with other biomarkers 
Amyloid PET Elevated Preclinical, MCI, Dementia Yes Continued investigation in large, varied cohorts 
Tau PET Elevated Preclinical, MCI, Dementia Yes Continued investigation in large, varied cohorts 
Table 1.1 summarizes the biomarker modalities covered in Chapter 1.2. Changes observed refers to the most commonly seen alterations in each biomarker in AD 
compared with cognitively normal individuals. Disease Stage when Reported refers to the stages of AD that a biomarker has published information available. 
Longitudinal data is available for the vast majority of the reported biomarkers, but further longitudinal research is required. The Major Obstacle column refers to 
only the most significant challenge for each biomarker. Continued investigation in large, varied cohorts is required to pinpoint the most useful diagnostic, 
prognostic or theragnostic characteristics of most biomarkers. Aβ42 and Tau(s) – are well recognized identifiers of AD pathology in living individuals but require 
further investigation as to the best application or technique for combinatorial analysis that will allow diagnosis or prognosis of AD on a within-person basis.
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1.3 Biomarkers in the Diagnosis and Prognosis of AD 
Clearly, a large body of work has been created in the study of biomarkers for AD. Despite this 
positive forward progress, an immense amount of work remains in defining high quality 
biomarkers that could be implemented worldwide. Figures 1.1-1.4 present a brief glimpse in to 
the evolution of our broad understanding of AD in terms of biomarkers.  
1.3.1 Hypothetical Biomarker Models 
In an ideal scenario, AD biomarkers will identify individuals during preclinical disease, well 
before the neuronal death that drives cognitive impairments and within a window allowing for 
secondary, or even primary, prevention of the disease. In 2009, the first of a series of 
hypothetical models was published showing how markers such as CSF Aβ42 and tau(s), fMRI, 
or FDG PET might change along the course of AD161. Biomarker behavior as a whole was in an 
early stage of exploring preclinical AD, and most biomarkers are grouped together or shown as 
changing in the very mild stage of AD.  
The second group of figures (Figure 1.2 and 1.3) were published in 2010 and 2013, 
respectively. The first of these figures is similar, grouping markers by Aβ, tau, brain structure, 
and clinical markers162. Both Figures 1.1 and 1.2 propose a temporal ordering of biomarkers 
shifting from normal to abnormal along a disease continuum, but the level of detail was 
necessarily low given the state of the field at the time.  
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Figure 1.1 Hypothesized Relationship Between the Timecourse of Changes in Various 
Biomarkers in Relation to the Neuropathology and Clinical Changes of Alzheimer’s Disease 
The first in a series of evolving proposed biomarker curves. From Craig-Schapiro et al., 2009161. 
Figure 1.2 Dynamic Biomarkers of the Alzheimer’s Pathological Cascade 
The second AD biomarker curve evolution. From Jack et al. 2010162: “Aβ is identified by CSF Aβ42 or 
PET amyloid imaging. Tau-mediated neuronal injury and dysfunction is identified by CSF tau or 
fluorodeoxyglucose-PET. Brain structure is measured by use of structural MRI. Aβ=β-amyloid. 
MCI=mild cognitive impairment.” 
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Figure 1.3 Revised Model of Dynamic Biomarkers of the Alzheimer’s Disease Pathological 
Cascade 
The third AD biomarker curve evolution. Adapted from Jack et al. 2013163: “Neurodegeneration is 
measured by FDG PET and structural MRI, which are drawn concordantly (dark blue). By definition, all 
curves converge at the top right-hand corner of the plot, the point of maximum abnormality. Cognitive 
impairment is illustrated as a zone (light green-filled area) with low-risk and high-risk borders.” The 
bottom axis reflects time rather than disease stage. 
The third iteration of hypothetical curves attempted to further incorporate known difficulties in 
representing a population through a single set of curves, as well as incorporated more recent 
findings for the temporal ordering of biomarkers163. For instance, CSF Aβ42 and amyloid PET 
reflect evidence of CSF amyloid abnormalities being detectable earlier than PET amyloid 
abnormalities. The sigmoidal curve shapes are also updated to reflect potential differing rates of 
change between the visualized biomarkers. Lastly, the uncertainty in individual cognitive reserve 
was acknowledged by adding a high- to low-risk development of cognitive impairment. As a 
reflection of this uncertainty, the x-axis was represented simply as “time” rather than “disease 
state”. The premise was to define the temporal ordering of biomarkers for eventual application 
on a person-by-person basis. The last, most recently updated model (Figure 1.4) was published 
in 20173. This model steps back from individual biomarkers to the combined groups of (1) 
amyloid, (2) cognitive performance, FDG-PET, tau PET, atrophy, and (3) clinical function, 
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reflecting the uncertainty in the application of biomarkers toward very specific disease-states or 
temporal orderings. The continued exploration of non-core CSF biomarkers such as VILIP-1, 
SNAP-25, Ng, YKL-40, and other non-CSF biomarkers has indeed introduced a higher level of 
uncertainty as to our ability to accurately pinpoint – if not diagnosis – prognosis in a single 
individual. 
These models are incredibly useful in allowing researchers a common visual scale with which to 
compare biomarkers and biomarker modalities with respect to clinical status or time. However, 
each of these sets of curves is modeled off of cross-sectional studies, with relatively little input 
from within-person longitudinal studies of biomarker change – a caveat that has been clearly 
acknowledged163. Having a clear picture of the general longitudinal, temporal changes in AD, as 
well as their relationship with the clinical syndrome of AD, is an area of incredibly active 
research. Constant thought is given as to the best translation from hypothetical models such as 
those shown in Figures 1.1-1.4 to functional clinical practice. The first example of data-driven 
biomarker curves was published using DIAN data, using cross-sectional data derive biomarker 
curves over the span of autosomal dominant AD (ADAD) by using the time difference in 
baseline biomarker measurements and each individuals parental age of AD onset as the basis for 
modeling biomarker changes over time, shown in Figure 1.527. Data from the DIAN study was a 
step toward indicating temporal changes in biomarkers from CSF Aβ42 to amyloid imaging 
changes, to CSF Tau, hippocampal atrophy and hypometabolism, and finally to mild cognitive 
decline. What remains are studies of within-person longitudinal changes that will best showcase 
temporal biomarker trajectories for diagnostic, prognostic, or theragnostic utility. 
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Figure 1.4 Change in Biomarkers Over Time 
 
 
 
 
 
 
 
 
The latest biomarker curve evolution. Adapted from Aisen et al. 20173: “Modified graph showing that 
amyloid accumulation (measured as low CSF Aβ or elevated amyloid PET standard uptake value ratio) 
occurs first and functional decline occurs late in the continuum of AD (as before), bug cognitive 
performance, FDG-PET, tau PET, and MRI atrophy change along a common, gradually steepening 
curve”. 
Figure 1.5 Comparison of Clinical, Cognitive, Structural, Metabolic, and Biochemical Changes 
as a Function of Estimated Years from Expected Symptom Onset 
Data derived biomarker curves from cross-sectional data using the DIAN cohort. From Bateman et al. 
201227: The normalized differences between mutation carriers and noncarriers are shown versus estimated 
years from expected symptom onset and plotted with a fitted curve. The order of differences suggests 
decreasing Aβ42 in the CSF (CSF Aβ42), followed by fibrillar Aβ deposition, then increased tau in the 
CSF (CSF tau), followed by hippocampal atrophy and hypometabolism, with cognitive and clinical 
changes (as measured by the Clinical Dementia Rating–Sum of Boxes [CDR-SOB]) occurring later. Mild 
dementia (CDR 1) occurred an average of 3.3 years before expected symptom onset. 
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1.3.2 Translation of Research Biomarkers to Clinical Settings 
As AD research moves forward, different predictions and diagnostic or prognostic models are 
beginning to materialize using the wealth of biomarker information amassed in the last 10-20 
years. Alongside the evolution of hypothetical models, working groups have formed, each tasked 
with aggregating the numerous and varied results from biomarker studies (which the hypothetical 
models do on a research-specific basis) and forming guidelines that may be applied in clinical 
settings. 
In 2011, the National Institute on Aging (NIA) along with the Alzheimer Association (AA) set 
forth diagnostic criteria and guidelines for AD dementia in which magnetic resonance imaging 
(MRI) or positron emission tomography (PET), and cerebrospinal fluid (CSF) proteins were 
pinpointed as the strongest biomarkers for the disease, albeit with the caveat that extensive 
biomarker validation was still needed164.  
In 2013, the International Work Group (IWG) published an update on criteria developed in 2007 
in which the presence of AD biomarkers indicates AD risk, while prodromal AD (MCI, by NIA-
AA criteria) and AD dementia can be diagnosed if an individual also has biomarkers consistent 
with AD. The IWG considers low CSF Aβ plus high CSF tau or P-tau, or abnormal amyloid 
imaging as molecular biomarkers of AD and MRI or FDG PET as topographic biomarkers165. 
As a follow-up to the NIA-AA guidelines, in 2016 a further modification was proposed. Whereas 
the 2011 guidelines set forth 3 stages of disease encompassing preclinical disease (underlying 
pathology in the absence of overt cognitive changes), Mild Cognitive Impairment (MCI) due to 
AD, and AD, the 2016 modifications propose a move from disease- or syndrome-centric 
classifications toward unbiased indicators of pathology or damage as indicated by biomarkers166. 
This evolution may be considered as the merging of the IWG and NIA-AA guidelines in to a 
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single classification scheme – though these guidelines do not specify “Alzheimer Disease” as a 
diagnosis, rather, they simply allow classification of whether or not an individual exhibits 
biomarker changes indicative of underlying AD pathology. Dubbed “A/T/N”, this classification 
scheme has three binary categories: amyloid pathology, as defined by CSF Aβ42 or amyloid 
imaging; tau pathology, as defined by CSF P-tau or tau PET; and neurodegeneration, as defined 
by CSF tau, FDG PET or MRI.  
It may seem that these diagnostic or classification schemes are nebulous or far from 
implementation on a large scale. However, each iteration of guidelines provides important 
updates that either pinpoint critical issues (such as inter- and intra-lab variability in biomarkers) 
in need of improvement or adjust the expectations of “ideal” AD diagnostic scenarios to those 
that fit more accurately with data from AD biomarker studies. Recently, a strategic roadmap for 
using biomarkers to diagnose AD at early stages was proposed that may aid in bringing the 
concepts proposed by the IWG, NIA-AA, and 2016 update together167. Specific challenges in 
biomarker development and implementation were clearly outlined to encourage continued 
investigation in a framework of five phases of development, outlined in Table 1.1, that roughly 
follow the paradigm of (1) casting a wide net for potential biomarkers; (2) developing reliable 
assays to measure promising biomarkers from step 1; (3) longitudinal studies of identified 
biomarkers paired with clinical changes to develop a full picture of disease; (4) application of 
high-performing biomarkers in prospective cohorts to assess accuracy of biomarkers in clinical 
and research settings, and (5) assess applicability of biomarkers in providing positive value in a 
clinical setting. 
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Table 1.2 Barriers to the Widespread Clinical Usage of Biomarkers for AD Diagnosis and Prognosis 
Phase Status Biomarkers Involved 
Phase 1 – exploratory 
studies 
Widely ongoing 
Non-pathologic CSF markers (eg VILIP-
1, SNAP-25, Ng, YKL-40, NfL); Imaging 
markers (tau PET, novel imaging analysis 
techniques); Blood-based biomarkers 
Phase 2 – assay 
development 
Currently developing 
Core CSF biomarkers; Non-pathologic 
CSF biomarkers; Imaging biomarkers 
Phase 3 – retrospective 
and longitudinal studies 
Limited cohorts available 
Ongoing in studies at large research 
centers and Alzheimer’s Disease Research 
Centers 
Phase 4 – prospective 
diagnostic accuracy 
studies 
Widely ongoing 
Promising biomarkers of all modalities 
have been tested in prospective cohorts 
with variable efficacy 
Phase 5 – disease burden 
reduction studies 
Minimal, in progress 
Psychiatric effects of diagnosis can be 
investigated, but not outcomes during or 
after treatment 
Information on research phase 1-5 drawn from Frisoni et al167. Information on Status and Biomarkers 
involved is drawn from information covered in Chapter 1. 
 
1.3.3 Relation of the Current Work to the Challenges Outlined by the Field 
The current work was initiated to explore CSF biomarker utility in a context specific to 
preclinical AD. The original hypothesis postulated that biomarkers of AD might change long 
before clinical symptoms manifest, and therefore that CSF protein levels in a subset of middle-
aged, cognitively normal individuals would reflect such changes longitudinally; these data will 
be covered in Chapter 2 and could apply to Phase 3 as outlined in Table 1.1. A secondary 
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hypothesis postulated that CSF biomarkers would change longitudinally in a temporally distinct 
manner as individuals progressed through different disease stages from preclinical through 
symptomatic AD; these data will be covered in Chapter 3 and could apply to Phase 3. The gold 
standard being sought is a biomarker or, more likely, panel of biomarkers capable of indicating 
disease state and prognosis at the level of a single individual. While the current work does not 
provide anywhere near such a level of detail, it is certainly a step forward for a number of the 
obstacles set forth in Table 1.1 and allows for longitudinal, within-person case studies relevant to 
the primary hypotheses; these data will be covered in Chapter 4 and could apply to Phase 3 and 
4. Lastly, as this work began in 2011, many topics in AD biomarkers have emerged necessitating 
further investigation of the analytic validation of CSF Aβ and tau which are widely considered 
the gold standard in pre-mortem diagnosis alongside amyloid and FDG PET and MRI measures; 
these data will be covered in Chapter 5 and could apply to Phase 2. 
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Chapter 2: Longitudinal Cerebrospinal Fluid 
Biomarker Changes in Preclinical Alzheimer 
Disease During Middle Age 
This work was published in the July 2015 issue of JAMA Neurology31. 
2.1 Abstract 
Importance 
Individuals in the presymptomatic stage of Alzheimer disease (AD) are increasingly being 
targeted for AD secondary prevention trials. How early during the normal life span underlying 
AD pathologies begin to develop, their patterns of change over time, and their relationship with 
future cognitive decline remain to be determined. 
Objective 
To characterize the within-person trajectories of cerebrospinal fluid (CSF) biomarkers of AD 
over time and their association with changes in brain amyloid deposition and cognitive decline in 
cognitively normal middle-aged individuals. 
Design, Setting, and Participants 
As part of a cohort study, cognitively normal (Clinical Dementia Rating [CDR] of 0) middle-
aged research volunteers (n=169) enrolled in the Adult Children Study at Washington 
University, St Louis, Missouri, had undergone serial CSF collection and longitudinal clinical 
assessment (mean, 6 years; range, 0.91-11.3 years) at 3-year intervals at the time of analysis, 
between January 2003 and November 2013. A subset (n=74) had also undergone longitudinal 
amyloid positron emission tomographic imaging with Pittsburgh compound B (PiB) in the same 
period. Serial CSF samples were analyzed for β-amyloid 40 (Aβ40), Aβ42, total tau, tau 
phosphorylated at threonine 181 (P-tau181), visinin-like protein 1 (VILIP-1), and chitinase-3-like 
protein 1 (YKL-40). Within-person measures were plotted according to age and AD risk defined 
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by APOE genotype (ε4 carriers vs noncarriers). Linear mixed models were used to compare 
estimated biomarker slopes among middle-age bins at baseline (early, 45-54 years; mid, 55-64 
years; late, 65-74 years) and between risk groups. Within-person changes in CSF biomarkers 
were also compared with changes in cortical PiB binding and progression to a CDR higher than 0 
at follow-up. 
Main Outcomes and Measures 
Changes in Aβ40, Aβ42, total tau, P-tau181, VILIP-1, and YKL-40 and, in a subset of 
participants, changes in cortical PiB binding. 
Results 
While there were no consistent longitudinal patterns in Aβ40, (P=.001-.97), longitudinal 
reductions in Aβ42 were observed in some individuals as early as early middle-age (P≤.05) and 
low Aβ42 levels were associated with the development of cortical PiB-positive amyloid plaques 
(area under receiver operating characteristic curve = 0.9352; 95% CI, 0.8895-0.9808), especially 
in mid middle-age (P<.001). Markers of neuronal injury (total tau, P-tau181, and VILIP-1) 
dramatically increased in some individuals in mid and late middle-age (P≤.02), whereas the 
neuroinflammation marker YKL-40 increased consistently throughout middle age (P≤.003). 
These patterns were more apparent in at-risk ε4 carriers (Aβ42 in an allele dose-dependent 
manner) and appeared to be associated with future cognitive deficits as determined by CDR.  
Conclusions and Relevance 
Longitudinal CSF biomarker patterns consistent with AD are first detectable during early 
middle-age and are associated with later amyloid positivity and cognitive decline. Such measures 
may be useful for targeting middle-aged, asymptomatic individuals for therapeutic trials 
designed to prevent cognitive decline. 
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2.2 Introduction 
Alzheimer disease (AD) is the most common cause of dementia in elderly individuals, 
accounting for up to 70% of all dementia cases, and is now estimated to be the third-leading 
cause of death after heart disease and cancer168. To date, clinical trials of potential disease-
modifying therapies for AD have met with little success in halting or slowing cognitive decline 
in patients who already have cognitive symptoms or dementia169. However, clinicopathologic 
and more recent biomarker data suggest that AD pathology begins to accrue approximately 10 to 
20 years before any cognitive signs or symptoms (termed asymptomatic or preclinical 
AD)9,27,64,170–175, thus providing a window of opportunity for the initiation of secondary 
prevention trials that aim to prevent the development of symptoms in individuals while they are 
still cognitively normal176. How early during the normal life span such pathologies begin to 
develop, their patterns of change over time, and their relationship with future cognitive decline 
remain to be determined. 
Because, by definition, preclinical AD eludes detection by current clinical measures, disease-
specific biomarkers are necessary to identify individuals in this asymptomatic stage. To this end, 
the Adult Children Study (ACS) of the Knight Alzheimer’s Disease Research Center at 
Washington University, St Louis, Missouri, was initiated. The ACS is a longitudinal clinical and 
biomarker research study of cognitively normal, middle-aged adults exhibiting different AD risk 
profiles including age, family history of AD, and APOE genotype (APOE ε4 carriers vs 
noncarrier)177. Participants undergo comprehensive, longitudinal clinical and psychometric 
assessments and evaluation of biomarkers in cerebrospinal fluid (CSF) and plasma, along with 
several imaging modalities. We hypothesized that biomarker patterns indicative of underlying 
AD pathology would be evident in a subset of cognitively normal individuals during middle age, 
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at a greater frequency in those at higher risk for AD (ie, older and/or carrying the ε4 allele of 
APOE), and would increase in severity over time, ultimately culminating in cognitive decline. 
The 3 CSF biomarker analytes that reflect the core neuropathologies in AD, β-amyloid 42 
(Aβ42; the primary constituent of amyloid plaques), total tau (a marker of neuronal injury and/or 
death), and hyperphosphorylated tau (P-tau; forms intraneuronal neurofibrillary tangles), 
demonstrate excellent diagnostic and prognostic utility in research cohorts64,178,179. Other recently 
identified biomarkers, including visinin-like protein 1 (VILIP-1) and chitinase-3-like protein 1 
(YKL-40) (markers of neuronal death and gliosis/neuroinflammation, respectively) have also 
demonstrated clinical utility in AD, especially when combined in an algorithm with CSF 
Aβ4261,62,65,101,180. This first report of longitudinal biomarker changes in the ACS cohort 
describes the within-person trajectories of these CSF biomarkers over time and their association 
with longitudinal changes on in vivo amyloid imaging and future cognitive decline as a function 
of risk conferred by APOE genotype. 
2.3 Methods 
Participants 
Participants were cognitively normal, community-dwelling research volunteers enrolled in the 
ACS at the Knight Alzheimer’s Disease Research Center at Washington University. Inclusion 
criteria include the following: (1) positive family history (≥1 biological parent with age at AD 
dementia onset <80 years) or negative family history (both biological parents living to age ≥70 
years in the absence of AD dementia); (2) aged 45 to 74 years at study entry (1 enrollee was aged 
43 years, 3 were aged 75 years, 3 were aged 76 years, and 1 was aged 81 years); (3) availability 
of an informant who knows the participant well; (4) normal cognition at study entry (defined as 
having a Clinical Dementia Rating [CDR]181 of 0; and (5) willingness in principle to complete all 
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study procedures at baseline and longitudinally. Exclusion criteria include the following: (1) 
presence of a neurological, psychiatric, or systemic illness that might affect cognition or interfere 
with longitudinal follow-up; (2) a known deterministic mutation for AD; and (3) medical 
contraindication to lumbar puncture for CSF collection or imaging. 
Specific inclusion criteria for the present analysis included the availability of data from at least 2 
serial clinical assessments and CSF collection procedures (mean [SD] interval between clinical 
assessment and CSF collection, 3.3 [3.8] years) as of September 2013; thus, this cohort 
represents a subset (n=169) of ACS participants to date. All procedures were approved by the 
Human Research protection Office at Washington University, and written informed consent was 
obtained from all participants and their informants. 
Clinical and Cognitive Assessments 
The presence or absence of dementia (and, when present, its severity) was operationalized with 
the CDR in accordance with standard protocols and criteria182. A CDR of 0 indicates cognitive 
normality, whereas CDRs of 0.5, 1, 2, and 3 are indicative of very mild, mild, moderate, and 
severe dementia, respectively181.  
Genotyping 
Using standard procedures, DNA was extracted from peripheral blood samples. Genotyping of 
APOE was performed by the Knight Alzheimer’s Disease Research Center Genetics Core as 
previously described183. 
CSF Collection and Processing 
A sample of CSF (20-30 mL) was collected by routine lumbar puncture at 8 AM after overnight 
fasting as described17. Samples were processed into 500 uL aliquots and immediately frozen at -
80oC. 
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CSF Biomarker Analyses 
The CSF samples were analyzed for Aβ and tau proteins using single-analyte enzyme-linked 
immunosorbent assays (ELISAs; research use only) from 2 different vendors. Samples were 
analyzed for Aβ1-40 (Aβ40), Aβ1-42 (Aβ42), total tau, and tau phosphorylated at threonine 181 
(P-tau181) using the Improved INNOTEST ELISA (Fujirebio Europe), a modified version of the 
assay most widely used in the field. In parallel, Aβ40, Aβ42, and total tau were measured at the 
same time (from the same sample aliquot) using a set of second-generation (precision-based and 
accuracy-based) EUROIMMUN ELISAs (EUROIMMUN). The Aβ42 to Aβ40 ratio was 
calculated to normalize the Aβ42 production concentrations to the total amount of Aβ (Aβ40 is 
the most abundant Aβ species in CSF)184–186. The ratio of total tau (P-tau181) to Aβ42 was also 
evaluated because it has been shown to be a predictor of future cognitive decline in elderly 
cohorts28,61,187,188. It must be stated at the outset that the focus of this study is on the clinical 
utility of the biomarker and that conclusions drawn from one assay can be confirmed or qualified 
with data derived from another immunoassay. The well-studied INNOTEST ELISA was 
considered a priori to be the reference assay; therefore, INNOTEST data are shown. 
The VILIP-1 concentration was measured using a 2-site immunoassay (Singulex)61. The YKL-40 
concentration was measured with the MicroVue ELISA (Quidel)101(p40). 
Longitudinal CSF samples from a given individual were run on the same assay plate (and same 
lot number) to minimize potential interpolate and interlot methodological variability. Samples 
underwent a single freeze-thaw cycle prior to assay, were thawed on wet ice (approximately 3 
hours) prior to analysis, and were all run in duplicate. Values had to pass quality control criteria, 
including coefficients of variation of 25% or lower, kit controls within the expected range as 
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defined by the manufacturer (where applicable), and measurement consistency of 2 common 
pooled CSF samples that were included on each plate. 
In Vivo Amyloid Imaging 
A subset (n=74) of the 169 participants with longitudinal CSF analysis had also undergone 
longitudinal in vivo amyloid imaging via positron emission tomography (PET) with Pittsburgh 
compound B (PiB)189–191 within approximately 12 months of CSF collection (mean [SD], 84.3 
[92] days). The PiB PET imaging was conducted with a Siemens 962 HR+ Emission Computer-
Aided Tomograph PET or Biograph 40 scanner (Siemens/CTI). Magnetic resonance imaing 
using magnetization-prepared rapid-acquisition gradient-echo T1-weighted imagine (1 x 1 x 1.25 
mm) was obtained for anatomical reference. 
Deposition of PiB in brain regions of interest was determined using FreeSurfer version 5.1 
software (Martinos Center for Biomedical Imaging)190,192,193, and a standardized uptake value 
ratio (SUVR) corrected for partial volume effects194 was calculated for each region of interest. 
The mean cortical SUVR was calculated from FreeSurfer regions within the prefrontal cortex, 
precuneus, and temporal cortex. Cerebellar cortex served as the reference region. Based on a 
study of 77 symptomatic and asymptomatic Knight Alzheimer’s Disease Research Center 
participants190, PiB positivity was defined as an SUVR of 1.42, commensurate with a mean 
cortical binding potential of 0.18 defined previously for PiB positivity189. 
Statistical Analysis 
Baseline demographic characteristics were summarized as mean (standard deviation) for 
continuous variables or number (percentage) for categorical variables. Demographic variables 
were compared across 3 age bins within the 2 APOE ε4 groups and between the ε4 carriers and 
noncarriers within each age bin using post hoc t tests within analysis of variance for continuous 
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variables or logistic regression for dichotomous variables. To quantify the within-person annual 
rate of change in CSF biomarkers, general linear mixed models with random intercepts and 
random time slopes at the participant level were used to regress the concentrations on time from 
study entry (baseline). These models incorporated baseline age category, APOE category, and 
time from study entry as fixed effects as well as all possible higher-order interactions among 
these factors. This facilitated the estimation of average baseline CSF biomarker concentrations as 
well as their change over time separately in each of the 6 participant groups (cross-classification 
of 3 baseline age categories by 2 APOE categories). The resulting estimated average within-
person annual rates of change in CSF biomarkers were compared among the 6 groups with 
model-derived approximate t tests with the approximate denominator df based on the 
Satterthwaite approximation195. Baseline comparisons between CSF biomarkers among the 
groups in Table 2.1 were also carried out within these general linear mixed models by testing the 
estimated average concentrations when time from study entry was equal to 0. These CSF 
biomarker comparisons, at baseline and on the longitudinal rate of change, were also reexamined 
after adjusting for family history, sex, and education by including fixed effects for these factors 
and their interactions with time from study entry. The general linear mixed model assumptions 
were evaluated via analyses of residuals. Owing to the preliminary nature of hypotheses 
examined in this cohort, no adjustment was made for multiplicity. For exploratory purposes, an 
optimal CSF Aβ42 cutoff was determined using the Youden Index after receiver operating 
characteristic analysis for discriminating between PiB-positive and PiB-negative individuals at 
baseline. For each biomarker, baseline and longitudinal comparisons between PiB-positive (PiB 
SUVR ≥ 1.42) and PiB-negative individuals were performed using general linear mixed models 
with fixed effects included for PiB category, time from study entry, and their interaction. We 
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used SAS version 9.3 statistical software (SAS Institute, Inc.) for all statistical analyses, with 
statistical significance defined as P < .05.  
2.4 Results 
Baseline data are presented in Table 2.1 and grouped into 6 bins: the absence (n=108) or 
presence (n=61) of at least 1 APOE ε4 allele (as an indicator of neutral and high AD risk, 
respectively) and middle-age bin at baseline (early [45-54 years], mid [55-64 years], or late [65-
74 years]). Ninety-nine participants underwent 2 serial CSF collections, 65 underwent 3 serial 
CSF collections, and 5 underwent 4 serial CSF collections, at intervals of approximately 3 years. 
Forty-five of the 61 ε4 carriers (74%) and 49 of the 108 ε4 noncarriers (45%) reported a positive 
family history. 
2.4.1 Comparison of the CSF Aβ40, Aβ42, and Total Tau Assays 
Data for the ACS cohort was acquired using two assays for Aβ40, Aβ42, and Tau. The data 
presented in Chapter 2 are the “Improved” INNOTEST data. With the exception of 
EUROIMMUN data in Table 2.1, analyses comparing the INNOTEST and EUROIMMUN 
assays are located in Chapter 5. 
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Table 2.1 Demographic Characteristics and Baseline Cerebrospinal Fluid Biomarkersa 
 APOE ε4 Noncarriers (n=108) APOE ε4 Carriers (n=61) 
Variable Early (n = 26)              Mid (n = 44) Late (n = 38) Early (n = 19) Mid (n = 17) Late (n = 25) 
Baseline age, mean (SD), y 50.1 (3.0) 59.4 (2.9) b 69.9 (3.5) b,c 49.6 (2.9) 59.3 (3.1) b 69.4 (3.6) b,c 
Female, No. (%) 17 (65) 32 (73) 22 (58) 14 (74) 11 (65) 16 (64) 
Positive family history, No. (%) 12 (46) 22 (50) 15 (39) 15 (79) d 13 (76) 17 (68) d 
APOE genotype, No.       
ε2/ε2 0 1 1 0 0 0 
ε2/ε3 3 8 6 0 0 0 
ε3/ε3 23 35 31 0 0 0 
ε2/ε4 0 0 0 2 2 2 
ε3/ε4 0 0 0 14 12 20 
ε4/ε4 0 0 0 3 3 3 
Education, mean (SD), y 16.1 (2.10) 16.9 (2.27) 15.6 (2.64) c 15.8 (1.95) 15.4 (3.45) d 16.3 (2.23) 
Baseline MMSE score, mean (SD) e 29.5 (0.65) 29.3 (1.10) 28.8 (1.22) b 29.8 (0.38) 28.9 (1.52) b 28.9 (1.39) b 
Received ≥1 CDR>0 at follow-up, No. f 0 1 4 1 3 5 
Participants with 2/3/4 serial LPs, No. 12/13/1 21/19/4 25/13/0 11/8/0 12/5/0 18/7/0 
LP interval, mean (SD), mo 3.3 (0.76) 3.3 (0.91) 3.1 (0.77) 3.3 (0.73) 3.6 (1.4) 3.2 (0.77) 
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Baseline biomarkers, mean (IQR)             
Improved INNOTEST ELISA       
Aβ40, pg/mL 12657 
(10461-14480) 
14319 
(12185-16371) 
15382b 
(12417-17906) 
14555 
(12984-16638) 
13103 
(10629-15838) 
14343 
(12199-16748) 
Aβ42, pg/mL 1293 
(1046-1525) 
1340 
(1132-1544) 
1270 
(1021-1608) 
1306 
(1193-1498) 
936.9 b,d 
(671-1116) 
969.7 b,d 
(733-1225) 
Aβ42 to Aβ40 ratio 0.1052 
(0.0900-0.1225) 
0.0972 
(0.0800-0.1100) 
0.0871b,c 
(0.0700-0.1000) 
0.0924 
(0.0800-0.1000) 
0.0719 b,d 
(0.0600-0.0850) 
0.0709 b,d 
(0.0550-0.0900) 
Total tau, pg/mL 202.3 
(146.0-243.2) 
259.0 
(182.6-278.7) 
324.3 b,c 
(205.2-389.3) 
257.7 
(194.4-314.6) 
298.0 
(210.2-391.6) 
321.4 
(198.6-413.2) 
P-tau181, pg/mL 39.8 
(27.7-50.3) 
51.2 
(37.2-55.4) 
58.8 b 
(41.7-68.5) 
47.7 
(38.5-55.4) 
54.4 
(37.9-67.8) 
55.4 
(38.2-69.8) 
Tau to Aβ42 ratio 0.1541 
(0.1200-0.1725) 
0.1908 
(0.1400-0.2200) 
0.3054 b,c 
(0.1500-0.3100) 
0.1986 
(0.1600-0.2300) 
0.4207 b,d 
(0.1900-0.4550) 
0.3816 b 
(0.2150-0.5200) 
EUROIMMUN ELISA       
Aβ40, pg/mL 4857 
(3525-6101) 
5408 
(4305-6220) 
5569 
(4347-6224) 
5535 
(4816-6433) 
5266 
(3966-7043) 
5257 
(4119-5942) 
Aβ42, pg/mL 616.1 
(438.1-683.1) 
616.1 
(495.90741.8) 
590.1 
(459.4-701.1) 
676.0 
(462.3-797.6) 
449.5 b,d 
(349.9-564.3) 
487.5 b,d 
(365.3-601.8) 
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Total tau, pg/mL 254.7 
(194.4-304.8) 
310.3 
(230.3-344.6) 
362.5 b,c 
(255.6-430.3) 
299.1 
(234.1-351.6) 
380.5 d 
(313.6-469.6) 
395.8 b 
(274.1-487.4) 
Tau to Aβ42 ratio 0.4050 
(0.3341-0.4851) 
0.5022 
(0.3900-0.5192) 
0.7023 b,c 
(0.4065-0.6874) 
0.4563 
(0.3675-0.5390) 
1.073 b,d 
(0.4680-1.1100) 
0.9342 b,d 
(0.5383-1.2250) 
VILIP-1, pg/mL 140.8 
(102.3-169.8) 
154.4 
(116.7-166.4) 
179.8 b,c 
(133.6-218.9) 
155.6 
(128.8-175.4) 
153.2 
(105.4-193.8) 
154.7 
(117.0-180.2) 
YKL-40, ng/mL 180.3 
(124.2-220.3) 
231.3 b 
(192.3-259.7) 
301.1 b,c 
(221.7-368.2) 
188.4 
(135.3-238.7) 
240.6 b 
(165.5-297.9) 
281.5b 
(201.8-353.8) 
Abbreviations: Aβ, β-amyloid; CDR, Clinical Dementia Rating; ELISA, enzyme-linked immunosorbent assay; IQR, interquartile range; LP, 
lumbar puncture; MMSE, Mini-Mental State Examination; P-tau181, tau phosphorylated at threonine 181; VILIP-1, visinin-like protein 1; YKL-40, 
chitinase-3-like protein 1. 
a Age groups indicate the ages within middle-age: early, ages 45-54; mid, ages 55-64; and late, ages 65-74 years 
b Significantly different from early within the same APOE ε4 group (P < .05) 
c Significantly different from mid within the same APOE ε4 group (P < .05) 
d Significantly different from the same age group of the other APOE ε4 group (P < .05) 
e The MMSE scores can range from 0 to 30, with 30 as a perfect score 
f A CDR of 0 indicates cognitively normal; a CDR higher than 0, cognitively abnormal  
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2.4.2 Baseline and Slope Analyses: CSF Biomarker Changes Occur in Middle 
Age 
Baseline biomarker levels (Table 2.1) and slopes of change within individuals (Table 2.2) were 
evaluated in the 6 bins defined earlier. Slopes were calculated as the representative mean of all 
annual individual slopes per age bin (extrapolated to 9 years for illustrative purposes) and 
superimposed on the spaghetti plots of the associated individual trajectories (Figure 2.1 shows 
the INNOTEST assay data for Aβ40, Aβ42, Aβ42 to Aβ40 ratio, total tau, P-tau181, and total tau 
to Aβ42 ratio; Figure 2.2 shows the data for VILIP-1 and YKL-40; see Figure 5.1 Chapter 5 for 
the EUROIMMUN assay data). Controlling for family history, sex, and education did not 
substantially influence the comparisons between age and ε4 categories. 
Aβ40, Aβ42, Aβ42 to Aβ40 Ratio  
Baseline levels of CSF Aβ40 (INNOTEST) were significantly higher in the late middle-aged 
group compared with the early middle-aged group in ε4 noncarriers (P = .004) (Table 2.1) but 
decreased significantly within individuals in the early (P = .04) and mid (P = .01) middle-aged 
groups over time (Table 2.2 and Figure 2.1A). In contrast, no significant differences were 
observed in ε4 carriers at baseline or longitudinally (Table 2.1 and Table 2.2). 
In contrast to Aβ40, robust decreases within individuals in all age groups were observed for 
Aβ42 in both risk groups (Figure 2.1B and Table 2.2), and this pattern was detectable in many 
participants as early as 45 to 54 years of age. While baseline concentrations did not differ among 
the age groups in the ε4 noncarriers, levels in ε4 carriers were significantly lower in the mid (P < 
.001) and late (P < .001) middle-aged groups compared with the early middle-aged group and 
also significantly lower than the levels in the mid (P < .001) and late (P < .001) middle-aged ε4 
noncarriers (Table 2.1). 
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Similar to the patterns observed for Aβ42 alone, the ratios of Aβ42 to Aβ40 were significantly 
lower in the mid (P = .02) and late (P = .005) middle-aged groups compared with the early 
middle-aged group in ε4 carriers (Table 2.1), and the within-person values significantly 
decreased over time in the 2 older age groups (both P < .001) (Figure 2.1C and Table 2.2). 
Although baseline ratios in the ε4 noncarriers were significantly lower in the late middle-aged 
group compared with the mid (P = .05) and early (P = .004) middle aged groups (Table 2.1), 
they did not change significantly within these low-risk individuals at any age (Figure 2.1C and 
Table 2).  
Total Tau and P-tau181 
Baseline total tau was higher in late middle-aged participants compared with early middle-aged 
participants in both risk groups, with intermediate levels in the mid middle-aged participants, 
although differences were statistically significant only in the ε4 noncarriers (P < .001 and P = 
.02, respectively) (Table 2.1). Within ε4 noncarriers, total tau increased significantly over time 
during late middle age (P < .001), while increases were observed earlier (mid and late middle-
age) in the higher-risk ε4 carriers (both p < .001) (Figure 2.1D and Table 2.2). Interestingly, the 
annual mean (SE) increase in total tau in mid middle-age was significantly higher in ε4 carriers 
(22.28 [4.45] pg/ml) compared with ε4 noncarriers (2.84 [2.68] pg/ml) (P < .001) (Table 2.2). 
Results for P-tau181 were virtually identical to those for total tau, including more robust 
elevations in the ε4 carriers during mid middle-age (Figure 2.1E and Table 2.2). 
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Table 2.2 Mean Annual Slopes of Within-Individual Longitudinal Change in Cerebrospinal Fluid Biomarkers During Middle Agea 
 APOE ε4 Noncarriers (n=108) APOE ε4 Carriers (n=61) 
Variable Early (n = 26) Mid (n = 44) Late (n = 38) Early (n = 19) Mid (n = 17) Late (n = 25) 
Aβ40             
Estimated Annual Slope, mean (SE), pg/ml -163.59 (80.50) -153.82 (61.81) -130.39 (77.20) 30.63 (102.86) 3.31 (107.75) 110.77 (97.06) 
Different from zero, P value .04b .01b .09 .77 .98 .26 
APOE ε4 carriers vs noncarriers, P value - - - .14 .21 .05 
Aβ42             
Estimated Annual Slope, mean (SE), pg/ml -14.81 (5.83) -19.34 (4.48) -22.80 (5.56) -14.99 (7.42) -29.22 (7.79) -26.76 (6.99) 
Different from zero, P value .01b <0.001b <0.001b .045b <0.001b <0.001b 
APOE ε4 carriers vs noncarriers, P value - - - .98 .27 .66 
Aβ42 to Aβ40 ratio             
Estimated Annual Slope, mean (SE), pg/ml 
0.00027 
(0.00042) 
-0.00023 
(0.00032) 
-0.00068 
(0.00042) 
-0.00090 
(0.00055) 
-0.00202 
(0.00057) 
-0.00220 
(0.00052) 
Different from zero, P value .52 .47 .10 .10 <0.001b <0.001b 
APOE ε4 carriers vs noncarriers, P value - - - .09 .007b .02b 
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Total tau             
Estimated Annual Slope, mean (SE), pg/ml 0.96 (3.44) 2.84 (2.68) 14.58 (3.08) c,d 5.40 (4.20) 22.28 (4.45) c 18.45 (3.85) c 
Different from zero, P value .78 .29 <0.001b .20 <0.001b <0.001b 
APOE ε4 carriers vs noncarriers, P value - - - .42 <0.001b .43 
P-tau181             
Estimated Annual Slope, mean (SE), pg/ml 0.23 (0.51) 0.32 (0.40) 1.84 (0.47) c,d 1.08 (0.63) 3.41 (0.67) c 1.92 (0.58) 
Different from zero, P value .66 .43 <0.001b .09 <0.001b .001b 
APOE ε4 carriers vs noncarriers, P value - - - .30 <0.001b .91 
Total tau to Aβ42 ratio             
Estimated Annual Slope, mean (SE), pg/ml 0.0026 (0.0084) 0.0081 (0.0066) 
0.0268 c 
(0.0071) 
0.0076 (0.0100) 
0.0538 c 
(0.0106) 
0.0478 c 
(0.0088) 
Different from zero, P value .76 .22 <0.001b .45 <0.001b <0.001b 
APOE ε4 carriers vs noncarriers, P value - - - .70 <0.001b .07 
VILIP-1       
Estimated Annual Slope, mean (SE), pg/ml -0.18 (1.03) -0.48 (0.80) 2.39 (1.01) d 0.79 (1.34) 5.17 (1.39) c 1.42 (1.27) d 
Different from zero, P value .86 .55 .02b .55 <0.001b .26 
APOE ε4 carriers vs noncarriers, P value - - - .56 <0.001b .55 
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YKL-40       
Estimated Annual Slope, mean (SE), pg/ml 4.80 (1.29) 4.26 (0.99) 6.91 (1.27) 6.25 (1.68) 10.83 (1.75) 4.90 (1.60) d 
Different from zero, P value <0.001b <0.001b <0.001b <0.001b <0.001b .002b 
APOE ε4 carriers vs noncarriers, P value - - - .50 .001b .32 
Abbreviations: Aβ, β-amyloid; P-tau181, tau phosphorylated at threonine 181; VILIP-1, visinin-like protein 1; YKL-40, chitinase-3-like protein 1; 
dashes, not applicable. 
a Age groups indicate the ages within middle-age: early, ages 45-54; mid, ages 55-64; and late, ages 65-74 years. Results for Aβ40, Aβ42, Aβ42 to 
Aβ40 ratio, total tau, P-tau181, and total tau to Aβ42 ratio are from the improved INNOTEST enzyme-linked immunosorbent assay 
b Statistically significant at P < .05 
c Significantly different from early within the same APOE ε4 group (P < .05) 
d Significantly different from mid within the same APOE ε4 group (P < .05)   
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Ratios of Total Tau and P-tau181 to Aβ42 
In ε4 noncarriers, the baseline total tau to Aβ42 ratio was significantly higher in late middle-age 
compared with both early (P = .005) and mid (P = .01) middle-age (Table 2.1). In at-risk ε4 
carriers, significantly higher ratios were observed even earlier (mid [P = .002] and late [P = .004] 
middle-age) compared with early middle-age (Table 2.1). Longitudinal patterns for the total tau 
to Aβ42 ratio were virtually identical to those of total tau, with significant within-person 
increases in the late middle-aged group in ε4 noncarriers (P < .001) and even earlier (mid and 
late middle-age) in the ε4 carriers (both P < .001) (Figure 2.1F and Table 2.2). Patterns for the 
P-tau181 to Aβ42 ratio were virtually identical to those of the total tau to Aβ42 ratio (data not 
shown).  
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Figure 2.1. Longitudinal Change in Cerebrospinal Fluid Biomarkers β-Amyloid 40 (Aβ40), 
Aβ42, Aβ42 to Aβ40 Ratio, Total Tau, Tau Phosphorylated at Threonine 181 (P-tau181), and 
Total Tau to Aβ42 Ratio During Middle Age 
Estimated group slopes and within-person changes for Aβ40 (A), Aβ42 (B), Aβ42 to Aβ40 ratio (C), total 
tau (D), tau phosphorylated at threonine 181 (P-tau181) (E), and total tau/Aβ42 ratio (F) are shown in the 
3 age bins for APOE ε4 noncarriers (top graph of each panel; n = 108 participants) and ε4 carriers 
(bottom graph of each panel; n = 61 participants). Annual slopes have been extrapolated to 9 years, and 
each slope begins at the mean baseline biomarker value from individuals in each age bin. Group 
baseline values and slopes represent the estimates reported in Table 1 and Table 2, respectively, 
for the different cohorts defined by baseline age in which biomarker concentrations were 
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regressed on time from study entry. Data are from the INNOTEST enzyme-linked 
immunosorbent assay (Fujirebio Europe). 
aSlope significantly different from 0 (P < .05). 
bSlope significantly different between APOE ε4 groups within a given age group (P < .05). 
 
2.4.3 Other Biomarkers of Neuronal Injury and Gliosis/Neuroinflammation 
VILIP-1 
The concentration of VILIP-1 was positively correlated with total tau during middle age 
(INNOTEST total tau: n = 401, Pearson r = 0.763 [95% CI, 0.719-0.801], P < .001; 
EUROIMMUN total tau: n = 403, Pearson r = 0.743 [95% CI, 0.696-0.784], P < .001), 
consistent with earlier reports in elderly cohorts. Similar to total tau, mean baseline VILIP-1 
concentration increased with age, with significantly higher levels in late middle-age compared 
with early (P = 0.008) and mid (P = .03) middle-age in the ε4 noncarriers (Table 2.1) and within-
person increases over time in late middle-age (P = .02) (Figure 2.2A and Table 2.2). While 
baseline levels of VILIP-1 in the at-risk ε4 carriers at baseline were not significantly different 
among the age groups, (Table 2.1), they significantly increased longitudinally within individuals 
at an earlier age (mid middle-age [P < .001]) compared with the ε4 noncarriers (late middle-age 
[P = .02]) (Figure 2.2A and Table 2.2). Also similar to total tau, the annual mean increase in 
VILIP-1 concentration in mid middle-age was greater in ε4 carriers compared with ε4 
noncarriers (P < .001).  
YKL-40 
Baseline CSF YKL-40 concentration was significantly higher in mid and late middle-age 
compared with early middle-age in both ε4 groups (all P ≤ .04) as well as in late middle-age 
compared with the mid middle-age in the ε4 noncarriers (P < .001) (Table 2.1). In both groups, 
YKL-40 concentration significantly increased within individuals over time in all age bins (P = 
.002 in late middle-age among ε4 noncarriers; all others, P < .001) (Figure 2.2B and Table 2.2). 
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In mid middle-age, YKL-40 concentration increased at a significantly higher rate in the ε4 
carriers compared with ε4 noncarriers (P = .001) (Table 2.2), similar to what was observed for 
the injury markers. 
Figure 2.2. Longitudinal Change in Cerebrospinal Fluid Biomarkers Visinin-Like Protein 1 
(VILIP-1) and Chitinase-3-Like Protein 1 (YKL-40) During Middle Age 
Estimated group slopes and within-person changes for VILIP-1 (A) and YKL-40 (B) are shown in the 3 
age bins for APOE ε4 noncarriers (top graph of each panel; n = 108 participants) and ε4 carriers (bottom 
graph of each panel; n = 61 participants). Annual slopes have been extrapolated to 9 years, and each slope 
begins at the mean baseline biomarker value from individuals in each age bin. Group baseline values and 
slopes represent the estimates reported in Table 1 and Table 2, respectively, for the different cohorts 
defined by baseline age in which biomarker concentrations were regressed on time from study entry. 
aSlope significantly different from 0 (P < .05). 
bSlope significantly different between APOE ε4 groups within a given age group (P < .05). 
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2.4.4 APOE ε4 Gene Dose Influences CSF Biomarker Patterns Consistent with 
the Presence of Preclinical AD During Middle Age 
Given the known APOE ε4 gene dosage effects on the risk of AD and age at dementia onset, we 
evaluated biomarker trajectories as a function of ε4 allele number. The majority (82%) of ε4 
noncarriers had the ε3/ε3 genotype, whereas the majority (75%) of ε4 carriers had the ε3/ε4 
genotype (Table 2.1). Nine participants were ε4 homozygotes (ε4/ε4 genotype). Trajectory 
patterns for Aβ40 did not differ as a function of ε4 allele dose (Figure 2.3A). In contrast, 
patterns differed dramatically for Aβ42 (Figure 2.3B) and the Aβ42 to Aβ40 ratio (Figure 2.3C) 
across the entire age range, with ε4 homozygotes falling among the lowest values, ε4 noncarriers 
typically falling among the highest, and heterozygotes falling in the middle range (although 
overlapping with many of the ε4 noncarriers). The longitudinal patterns for total tau, total tau to 
Aβ42 ratio, VILIP-1, and YKL-40 in ε4 carriers appeared to overlap to a greater extent with 
those for ε4 noncarriers (Figure 2.3D-F). However, the number of ε4 homozygotes is too small 
to perform rigorous statistical analyses in the current cohort. 
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Figure 2.3 Longitudinal Biomarker Trajectories in Individuals with Different APOE Genotypes  
Within-person trajectories of CSF A) Aβ40, B) Aβ42, C) Aβ42/Aβ40 Ratio, D) Tau, E) Tau/Aβ42 Ratio, F) VILIP-1, and G) YKL-40 are plotted 
as a function of age. Aβ40, Aβ42 and tau were measured with the INNOTEST assay. Colors identify APOE genotype:  no ε4 alleles (gray, ε4-/-; 
ε2/ε2, ε2/ε3, ε3/ε3), one ε4 allele (purple, ε4+/-; ε2/ε4, ε3/ε4) and two ε4 alleles (orange, ε4+/+; ε4/ε4). 
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2.4.5 Association of CSF Aβ42 and In Vivo Amyloid Imaging During Middle 
Age 
Because studies to date evaluating the concordance of CSF Aβ42 concentrations with in vivo 
amyloid load have focused on elderly cohorts, it was of interest to characterize this association in 
middle-age, a time during which a subset of individuals are expected to be in the very earliest 
stages of preclinical AD. This analysis used data from a subset of 74 participants (n = 50 ε4 
noncarriers; n = 24 ε4 carriers) within the longitudinal CSF cohort who had also undergone 
longitudinal in vivo PiB PET imaging within 376 days (mean [SD], 84.3 [92] days) of CSF 
collection. Twenty of these individuals were considered PiB positive (mean cortical SUVR ≥ 
1.42) at baseline, follow-up, or both (Figure 2.4A). Of these 20 individuals, 10 (50%) were ε4 
noncarriers and 10 (50%) were ε4 carriers. Although there was no significant association 
between the cross-sectional patterns (P = .12) or longitudinal trajectories (P = .65) of Aβ40 and 
cortical PiB binding (Figure 2.4B), PiB positivity was associated with low baseline levels of 
CSF Aβ42 (P < .001) but not longitudinal change (P = .37) (Figure 2.4C). However, 15 PiB-
negative individuals (20%) had concentrations of Aβ42 that were as low as those who were PiB-
positive. Because low Aβ42 values could conceivably reflect low production of all Aβ species 
rather than an amyloidosis-specific decrease in Aβ42, we also evaluated the relationship between 
PiB and the Aβ42 to Aβ40 ratio (Figure 2.4D). Twelve of the PiB-negative participants (16%) 
had Aβ42 to Aβ40 ratios at some point that were as low as those who were PiB-positive. 
Notably, all 4 ε4 homozygotes in this subcohort had a low Aβ42 concentration and a low Aβ42 
to Aβ40 ratio at both baseline and follow-up (Figure 2.4C and D), including the 2 young 
participants (aged <55 years at baseline) who were PiB-negative (Figure 2.4C and D, solid black 
lines). The PiB-positive individuals typically had higher baseline (P < .001) and longitudinally 
increasing (P < .001) levels of total tau (and P-tau181 [scatterplots not shown]) compared with 
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those who were PiB-negative (Figure 2.4E). The PiB associations with baseline (P = .04) and 
longitudinal (P = .004) VILIP-1 concentrations were similar to total tau but less concordant 
(Figure 2.5A). Being PiB-positive was not significantly associated with YKL-40 levels at 
baseline (P = .08) but was associated with greater longitudinal increases (P = .04) (Figure 2.5B). 
Overall, Aβ42, Aβ42 to Aβ40 ratio, total tau, and P-tau181 appeared to be more strongly 
associated with PiB positivity than were Aβ40, VILIP-1, and YKL-40. 
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Figure 2.4. Association Between Longitudinal Patterns of Cerebrospinal Fluid Biomarkers β-
Amyloid 40 (Aβ40), Aβ42, Aβ42 to Aβ40 Ratio, and Total Tau, Cortical Pittsburgh Compound 
B (PiB) Standardized Uptake Value Ratio (SUVR), and Age 
A subset (n = 74) of Adult Children Study participants had undergone longitudinal amyloid imaging via 
PiB positron emission tomographic imaging within 376 days (mean [SD], 84.3 [92] days) of 
cerebrospinal fluid collection. Biomarker measures include cortical PiB SUVR (A), Aβ40 (B), Aβ42 (C), 
Aβ42 to Aβ40 ratio (D), and total tau (E). The Aβ40, Aβ42, and total tau were analyzed by INNOTEST 
enzyme-linked immunosorbent assay (Fujirebio Europe). Being PiB positive was defined as having a 
mean cortical PiB SUVR higher than 1.42 and is represented by the dashed horizontal line in panel A. 
Gray lines indicate PiB negative at baseline and follow-up (n = 52); solid colored lines, PiB positive at 
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both baseline and follow-up (n = 14); dashed colored lines, PiB negative at baseline but positive at 
follow-up (n = 6); and solid black lines, PiB negative with discordant (low) cerebrospinal fluid Aβ 
measures at baseline and follow-up (n = 2). Colored solid and dashed lines are each differently colored 
only to facilitate visual comparisons across all analytes for each PiB-positive individual. 
Figure 2.5. Association Between Longitudinal Patterns of Cerebrospinal Fluid Biomarkers 
Visinin-Like Protein 1 (VILIP-1) and Chitinase-3-Like Protein 1 (YKL-40), Cortical Amyloid, 
and Age 
A subset (n = 74) of Adult Children Study participants had undergone longitudinal amyloid imaging via 
Pittsburgh compound B (PiB) positron emission tomographic imaging within 376 days (mean [SD], 84.3 
[92] days) of cerebrospinal fluid collection. Biomarker measures include VILIP-1 (A) and YKL-40 (B). 
Being PiB positive was defined as having a mean cortical PiB standardized uptake value ratio higher than 
1.42 (see dashed horizontal line in Figure 3A). Gray lines indicate PiB negative at baseline and follow-up 
(n = 52); solid colored lines, PiB positive at both baseline and follow-up (n = 14); dashed colored lines, 
PiB negative at baseline but positive at follow-up (n = 6); and solid black lines, PiB negative with 
discordant (low) cerebrospinal fluid β-amyloid measures at baseline and follow-up (n = 2). Colored solid 
and dashed lines are each differently colored only to facilitate visual comparisons across all analytes for 
each PiB-positive individual. 
2.4.6 Aβ42 Cutoff as Estimated Using PiB at Baseline 
Using only baseline CSF and PiB obtained within 376 days (mean [SD], 89.9 [95] days), a 
slightly larger subcohort of 105 participants was used to calculate a cutoff for CSF Aβ42 
(INNOTEST) based on PiB positivity. The optimal cutoff in this cohort is 1041 pg/mL 
(sensitivity = 1; specificity = 0.82), with an area under the receiver operating characteristic curve 
of 0.9352 (95% CI, 0.8895-0.9808).  
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2.4.7 Case Study of Participants Who Received a CDR Higher Than 0 at 
Clinical Follow-up 
Biomarker studies in cognitively normal elderly cohorts have demonstrated prognostic utility of 
baseline CSF measures for predicting future cognitive decline. To assess whether this 
relationship exists even earlier in the preclinical stages (during middle-age), as a preliminary 
analysis we compared the biomarker trajectories in participants who received a CDR higher than 
0 at some point during clinical follow-up with those who retained a CDR of 0. Of the 169 
participants evaluated, all of whom were cognitively normal (CDR of 0) at the time of baseline 
CSF collection, 14 received a CDR of 0.5 at some point during follow-up (mean [SD], 6.55 
[1.94] years; median, 6.15 years; range, 4.21-10.28 years), and 3 of these progressed further to a 
CDR of 1. The remaining 155 participants had a CDR of 0 at all follow-up (mean [SD], 6.01 
[1.94] years; median, 6.21 years; range 0.98-11.32 years). The duration of follow-up did not 
differ significantly between the groups (P > .05). All individuals who progressed to a CDR 
higher than 0 were older than 61 years at baseline. There was no apparent relationship between 
baseline or longitudinal trajectories of Aβ40 and cognitive status (Figure 2.6A). In contrast, the 
majority of progressors exhibited low Aβ42 (Figure 2.6B) and Aβ42 to Aβ40 ratio (Figure 
2.6C) at baseline and follow-up and high total tau and total tau to Aβ42 ratio (Figure 2.6D and 
E). Patterns of VILIP-1 and YKL-40 did not appear to differ between the clinical groups (Figure 
2.6F and G). However, the number of clinical progressors is too small to perform rigorous 
statistical analyses in the current cohort. 
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Figure 2.6 Cerebrospinal Fluid Biomarker Trajectories in Participants Receiving a Clinical Dementia Rating Higher Than 0 at Some 
Point During Clinical Follow-up 
Within-person trajectories of cerebrospinal fluid β-amyloid 40 (Aβ40) (A), Aβ42 (B), total tau (C), total tau to Aβ42 ratio (D), visinin-like protein 
1 (VILIP-1) (E), and chitinase-3-like protein 1 (YKL-40) (F) are plotted as a function of age. The Aβ40, Aβ42, and total tau were analyzed by 
INNOTEST enzyme-linked immunosorbent assay (Fujirebio Europe). Fourteen individuals received a Clinical Dementia Rating of 0.5 or 1 at 
some point during follow-up (mean [SD], 6.55 [1.94] years; range, 4.21–10.28 years). Orange lines indicate individuals who received a Clinical 
Dementia Rating higher than 0 at available follow-up visits; gray lines, individuals who did not receive a Clinical Dementia Rating higher than 0. 
57 
 
2.5 Discussion 
Our results demonstrate the following: (1) levels of CSF Aβ42 in some cognitively normal 
individuals decrease over time, starting as young as early middle age (45-54 years); (2) in mid 
middle-age (55-64 years), reductions in Aβ42 are associated with the development of PiB-
positive amyloid plaques; (3) elevations in neuronal injury markers total tau, P-tau181, and (to a 
lesser extent) VILIP-1 increase dramatically in some individuals in mid and late (65-74 years) 
middle-age; (4) the gliosis/neuroinflammation marker YKL-40 increases throughout middle-age; 
(5) these biomarker changes are observed in both risk groups defined by APOE genotype but are 
more evident in ε4 carriers and (for amyloid-related measures) in an allele dose-dependent 
manner; and (6) these AD-consistent trajectories are not clinically benign but instead are 
associated with future cognitive decline. These observations were confirmed in both evaluated 
immunoassays for Aβ42 and total tau. 
Reductions in CSF Aβ42 concentration within certain individuals throughout middle-age suggest 
an ongoing pathological process that for some people starts quite early (ages 45-54 years). 
Levels may begin to decrease even earlier, but additional investigation in younger cohorts is 
needed to test this hypothesis. During middle-age, the timing of this decrease is influenced by ε4 
allele dosage, consistent with studies demonstrating a major influence of APOE genotype on Aβ 
aggregation and clearance196,197. Baseline and follow-up Aβ42 levels are among the lowest in ε4 
homozygotes compared with heterozygotes and ε4 noncarriers, with reduction evident at earlier 
ages. Such effects are consistent with the ε4 dosage effects on age at dementia onset198. 
Regardless of when Aβ42 levels begin to decrease during the preclinical period, these decreases 
did not coincide with the presence of amyloid detectable by PiB PET until mid middle-age. The 
Aβ42 level was stably low or beginning to decline in some individuals while cortical PiB binding 
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was still below the threshold of positivity, and PiB binding did not begin to increase until the 
CSF Aβ42 level was already relatively low. Thus, it seems likely that Aβ42 aggregation can be 
detected earlier with CSF analysis than with cortical PiB PET imaging, consistent with recent 
studies in autosomal dominant AD27,199. This is highlighted by 2 high-risk early middle-aged ε4 
homozygotes who had stable, low Aβ42 levels (and Aβ42 to Aβ40 ratios) in longitudinal 
samples but were PiB negative. This observation may reflect sequestration of Aβ42 into 
oligomeric forms undetectable with the current assays or its deposition in nonfibrillar (PiB-
negative) diffuse plaques. In support of the latter, low CSF Aβ42 concentration in the absence of 
PiB positivity has been reported in a case in which numerous diffuse plaques, but few neuritic 
plaques, were observed at autopsy200. However, the early middle-age bin of the longitudinal PiB 
subcohort is quite small; subregional PiB analyses and evaluation of future longitudinal PiB scan 
in ACS participants are necessary to rigorously evaluate PiB changes in early middle-age.  
The calculated CSF Aβ42 cutoff in this cohort is quite high at 1041 pg/mL, higher than 
previously reported using the INNOTEST kit (typically 450-650 pg/mL)17,20,201. This apparent 
discrepancy may reflect the younger age of the ACS cohort. Most likely it reflects the fact that 
we used a newer modified, improved INNOTEST assay. This cutoff is not suggested for clinical 
use but was instead provided to evaluate amyloid positivity using CSF measures – similar to 
protocols being considered for enrollment in AD prevention trials. Using this cutoff, 51 of the 
169 participants (30%) would be considered amyloid positive and eligible for clinical trial 
enrollment based on baseline CSF Aβ42 concentration alone. Further longitudinal follow-up is 
needed to determine what percentage of these individuals will present with cognitive decline, 
which will in turn enable analysis of the efficacy of CSF Aβ42 concentration at baseline for 
determination of preclinical AD.  
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In contrast to the early changes in Aβ42, increases in total tau, P-tau181, and VILIP-1 are 
typically not apparent until later (ages ≥55 years). Notably, the rate of increase was significantly 
greater in the ε4-carrying at-risk group during mid middle-age, coincident with continuing, 
robust decreases in Aβ42 level. It was in this age range that many participants with the AD 
biomarker pattern began to exhibit cognitive decline. Interestingly, the absolute slopes (ie, rates 
of increase) of these neuronal injury markers in the ε4 carriers actually decreased from mid to 
late middle-age. This pattern is consistent with a potential slowing of an earlier robust phase of 
neuronal injury or perhaps reflects neuronal dysfunction that adversely affects the normal 
cellular secretion or release of these proteins. It will be interesting to determine whether this 
pattern is also observed in those at lower risk (ε4 noncarriers), albeit at older ages, how it 
compares with proposed early markers of synaptic function currently in development, and 
whether this proposed slowing continues into the symptomatic phase as has been reported in 
individuals with autosomal dominant AD64 and late-onset AD dementia202. The rate accelerations 
in these markers at mid middle-age observed here in the at-risk group are consistent with the 
concept of an age-related transition between stage 1 (amyloid alone) and stage 2 (amyloid plus 
neuronal injury) of preclinical AD proposed by the National Institute on Aging-Alzheimer’s 
Association Preclinical AD Working Group203. Although these proposed stages are currently 
defined by biomarker measures obtained at a single point in time, it is possible that a longitudinal 
biomarker metric may have more utility. This hypothesis awaits further investigation.  
The consistent pattern of increases in YKL-40 level in all age bins suggests that 
neuroinflammation/gliosis (the hypothesized cause of the increase in YKL-40 level) is a process 
that occurs normally with aging. However, the particularly robust increases observed in at-risk ε4 
carriers during mid middle-age suggest that this age-related process may be further exacerbated 
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in the presence of insults including amyloid deposition and neuronal injury. Whether this 
neuroinflammatory process contributes to the concomitant increase in neuronal injury remains to 
be determined.  
This study is not without limitations. As by design the ACS cohort enrolls participants with and 
without family history of AD for longitudinal imaging and CSF biomarker studies, participants 
may not be representative of the general population. Despite the large number of participants in 
this unique cohort, there are fewer in the ε4-carrying group, and most participants at the time of 
analysis had only 2 longitudinal samples available. While some individuals had 10 years of 
clinical follow-up, others had only 4. Although the results provide support for a scenario in 
which changes in amyloid-related processes precede those of tau or other neurodegeneration-
related processes, additional analyses during a longer period are required to determine the precise 
sequence of biomarker changes within a given individual. Furthermore, as expected in such a 
young, asymptomatic cohort, relatively few participants in this initial report had received a CDR 
greater than 0 during follow-up. Continued evaluation of longer clinical follow-up will provide 
an opportunity to better elucidate the biomarker patterns in middle-age that predict future 
cognitive decline.  
2.5.1 Conclusions 
The present groupwide analyses are supportive of a preclinical period of AD in which biomarker 
patterns consistent with underlying disease pathology are first detectable during middle-age, the 
timing of which is influenced by APOE genotype, with amyloid changes occurring prior to 
neuronal injury. However, proposals to use biomarkers in clinical settings require demonstration 
of their utility on a patient-by-patient basis. Importantly, our preliminary findings of an 
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association between CSF biomarker positivity in specific individuals who go on to develop 
cognitive deficits within a few years provide support for such potential use.   
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Chapter 3: Longitudinal Decreases in 
Multiple Cerebrospinal Fluid Biomarkers of 
Neuronal Injury in symptomatic Late Onset 
Alzheimer’s Disease 
This work is currently under review. 
3.1 Abstract 
Introduction  
Individuals in early stages of Alzheimer’s disease (AD) are a targeted population for secondary 
prevention trials aimed at preserving normal cognition. Understanding within-person 
biomarker(s) change over time is critical for trial enrollment and design. 
Methods 
Longitudinal cerebrospinal fluid (CSF) samples from the Alzheimer’s Disease Neuroimaging 
Initiative were assayed for novel markers of neuronal/synaptic injury (VILIP-1, Ng, SNAP-25) 
and neuroinflammation (YKL-40) and compared with Aβ42, Tau, and P-Tau181. General linear 
mixed models were used to compare within-person rates of change in three clinical groups 
(cognitively normal, mild cognitive impairment and AD) further defined by β-amyloid status. 
Results 
Levels of injury markers were highly positively correlated. Despite elevated baseline levels as a 
function of clinical status and amyloid-positivity, within-person decreases in these measures 
were observed in the early symptomatic, amyloid-positive AD group. 
Discussion 
Knowledge of within-person biomarker change will impact interpretation of biomarker outcomes 
in clinical trials that are dependent on disease stage. 
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3.2 Introduction 
Clinical trials of potential disease-modifying therapies for Alzheimer’s Disease (AD) have 
failed to slow cognitive decline in patients who have dementia or milder cognitive symptoms 
(e.g., mild cognitive impairment, MCI)169. Since AD pathology begins to develop ~20 years 
before cognitive decline (preclinical AD)27,204, it is possible that trial participants were too far 
along in the disease process for such therapies to impact cognition. Therefore, individuals at 
earlier stages, including the asymptomatic, preclinical stage (defined by biomarkers), are now 
receiving intense focus for secondary prevention trials aimed at preserving normal cognitive 
function. Understanding the patterns of biomarker(s) change over time is critical for defining 
where individuals fall along the pathologic disease cascade. 
Cross-sectional studies indicate that β-amyloid (Aβ)-related biomarkers become abnormal 
first, followed by markers of tau-related neuronal injury, both during the preclinical period205. 
Elevated injury markers in the presence of amyloid positivity then become a strong predictor of 
subsequent cognitive decline44. Interestingly, while regional brain atrophy then ensues, with 
abnormality increasing with symptomatic progression206, a recent study of individuals with 
autosomal dominant AD (ADAD) reported longitudinal decreases in CSF levels of neuronal 
injury markers including Tau, P-Tau181 and visinin-like protein 1 (VILIP-1) in symptomatic 
mutation carriers64, suggesting a slowing of acute neurodegenerative processes and/or a decrease 
in the number of viable neurons contributing to the pools of these markers in this later stage of 
the disease. Regardless of the mechanism, if confirmed in an independent cohort of persons 
developing late onset AD (LOAD), such a pattern will likely have an impact on interpretation of 
biomarker outcomes in clinical trials that is dependent on the disease stage. To this end, the 
present study evaluated the patterns of within-person longitudinal change in a variety of standard 
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(Tau, P-Tau181) and novel (VILIP-1, neurogranin, SNAP-25) CSF neuronal injury biomarker 
levels in individuals spanning the full range of AD, including normal, preclinical AD, MCI due 
to AD and symptomatic AD, and a comparison of these changes with regional brain atrophy and 
cognitive decline. 
3.3 Methods 
ADNI Study Design 
CSF Aβ42, total tau (Tau) and phospho-tau181 (P-Tau), demographic, imaging and cognitive 
data were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database 
(http://adniloni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, led by 
Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test 
whether serial magnetic resonance imaging (MRI), biological markers, and clinical and 
neuropsychological assessment can be combined to measure the progression of mild cognitive 
impairment (MCI) and early AD. ADNI participants have been recruited from more than 50 sites 
across the USA and Canada. Regional ethical committees of all institutions approved of the 
study, and all participants provided written informed consent. For up-to-date information, see 
www.adni-info.org.  
Study Participants 
The ADNI cohort in the present study consisted of all cognitively normal (CN) 
participants and those with MCI or AD dementia (AD) with available CSF samples from at least 
two visits as of April 2012. This cohort included 152 individuals across ADNI1, ADNI GO and 
ADNI2 (n=56 CN, n=73 MCI, n=17 AD). Demographic and cognitive data were downloaded in 
August 2015 and were collected as described (adni.loni.usc.edu/methods/documents/). By 
definition, individuals in the CN group all had a clinical dementia rating (CDR) score of 0 at the 
time of lumbar puncture (LP) and a Mini-Mental State Examination (MMSE) score ≥ 24. 
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Individuals with MCI also scored ≥ 24 on the MMSE but exhibited subjective memory loss (>1 
standard deviation below the normal mean of the delayed recall of the Wechsler Memory Scale 
Logical Memory II), received a CDR of 0.5, preserved activities of daily living and the absence 
of dementia. The AD group met the definition of probable AD according to criteria established 
by the National Institute of Neurological and Communicative Disorders and Stroke and the 
Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA)207, had MMSE 
scores of 20-26 and CDRs of 0.5 or 1.  Groups were designated by clinical diagnosis at the time 
of initial available CSF sample in the longitudinal cohort (defined herein as baseline). 
ADNI Clinical, CSF and Imaging Data 
Scores for MMSE and Alzheimer’s Disease Assessment Scale-cognitive 11 (ADAS11) and 
ADAS13 were downloaded from the LONI site in August 2015 via ADNIMerge R Package. 
Values for CSF Aβ42 (INNOBIA AlzBio3; Fujirebio, Ghent, Belgium) were downloaded at the 
same time from two datasets (UPENNBIOMK4 and UPENNBIOMK6) and were used to define 
amyloid-positivity based on a published, autopsy-confirmed cut-off value (<192 pg/ml)208. For 
statistical analyses, values for Aβ42, total Tau (Tau) and Ptau181 (P-Tau) generated by a single 
lot number of the novel, fully automated, electrochemiluminescent Elecsys® immunoassays 
(Roche Diagnostics, Basel, Switzerland) were downloaded from the LONI site in March 2017 
from a single dataset (UPENNBIOMK9). The Elecsys® system aims to offer a fully automated 
CSF biomarker test for AD capable of achieving In Vitro Diagnostic (IVD) capability and offers 
some improvements over current Research Use Only (RUO) assays including: reduction in 
manual steps, improved precision and accuracy both within labs and between labs, and improved 
lot-to-lot reagent performance. The Elecsys® Aβ42 immunoassay in use is not a commercially 
available IVD assay. It is an assay currently under development and for investigational use only. 
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The measuring range of the assay is 200 (lower technical limit) – 1700 (upper technical limit) 
pg/ml. The performance of the assay beyond the upper technical limit has not been formally 
established. Therefore, values above the upper technical limit have been truncated at 1700 pg/ml. 
In the current study, baseline analyses excluded these data. Longitudinal statistical analyses were 
run with and without these truncated values and performed nearly identically.  
Magnetic resonance imaging (MRI) data for the left and right hippocampal (HP) volume (white 
matter parcellation) and left and right entorhinal cortex (EC) thickness, two regions known to be 
affected early in AD, were also analyzed. EC thickness and HP volume were downloaded in 
November 2016 from the file UCSFFSL_02_01_16. Acquisition of 1.5 Tesla MRI and data 
processing methods are as described (adni.loni.usc.edu/methods/mri-analysis/). Data were 
processed with FreeSurfer v4.4, and only values that passed all quality control (QC) standards 
were included in the analyses. Values for left and right HP and EC thickness were added together 
to create a value for “total” HP volume and EC thickness. 
Novel CSF Analytes 
Samples were analyzed for YKL-40 (also known as chitinase 3-like 1, a marker of 
gliosis/neuroinflammation)209, visinin-like protein 1 (VILIP-1, a neuronal calcium sensor protein 
and marker of neuronal injury)210, neurogranin (Ng, a post-synaptic protein and marker of 
synaptic dysfunction)106 and synaptosomal-associated protein 25 (SNAP-25, a pre-synaptic 
protein and marker of synaptic dysfunction) [19]. YKL-40 was measured with a plate-based 
enzyme-linked immunoassay (ELISA) (MicroVue ELISA; Quidel, San Diego, CA)31. VILIP-
161,62, NG63,69 and SNAP-25 were measured using microparticle-based immunoassays using the 
Singulex (now part of EMD-Millipore; Alameda, CA) Erenna system, and employed antibodies 
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developed in the laboratory of Dr. Jack Ladenson at Washington University. All samples (each 
on the same freeze/thaw cycle) were run in triplicate on a single lot number for VILIP-1, SNAP-
25 and Ng and in duplicate for YKL-40. Within-person longitudinal samples were run on the 
same assay plate to reduce inter- and intra-plate variability. Quality control for VILIP-1, SNAP-
25 and Ng included analysis of three internal standard CSF pools run on each plate and two 
internal pools for YKL-40. See Appendix for assay details.  
Statistical Analysis 
Since the study intent was to compare baseline biomarker levels and their longitudinal change 
over time in individuals who span the AD continuum (from no disease [normal], to preclinical 
AD, to MCI due to AD, to AD), participants in the three diagnostic categories (CN, MCI, AD) 
were further stratified into β-amyloid-positive (Aβ+) versus amyloid-negative (Aβ-) at baseline 
based on the published ADNI CSF Aβ42 cut-off of <192pg/mL208. Baseline characteristics for 
the five resultant groups (CN-, CN+, MCI-, MCI+, AD+) were summarized as mean (standard 
deviation [SD)]) for continuous variables or number (percentage) for categorical variables. 
Group differences among the various measures were assessed using one-way ANOVA and post-
hoc Tukey tests. Correlations between measures were assessed via Spearman correlation. 
Biomarker concentrations, cognitive performance and MRI measures within individuals over 
time were compared among the five groups (all AD individuals were Aβ+) by general linear 
mixed models with random intercepts/slopes at the subject level to allow estimation and 
comparison of within-person rates of change211. In addition to the mean intercept and slope for 
each group (unadjusted models), covariates including age at baseline, APOE ε4 carriage, sex, 
education, and their interactions with subject groups on the intercepts and slopes, were also 
included as fixed effects (see Appendix). All general linear mixed models assumed a subject 
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level random effect on intercept and slope and were fitted using the maximum likelihood 
method. Statistical tests were based on the approximate F or t- tests with denominator degrees of 
freedom approximated by the Satterthwaite methods212. All analyses were performed with SAS 
version 9.4 (SAS Institute Inc.), with statistical significance defined as p < 0.05. 
3.4 Results 
3.4.1 Demographics 
Of the 152 ADNI participants who met the criteria for having longitudinal CSF samples (range 
2-7 LPs over 1-7 years of follow up [mean (SD) = 4.0 (1.62)] and a mean (SD) LP interval of 16 
(8.6) months), four were omitted from the dataset due to missing values for CSF Aβ42 (via 
AlzBio3) required to define baseline amyloid status (Aβ+ vs Aβ-). Participants in the final 
dataset of n=148 were 38% female, between 58 and 90 years of age at the time of initial LP 
(mean [SD] = 75 [7.13]), and 68% were APOE ε4-positive (Table 1). As expected, baseline HP 
volume and EC thickness were different among the groups (CN>MCI>AD) (p<0.0001). 
Performances on MMSE, ADAS11 and ADAS13 were also as expected, with the MCI and AD 
groups performing worse than the CN group (p<0.0001).  
When the clinical groups were dichotomized into amyloid-positive (Aβ+) and amyloid-
negative (Aβ-)208), neuronal injury/inflammation biomarker levels were higher (more AD-like) 
in the Aβ+ compared to the Aβ- groups, both among and within each clinical group (Table 2). 
Positive correlations were observed among the injury markers at baseline, strongest among tTau, 
VILIP-1 and Ng (Spearman r= 0.798-0.853) (Appendix Table 1). SNAP-25 was moderately 
correlated with the other injury markers (r= 0.619-0.720), and as expected, Tau and P-tau 
exhibited the highest positive correlation (r= 0.975). Elecsys Aβ42 was positively correlated with 
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AlzBio3 Aβ42 (r=0.869) and negatively correlated with Tau, P-tau and SNAP-25 (r=-0.214, -
0.324 and -0.240, respectively). YKL-40 was significantly, but weakly, correlated with the injury 
markers (r= 0.307-0.422) but not Aβ42. 
Table 3.1 Study Demographics 
A – Significantly different from CN Aβ- 
B – Significantly different from CN Aβ+ 
C – Significantly different from MCI Aβ- 
D – Significantly different from MCI Aβ+ 
E – Significantly different from AD Aβ+ 
 
Abbreviations: Aβ, amyloid-β status; AD, Alzheimer disease; ADAS 11; Alzheimer’s Disease Assessment 
Scale-cognitive test, version 11 (higher score is worse performance; ADAS 13, Alzheimer’s Disease 
Assessment Scale-cognitive test, version 13 (higher score is worse performance); APOE, apolipoprotein E; 
CDR, Clinical Dementia Rating score; CDR-SB, CDR sum of boxes; CN, cognitively normal; EC, entorhinal 
cortex; HP, hippocampus; LP, lumbar puncture; MCI, mild cognitive impairment; MMSE, Mini-Mental 
State Examination 
  
AD
Aβ- Aβ+ Aβ- Aβ+ Aβ+
N 35 21 18 58 16
Baseline age, mean (SD) 76 (5.7) 76 (3.7) 77 (7.3) 74 (6.5) 74 (6.7)
Gender, F/M (%F) 14/21 (40%) 10/11 (48%) 4/14 (22%) 18/40 (31%) 11/6 (65%)
Education, mean (SD), y 16 (3.1) 16 (3.4) 17 (1.8) 16 (2.8) 15 (3.0)
APOE  ε4 allele, +/- (%+) 3/32 (9%) 9/12 (43%) 0/18 (0%) 40/18 (69%) 13/4 (77%)
# CDR 0/0.5/1, n 35/0/0 21/0/0 0/18/0 0/57/1 0/10/6
CDR-SB, mean (SD) 0.029 (0.12)C-E 0.024 (0.11)C-E 1.25 (0.55)A,B,E 1.61 (0.85)A,B,E 4.24 (1.49)A-D
MMSE, mean (SD) 29.1 (1.1)C-E 29.4 (0.9)C-E 27.6 (1.8)A,B,E 26.8 (1.8)A,B,E 23.7 (1.7)A-D
ADAS 11, mean (SD) 5.3 (2.2)C-E 7.1 (3.3)D,E 9.9 (4.1)A,E 11.7 (5.1)A,B,E 18.7 (6.1)A-D
ADAS 13, mean (SD) 8.4 (3.5)C-E 10.5 (3.9)D,E 15.5 (5.9)A,E 19.5 (7.1)A,B,E 28.9 (7.4)A-D
# LP's  2/3/4/5/6/7, n 0/15/7/8/5/0 0/8/6/4/3/0 0/5/10/2/1/0 2/26/18/5/6/1 1/9/5/1/0/0
LP interval, mean (SD), 
mo 17.01 (9.44)
E 17.55 (10.40)E 16.92 (8.98) 15.90 (7.92) 12.73 (2.86)A,B
LP follow-up, mean (SD, 
Range), mo 52.9 (19.7, 23-86)
E 55.0 (17.0, 26-85)E 49.8 (17.9, 24-87)E 45.0 (18.9, 16-86)E 30.2 (10.2, 12-50)A-D
Total EC thickness, mean 
(SD), mm 6.88 (0.84)
C-E 6.88 (0.95)C-E 6.32 (0.96)A,B,E 6.44 (0.87)A,B,E 5.26 (0.82)A-D
Total HP volume, mean 
(SD), mm3
6577 (815)C-E 6553 (886)C-E 5818 (978)A,B,E 5861 (880)A,B,E 5117 (848)A-D
CN MCI
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3.4.2 Patterns of Neuronal Injury and Neuroinflammatory Markers 
Participant-level CSF biomarker trajectories were plotted for each of the five amyloid-defined 
clinical groups (see Appendix Figure 1 for spaghetti plots). General linear mixed models (with 
random intercepts/slopes at the subject level) were then used to estimate and compare baseline 
biomarker levels and within-person rates of change in the five groups. Results adjusting for sex, 
APOE ε4 status, education, baseline age, and total ventricular volume are provided in the 
Appendix. 
Elecsys® tTau 
Baseline Tau levels were significantly elevated in the AD+ group compared to all other groups 
(all p≤0.01) and the MCI+ compared to the MCI- and CN- (p<0.0001) and  CN+ groups (p=0.02) 
(Table 2). Longitudinally, Tau levels significantly increased in both CN (both p<0.05) and the 
MCI+ groups (p<0.0001) (Figure 1, Table 2). Tau levels decreased longitudinally in the AD+ 
group, but this change did not reach statistical significance (p=0.095). 
Elecsys® pTau 
P-tau levels at baseline were significantly elevated in the AD+ compared to all other groups (all 
p<0.01), MCI+ compared to MCI- and CN- (both p<0.0001) and CN+ groups (p=0.02), and the 
CN+ compared to the MCI- and CN- groups (both p<0.03) (Table 2). Longitudinally, P-tau 
levels significantly increased in the CN+ (p=0.001) and trended toward increase in the MCI+ 
group (p=0.055). Strikingly, P-tau levels significantly declined in the AD+ group (p≤0.0001) 
(Figure 1, Table 2), with rate of change greater than the change in all other groups (p<0.001). 
VILIP-1 
Levels of baseline VILIP-1 were significantly higher in the MCI+ and AD+ compared to both 
the MCI- and CN- groups (all p≤0.01) (Table 2). The amyloid-positive groups did not differ 
from one another (all p>0.05). Longitudinally, as with P-tau, VILIP-1 levels strongly and 
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significantly decreased in the AD+ group (p=0.006), whereas no significant changes were 
observed in the other groups (Figure 1, Table 2).  
SNAP-25 
SNAP-25 values at baseline were significantly higher in the AD+ and MCI+ compared to the 
CN- (both p<0.0003), CN+ (p=0.001 and p=0.01, respectively), and MCI- groups (both 
p<0.0001) (Table 2). Longitudinally, SNAP-25 levels declined significantly in the AD+ group 
(p=0.05), whereas no significant changes were observed in the other groups (Figure 1, Table 2). 
Ng 
Baseline levels of Ng were significantly higher in the AD+ group than the CN- (p=0.003), CN+ 
(p=0.02), and MCI- (p=0.0006) groups, although not between the MCI+ and AD+ groups 
(p=0.10) (Table 2). Levels were also higher in the MCI+ compared to the CN- (p=0.004) and 
MCI- (p=0.02) groups. Longitudinally, Ng markedly and significantly decreased in the AD+ 
group (p<0.0001), whereas no significant changes were observed in the other groups (Figure 1, 
Table 2).  
YKL-40 
In contrast to the markers of neuronal injury, baseline levels and longitudinal patterns of change 
in the neuroinflammatory marker, YKL-40, exhibited a large degree of within-group variability. 
Baseline YKL-40 was significantly higher in the AD+ compared to the MCI- (p=0.04) but not 
the other groups (Table 2). Longitudinally, all groups showed an increase in mean levels over 
time, but this increase was statistically significant only in the MCI+ group (p=0.03) (Figure 1, 
Table 2), perhaps due to less variability (smaller SD) within that group. 
Elecsys® Aβ42 
Although CSF Aβ42 (as measured in ADNI by AlzBio3) was used a priori to define amyloid 
status in the clinical groups, we were also interested in evaluating the patterns of this biomarker 
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using the novel Elecsys® platform. As expected, baseline Aβ42 levels (via Elecsys®) were 
significantly lower in all Aβ+ compared to Aβ42- groups (all p<0.0001) (Table 2). 
Longitudinally, levels decreased in all groups (and at similar rates), although only the AD+ and 
CN- groups reached statistical significance (p=0.04 and p=0.0004, respectively) (Figure 1, 
Table 2). 
Table 3.2 Baseline CSF biomarker levels and estimated within-person annual change over time 
 
A – Significantly different from CN Aβ- 
B – Significantly different from CN Aβ+ 
C – Significantly different from MCI Aβ- 
D – Significantly different from MCI Aβ+ 
E – Significantly different from AD Aβ+ 
F – Statistically significant slope 
AD
Aβ- Aβ+ Aβ- Aβ+ Aβ+
N 35 21 18 58 16
Baseline CSF Biomarkers
Elecsys Aβ42, mean (SD), pg/ml 1413 (284)B,D,E 687 (274)A,C 1404 (318)B,D,E 590 (187)A,C 578 (214)A,C
Elecsys tTau, mean (SD), pg/ml 230 (70.8)D,E 272 (84.9)D,E 215 (68.2)D,E 331 (117.5)A-C,E 407 (167.5)A-D
Elecsys pTau, mean (SD), pg/ml 20.3 (6.30)B,D,E 27.4 (9.56)A,C-E 18.1 (5.83)B,D,E 33.7 (13.62)A-C,E 42.8 (19.90)A-D
VILIP-1, mean (SD), pg/ml 143.3 (44.9)D,E 152.6 (49.8) 140.5 (50.2)D,E 176.7 (61.0)A,C 185.6 (70.1)A,C
SNAP-25, mean (SD), pg/ml 4.45 (1.5)D,E 4.66 (1.4)D,E 3.72 (1.3)D,E 6.01 (2.2)A-C 6.84 (3.3)A-C
Ng, mean (SD), pg/ml 2302 (1066)D,E 2339 (953)E 1962 (945)D,E 2836 (1426)A,C 3383 (1576)A-C
YKL-40, mean (SD), ng/ml 384.1 (20.08) 399.6 (19.4) 361.6 (19.4)E 401.3 (17.87) 471.9 (41.86)C
CSF Biomarker Estimated Annual Slope
Elecsys Aβ42, pg/ml (SE) -20.91 (5.6) -7.96 (7.27) -2.38 (8.4) -7.82 (5.17) -29.48 (14.2)
p value 0.0004F 0.28 0.78 0.13 0.039F
Elecsys tTau, pg/ml (SE) 4.29 (2.1)E 6.75 (2.7)E 1.10 (3.1) 7.55 (1.8)E -7.11 (4.2)A,B,D
p value 0.048F 0.015F 0.72 <0.0001F 0.095
Elecsys pTau, pg/ml (SE) 0.39 (0.2)E 0.88 (0.3)C,E 0.028 (0.3)B,E 0.35 (0.2)E -1.65 (0.4)A-D
p value 0.069 0.0013F 0.93 0.055 <0.0001F
VILIP-1, pg/ml (SE) -0.23 (1.0)E 0.89 (1.2)E -0.21 (1.4)E -0.96 (0.9)E -6.31 (2.3)A-D
p value 0.81 0.48 0.88 0.27 0.006F
SNAP-25, pg/ml (SE) -0.0453 (0.042) 0.00279 (0.053) 0.00715 (0.060) -0.0387 (0.037) -0.172 (0.088)
p value 0.28 0.96 0.91 0.29 0.05F
Ng, pg/ml (SE) -2.74 (26.1)E 19.88 (33.6)E 15.5521 (38.2)E -38.6334 (23.6)E -232.43 (58.9)A-D
p value 0.92 0.56 0.68 0.10 <.0001F
YKL-40, ng/ml (SE) 4.51 (3.5) 6.29 (4.3) 5.54 (4.9) 6.37 (3.0) 1.68 (7.1)
p value 0.20 0.15 0.26 0.035F 0.81
CN MCI
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Bold – Slope that is statistically different from zero 
All significance at least p<0.05 
 
Abbreviations: Aβ, amyloid-β status; AD, Alzheimer disease; CN, cognitively normal; MCI, mild cognitive 
impairment; Ng, neurogranin; P-tau, phospho-tau181; SNAP-25, synaptosomal associated protein-25; 
Tau, total tau; VILIP-1, visinin-like protein 1 
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Figure 3.1 Baseline Biomarker Values and Estimated Within-person annual Change in CSF 
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Baseline biomarker values (top panel) and estimated group slopes for Aβ42 (A), tTau (B), pTau (C), 
VILIP-1 (D), SNAP-25 (E), Ng (F), and YKL-40 (G). Baseline is shown for each individual, estimated 
group slopes are shown as average annual change in 5 bins defined by diagnostic group and amyloid 
status, extrapolated to show 5 years of change.   
A Different from CN- group 
B
 Different from CN+ group 
C Different from MCI+ group 
D Different from AD+ group 
E Different from MCI group 
* Different from 0. 
3.4.3 Cognitive Measures 
Cognitive Measures 
As expected, cognitive performance differed with clinical diagnosis, particularly in the Aβ+ 
symptomatic groups. Furthermore, Aβ+ individuals exhibited longitudinal changes in MMSE 
and ADAS11/13 that are consistent with a worsening of cognitive performance and often at a 
faster rate than the Aβ- groups. See Appendix Figure 2 for spaghetti plots.   
MMSE   
Baseline MMSE was lower (indicative of worse performance) in the AD+ group than any other 
group (all p<0.0001), lower in the MCI+ compared to the MCI- (p=0.03) and both CN groups 
(both p<0.0001), and in the MCI- compared to both CN groups (both p<0.03) (Table 3). In the 
AD+ and MCI+ groups, MMSE was decreasing significantly (both p<0.0001) and at a faster rate 
in the AD+ compared to the MCI+ group (p<0.0001) (Table 3).  
ADAS11 and ADAS13 
At baseline, ADAS11 was significantly elevated (indicating worse performance) in the AD+ 
compared to both CN groups (both p<0.0001), both MCI groups compared to both CN groups 
(both p<0.02), and in the AD+ compared to both MCI groups (both p<0.0001) (Table 3). 
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Longitudinally, ADAS11 score significantly increased in the AD+ and MCI+ groups (both 
p<0.0001) and at a significantly faster rate in the AD+ versus the MCI+ group (p<0.0001) 
(Table 3).  
Baseline ADAS13 performance was similar to ADAS11 except that the MCI+ group was also 
significantly elevated (worse performance) compared to the MCI- group (p=0.05) (Table 3). 
Longitudinally, ADAS13 was significantly increasing in all three Aβ+ groups (all p<0.004), at a 
faster rate in the AD+ compared to the MCI+ (p=0.0005) and CN+ (p<0.0001) groups, and at a 
faster rate in the MCI+ than the CN+ group (p=0.02) (Table 3).  
3.4.4 Volumetric MRI Measures 
As expected, HP volume and EC thickness were smaller at baseline in the AD+ compared to the 
other groups. However, all but the CN- group exhibited significant atrophy over time, albeit at 
different rates. See Appendix Figure 3 for spaghetti plots.   
Hippocampal Volume 
HP volume at baseline was significantly smaller in the AD+ compared to all other groups 
(p<0.001 for both CN groups; p=0.03 for both MCI groups) and in both MCI groups compared 
to the CN groups (MCI- vs CN- [p=0.003] and CN+ [p=0.01]; MCI+ vs CN- and CN+ [both 
p≤0.0007]) (Table 3). Longitudinally, all groups exhibited significant HP shrinkage over time 
(all p≤0.0001) (Table 3). Volume in the AD+ and MCI+ groups decreased at a significantly 
faster rate than in both CN groups (p≤0.003 and p≤0.001, respectively) and the MCI- group 
(p=0.04 and p=0.003, respectively). The rate of atrophy in the MCI- group was faster than the 
CN- group (p=0.0009) and in the CN+ compared to the CN- group (p=0.03).  
Entorhinal Cortex Thickness 
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At baseline, EC thickness was significantly smaller in the AD+ compared to all other groups 
(p≤0.0003), in the MCI+ compared to the CN groups (p=0.0004 for CN- and p=0.01 for CN+) 
(Table 3). MCI-was also significantly thinner than the CN- group (p=0.03) and at the 
significance level compared to the CN+ group (p=0.05). Longitudinally, EC thickness was 
declining in all but the CN- group (all p≤0.0003) and at a faster rate in the AD+ compared to the 
CN+ (p=0.005) and MCI- (p=0.007) groups (Table 3). The EC in the MCI+ group was also 
shrinking more quickly than the CN+ and MCI- groups (both p≤0.0001).  
Table 3.3 Baseline cognitive performance and imaging measures and estimated within-person 
annual change over time 
 
A – Significantly different from CN Aβ- 
B – Significantly different from CN Aβ+ 
C – Significantly different from MCI Aβ- 
D – Significantly different from MCI Aβ+ 
E – Significantly different from AD Aβ+ 
AD
Aβ- Aβ+ Aβ- Aβ+ Aβ+
N 35 21 18 58 16
Baseline Cognitive and Imaging Biomarkers
MMSE, mean (SD) 29.1 (1.1)C-E 29.4 (0.9)C-E 27.6 (1.8)A,B,D,E 26.8 (1.8)A-C,E 23.7 (1.7)A-D
ADAS 11, mean (SD) 5.3 (2.2)C-E 7.1 (3.3)C-E 9.9 (4.1)A,B,E 11.7 (5.1)A,B,E 18.7 (6.1)A-D
ADAS 13, mean (SD) 8.4 (3.5)C-E 10.5 (3.9)C-E 15.5 (5.9)A,B,D,E 19.5 (7.1)A-C,E 28.9 (7.4)A-D
Total EC thickness, mean (SD), 
mm 6.88 (0.84)
C-E 6.88 (0.95)C-E 6.32 (0.96)A,B,E 6.44 (0.87)A,B,E 5.26 (0.82)A-D
Total HP volume, mean (SD), 
mm3
6577 (815)C-E 6553 (886)C-E 5818 (978)A,B,E 5861 (880)A,B,E 5117 (848)A-D
Cognitive and Imaging Estimated Annual Slope
MMSE, points (SE) -0.051 (0.2)D,E -0.22 (0.2)D,E -0.039 (0.2)D,E -1.26 (0.1)A-C,E -2.49 (0.3)A-D
p value 0.76 0.30 0.87 <0.0001F <0.0001F
ADAS 11, points (SE) 0.20 (0.3)D,E 0.75 (0.4)D,E 0.30 (0.4)D,E 2.06 (0.3)A-C,E 4.74 (0.6)A-D
p value 0.52 0.06 0.50 <0.0001F <0.0001F
ADAS 13, points (SE) 0.37 (0.3)D,E 1.25 (0.4)D,E 0.53 (0.5)D,E 2.43 (0.3)A-C,E 4.98 (0.7)A-D
p value 0.27 0.0042F 0.27 <0.0001F <0.0001F
Total EC thickness, mm (SE) -0.0401 (0.022)B-E-0.118 (0.023)A,D,E-0.118 (0.031)A,D,E -0.261 (0.018)A-C -0.295 (0.057)A-C
p value 0.069 <0.0001F 0.0003F <0.0001F <0.0001F
Total HP volume, mm3 (SE) -59.4 (14.5)B-E -111.2 (18.2)A,D,E -145.9 (20.5)A,D,E -216.3 (11.9)A-C -230.8 (36.0)A-C
p value 0.0001F <0.0001F <0.0001F <0.0001F <0.0001F
CN MCI
78 
 
F – Statistically significant slope 
Bold – Slope that is statistically different from zero 
All significance at least p<0.05 
 
Abbreviations: Aβ, amyloid-β status; AD, Alzheimer disease; ADAS 11; Alzheimer’s Disease Assessment 
Scale-cognitive test, version 11 (higher score is worse performance); ADAS 13, Alzheimer’s Disease 
Assessment Scale-cognitive test, version 13 (higher score is worse performance); CN, cognitively normal;  
EC, entorhinal cortex; HP, hippocampal; MCI, mild cognitive impairment; MMSE, Mini-Mental State 
Examination (0-30, with 30 as perfect score) 
 
3.5 Discussion 
Our primary finding is the decrease over time in the concentration of several different CSF 
markers of neuronal injury (Tau, P-tau, VILIP-1, SNAP-25, Ng) in individuals once they have 
developed symptomatic AD. In contrast, elevations in Tau, but not the other injury markers, were 
observed at earlier stages (amyloid-positive MCI and CN groups). These findings replicate 
similar longitudinal patterns (for Tau, P-tau and VILIP-1) reported in a cohort of autosomal-
dominant AD64, thus supporting a commonality in neuropathologic processes in sporadic and 
genetic forms of the disease. Knowledge of such within-person patterns of change has important 
implications for clinical trials in MCI and early stage AD in terms of the use of biomarker 
concentrations as pathologic endpoints in determining treatment efficacy for neuronal integrity. 
While all the injury markers decreased over time in the AD+ group, the reduction in Ng was 
especially robust. Neurogranin is a calmodulin-binding postsynaptic neuronal protein213,214 
thought to be involved in activity-dependent synaptic plasticity and long-term potentiation215. 
Levels are reduced in AD brain216,217 and elevated in AD CSF73,106 , with high levels predictive 
of progression from mild cognitive impairment (MCI) to AD dementia68,69,72,218. Since elevations 
in CSF Ng are associated with brain atrophy69,218 and reduced brain glucose uptake218, it is 
considered a marker of synaptic dysfunction/loss. 
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Although less is known about SNAP-25 (a pre-synaptic t-SNARE molecule that plays a crucial 
role in calcium-dependent exocytosis of synaptic vesicles) in AD, like Ng, levels are reduced in 
brain219 and elevated in CSF80 compared to controls. Although both synaptic markers were 
decreasing longitudinally in the AD+ group, Ng was dropping at more than twice the rate as 
SNAP-25 (annual decreases of 6.9% vs 2.5%, respectively) and the other markers (1.8% Tau, 
3.9% P-tau, and 3.4% VILIP). Interestingly, Aβ42 was also significantly decreasing annually by 
5% in the early AD+ group but less so in the other groups. Although levels of Aβ42 are known 
to drop early in the disease and then plateau as amyloid continues to accumulate204, 63% (10/16) 
of individuals in the current AD group were at very early symptomatic stages (CDR 0.5). 
Baseline levels of YKL-40, an astrocyte-derived protein with presumed neuroinflammatory 
properties220, also increased with clinical severity as reported previously221, but we observed a 
high level of within-group variability in longitudinal patterns. It is likely that YKL-40 reflects 
neuroinflammatory components not specifically due to AD. Interestingly, levels appeared to 
increase with age in the AD+ group (Appendix Figure 1) as has also been observed in 
cognitively normal middle-aged individuals31. Further studies regarding the role of YKL-40 in 
neurodegenerative diseases are warranted222,223. 
Despite the fact that there were strong positive correlations among levels of the various injury 
markers, consistent with previous reports69,70, discordance in patterns of longitudinal change over 
time for tTau was observed in the amyloid-positive MCI group (robust increases in Tau but no 
statistical change in the other markers, including P-tau). CSF Tau levels are known increase in 
response to acute neuronal death as occurs in response to stroke, traumatic brain injury and 
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Creutzfeld-Jakob disease (CJD)224, thus suggesting a robust phase of neuronal death and/or 
alterations in the normal metabolism of tau at the very early (MCI) symptomatic stage of AD, the 
time during which the first signs of cognitive impairment are evident. The reason(s) for a lack of 
within-person increase in these other injury markers remains unclear but may have something to 
do with the relatively short follow-up time in the current cohort (mean 4.0 ± 1.61 years) and/or 
the lack of information regarding how long a given individual had been in their designated 
clinical group at the time of baseline LP (i.e., where in the natural progression of the disease). 
Alternatively, such discordance may indicate that these markers reflect different processes 
associated with synaptic dysfunction and/or neuronal injury70. A full understanding of biomarker 
trajectories will require serial samples being collected from a larger number of individuals over a 
long period of time as they progress from one clinical stage to the next. 
The biological reason(s) for reductions in CSF injury markers over time in early AD is unclear. 
In fact, very little is known about the normal metabolism of these markers that would lead to 
their appearance in the CSF in both normal and pathological settings. While it is conceivable that 
such reductions simply reflect a general dilution of CSF proteins that would come with 
increasing ventricular volume associated with overall brain atrophy, reductions were still 
observed after controlling for ventricular volume.  It is possible that longitudinal reductions from 
an elevated baseline during early AD reflect a slowing of acute neurodegenerative processes with 
symptomatic disease progression and/or neuronal death leading to a smaller number of neurons 
that remain and contribute to the pool in CSF. Unlike structural MRI and amyloid (and tau) PET 
imaging measures that reflect cumulative change over the course of the disease, CSF measures 
reflect a snapshot in time, thus measuring different things. Indeed, hippocampal and EC atrophy 
continued over the course of the disease even in the face of decreasing levels of injury markers in 
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the CSF. It is therefore not unexpected that there exists some discordance when defining 
biomarker positivity (and notably for neuronal injury), as a function of imaging versus CSF225. 
This issue is important to consider when selecting biomarker modalities (CSF and/or imaging) 
for use in screening and/or outcome measures in clinical trials. 
This study is not without limitations. The cohort with longitudinal CSF samples available for 
analysis was relatively small which, when divided into five groups, may limit statistical power to 
detect longitudinal changes, especially in the preclinical and early symptomatic AD groups. 
Although serial LP follow-up was longer than in previous longitudinal ADNI CSF studies226,227, 
it was still relatively short (3-5 years). Also, despite the groups being dichotomized as amyloid-
positive versus -negative in order to ascertain plaque status in the clinical groups, there was 
considerable overlap in clinical and biomarker patterns between individuals, especially in the 
MCI and AD groups. Finally, due to the small numbers of individuals in the clinical/biomarker 
groups, statistical models were not adjusted for multiple comparisons. 
3.5.1 Conclusions 
The present results underscore the importance of evaluation of true longitudinal, serial measures 
of CSF biomarkers from individuals as they progress through the normal course of the disease as 
opposed to the more traditional approach of inferring longitudinal change by comparing cross-
sectional data from groups of individuals at different disease stages. Indeed, concentrations of 
each of the markers have been reported to be elevated in AD compared to MCI and cognitively 
normal controls221. While we also observed such elevations in baseline levels of these injury 
markers among the different clinical/amyloid groups, the within-person patterns of change over 
time were different. For clinical trial purposes, given the stage-specific differences in the 
direction of true longitudinal change in these biomarkers, a “positive” biomarker outcome would 
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be different depending on the characteristics of the trial cohort. For example, a slowing of the 
course of neuronal injury may be indicated by a slowing of the rate of increase in CSF Tau in 
individuals who are early in the disease process (MCI), but perhaps a stabilization or even a 
slowing or reversal of the downward trajectory later in the disease (mild AD), potentially 
reflected as a longitudinal increase or as no decrease in this marker. Such possibilities warrant 
consideration in clinical trial design. 
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Chapter 4: ACS and ADNI Case Studies 
In the previous chapters, data was discussed that covered CSF and imaging biomarkers across 
two very different cohorts. Because biomarker investigation is not yet at the level of single-
person analysis, the data presented thus far has involved the grouping of individuals within each 
cohort by similar risk factors – APOE genotype and age for the ACS in Chapter 2 and CSF 
amyloid positivity and cognitive status for the ADNI study in Chapter 3 – and outlining baseline 
and longitudinal characteristics within each risk factor grouping. Elucidating biomarker patterns 
in this way is only one step forward; for a biomarker or panel of biomarkers to be useful, they 
must be able to identify disease within an individual. The current chapter is dedicated to 
exploring biomarker profiles in specific individuals chosen from both the ACS and ADNI 
Cohorts.  
4.1 Case Studies from the ACS Cohort 
The ACS was a particularly interesting cohort to study longitudinally because of the relatively 
young age at baseline (45-74 years) of study participants. It also represented a significant 
challenge in that few participants showed cognitive decline during their participation in the study 
(14 of 169, 8%), even as of the writing of this document in October 2017, forcing reliance on 
biomarker behavior as the primary indicator of AD.  
4.1.1 Methods 
To best visualize longitudinal change, the case study cohort was restricted from the ACS cohort 
defined in Chapter 2 to only individuals with 3 or 4 serial LP’s, then defined by amyloid status 
according to CSF Aβ42 levels, see Table 4.1 for details. Ten individuals were Aβ- at baseline 
but converted to Aβ+ at a future LP, defined as having levels above and below 1,041 pg/ml CSF 
Aβ42, respectively, according to the cutoff defined in Chapter 2; this group is identified as the 
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converter group (Aβ42 Converter). Thirteen individuals had baseline levels of CSF Aβ42 below 
the cutoff at baseline and all follow-up LP’s, hereafter identified as stable amyloid positive 
(Stable Aβ42+). Thirteen individuals had CSF Aβ42 levels >1,041 pg/ml at baseline and all 
follow up LP’s, identified as stable amyloid negative (Stable Aβ42-). 
Multiple graphing paradigms were considered for showing CSF Aβ42, Aβ40, Tau, P-tau181, 
YKL-40, VILIP-1, and the Aβ42/Aβ40 and Tau/Aβ42 ratios on a single graph. It was determined 
after finalizing each paradigm that the Aβ42/Aβ40 ratio, VILIP-1, and YKL-40 were too variable 
to be of use on an individual basis in this cohort. The only CSF biomarkers graphed in Figures 
4.1-4.6, therefore, were CSF Aβ42, Tau, P-tau181, and the Tau/Aβ42 ratio. Each figure shows 
graphs for individuals within 5-year age bins by baseline LP: 45-49 years old, 50-54 years old,  
55-59 years old, 60-64 years old, 65-69 years old, and 70-74 years old at baseline. 
In determining which graphing paradigm to best illustrate the longitudinal changes of multiple 
biomarkers, a number of options were considered. Transforming each biomarker to a z-score, 
while putting all biomarkers on the same scale, gave a skewed picture of the case study data 
because the ACS dataset biomarkers are quite homogenous and therefore z-scores largely 
centered close to the mean for each of the 36 individuals in the case study cohort. Percent change 
from BL was also considered, but this only gave an indication of whether biomarkers were 
changing within an individual and in what direction – a critical piece of data was lost because 
percent change does not take in to account the original biomarker level, which is particularly 
important when considering biomarker cutoffs or positivity. The last considered paradigm is 
common in AD CSF biomarker research and involves splitting a cohort in to tertiles for analysis. 
However, because the ACS case study cohort was small, increased granularity was required to 
see differences within and between individuals, so quintiles were calculated for each CSF 
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biomarker based on the overall ACS cohort. For each of the 36 individuals in the case study 
cohort, the baseline level of each biomarker was graphed as a quintile (1-5), allowing a 
straightforward visualization of the baseline biomarker levels within each individual in the 
context of the ACS cohort as a whole. 
Most individuals, though, remained within a given quintile for each followup LP which gave the 
impression of no longitudinal change when followup was also graphed as a quintile. As an 
example, the quintiles for Aβ42 are: Q1, 310-768 pg/ml; Q2, 769-1226 pg/ml; Q3, 1227-1683 
pg/ml; Q4, 1684-2141 pg/ml; and Q5 2142-2599 pg/ml. A given individual could have a baseline 
Aβ42 level of 1224 pg/ml and a follow up of 770 pg/ml, a substantial drop in concentration, and 
still be graphed within the second quintile for both time points, resulting in the visual of a 
straight line between the baseline and first followup LP. The final paradigm considered was 
unorthodox, but for visualization purposes allowed the comparison of all CSF biomarkers by 
graphing baseline in quintiles, while each followup LP was graphed as absolute percent change. 
Again, as an example, if an individual had a baseline CSF Aβ42 value of 1224 pg/ml, time 0 (T0) 
would be visualized at quintile 2. For a followup value of 770 pg/ml, the percent change from T0 
to T1 is -63%. In the following figures, this translated to T0 = “2” and T1 = “1.26”. The absolute 
percent change is the same, whether discussing the original biomarker level or the quintile proxy, 
and graphing in this manner allowed the visualization of baseline status and the magnitude and 
direction of change for each of the 5 biomarkers on a single, within-person graph.  
A second set of graphs was designed to show biomarker changes within the overall context of 
age because the non-core biomarkers VILIP-1, YKL-40, and the Aβ42/Aβ40 Ratio were difficult 
to interpret on a within-person level – potentially due to age-related influences on these CSF 
biomarker values. In this graphing paradigm all individuals in the stable Aβ42- (n=13), Aβ42 
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converters (n=10), and stable Aβ42+ (n=13) were graphed by group Aβ42 status. Instead of 
baseline biomarker being represented as a quintile at T0, baseline quintile is graphed at the age 
of each individual baseline LP; all follow up LP’s are graphed as absolute percent change at the 
corresponding age at LP. Each Aβ42 status group is represented by two graphs, for a total of six 
graphs in Figure 4.7: the core biomarkers and Aβ40 are contained in one graph and the non-core 
biomarkers VILIP-1, YKL-40, and Aβ42/Aβ40 Ratio are on a second graph. Baseline quintile 
and absolute percent change for the core biomarkers and Aβ40 are identical to the data graphed 
in Figures 4.1-4.6.  
4.1.2 Results 
The case study cohort was split in to six groups based on baseline age matching – Group 1, 45-
49 years; Group 2, 50-54 years; Group 3, 55-59 years; Group 4, 60-64 years; Group 5, 65-69 
years; Group 6, 70-74 years. Table 4.1 contains demographic information on each participant. 
Of the 36 individuals comprising the case study cohort: 23 were female (64%), 11 had at least 
one APOE ε4 allele (31%), 6 had one ε2 and one ε3 allele (17%), and 19 had two ε3 alleles 
(53%) (percentages add up to 101 due to rounding). After baseline LP, each of the 36 individuals 
had between 4 and 9 years of follow up LP data with LP’s performed approximately every 3 
years, and between 7 and 13 years of clinical follow up. Only 4 of 36 individuals were assigned a 
CDR >0 at any point during clinical follow up (11%), and these were exclusively in the stable 
Aβ42+ group. Statistical analyses were not performed on this cohort for two reasons: (1) 
individuals were selected from a volunteer population already considered to be different from the 
general population due to recruitment based on a family history of AD (as outlined in Chapter 2) 
and high levels of education and (2) only 36 individuals are represented in this cohort. 
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Table 4.1. Demographic Information on the 36 ACS Case Study Cohort Individuals. 
 
 
Stable Aβ42- Aβ42 Converter Stable Aβ42+ 
n 13 10 13 
45-49 Years at BL LP 
 
A 
 
B D E 
 
C 
 Avg. LP Interval (Yr) 
 
4.0 
 
3.0 2.9 3.2 
 
2.9 
 LP Followup (Yr)  8  6 6 6  6  
Clinical Followup 
(Yr) 
 
12 
 
12 9 9 
 
10 
 Aβ42 Conversion  --  Year 3 Year 3 Year 7  --  
Clinical Followup 
After Conversion (Yr) 
 
-- 
 
9 6 2 
 
-- 
 Clinical Status    CN  CN CN CN  CN 
 
PiB Status 
 
Stable 
Negative 
 
-- -- 
Stable 
Negative 
 
Stable 
Negative 
 Sex  M  M F F  F  
APOE ε Alleles  3/3  3/3 3/3 3/3  3/3  
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Table 4.1 Cont. 
50-54 Years at BL LP F I K G J 
  
H 
 Avg. LP Interval (Yr) 2.9 3.1 3.2 3.0 3.1 
  
3.2 
 LP Followup (Yr) 6 9 6 6 6   7  
Clinical Followup 
(Yr) 
9 12 12 12 9 
  
12 
 Aβ42 Conversion -- -- -- Year 3 Year 6   --  
Clinical Followup 
After Conversion (Yr) 
-- -- -- 9 3 
  
-- 
 Clinical Status  CN CN CN CN CN   CN  
PiB Status 
Stable 
Negative 
-- -- -- Year 6 
  
-- 
 Sex F M M F M   M  
APOE ε Alleles 3/4 3/3 2/3 4/4 3/4   2/3  
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Table 4.1 Cont. 
55-59 Years at BL LP L O 
 
M P 
 
N Q R 
Avg. LP Interval (Yr) 3.1 2.9 
 
3.4 3.1 
 
3.0 3.3 3.1 
LP Followup (Yr) 9 6  7 9  6 7 6 
Clinical Followup 
(Yr) 
12 13 
 
10 13 
 
11 9 9 
Aβ42 Conversion -- --  Year 7 Year 9  -- -- -- 
Clinical Followup 
After Conversion (Yr) 
-- -- 
 
3 4 
 
-- -- -- 
Clinical Status  
CN CN  CN CN  CN CN 
CDR 0.5 
at year 9 
PiB Status 
-- -- 
 
-- Year 9 
 
Stable 
Negative 
PiB+ at 
year 3 
Stable 
Positive 
Sex F F  F M  M F F 
APOE ε Alleles 3/3 2/3  3/3 3/3  3/3 3/3 4/4 
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Table 4.1 Cont. 
60-64 Years at BL LP S V X 
 
T 
 
U W 
 
Avg. LP Interval (Yr) 2.1 3.1 3.3  2.7  3.1 3.0  
LP Followup (Yr) 6 6 7  5  6 9  
Clinical Followup 
(Yr) 
10 10 9    8 12  
Aβ42 Conversion -- -- --  Year 3  -- --  
Clinical Followup 
After Conversion (Yr) 
-- -- --    -- --  
Clinical Status CN CN CN 
   
CN CN 
 
PiB Status 
Stable 
Negative 
Stable 
Negative 
Stable 
Negative 
 --  
Stable 
Positive 
Stable 
Positive 
 
Sex F M F  F  F F  
APOE ε Alleles 3/3 3/3 3/3  3/4  3/4 3/3  
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Table 4.1 Cont. 
65-69 Years at BL LP Y BB DD 
 
Z 
 
AA CC EE 
Avg. LP Interval (Yr) 2.1 2.5 2.6  3.0  3.0 3.1 3.1 
LP Followup 4 5 5  6  6 6 6 
Clinical Followup 
(Yr) 
8 9   10  9 9 10 
Aβ42 Conversion -- -- --  Year 6  -- -- -- 
Clinical Followup 
After Conversion (Yr) 
-- -- --  4  -- -- -- 
Clinical Status 
CN CN   CN  CN 
CDR 0.5, 
Yr 4; CDR 
1, Yr 9 
CN 
PiB Status 
Stable 
Negative 
-- 
Stable 
Negative 
 
Stable 
Negative 
 Year 6 
Stable 
Positive 
Stable 
Negative 
Sex F F M  M  F M M 
APOE ε Alleles 2/3 2/3 2/3 
 
3/4 
 
3/4 3/4 3/3 
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Table 4.1 Cont. 
70-75 Years at BL LP 
 
FF 
  
GG 
 
HH II JJ 
Avg. LP Interval (Yr)  3.0   3.1  2.8 2.5 3.0 
LP Followup (Yr)  6   6  6 5 6 
Clinical Followup 
(Yr) 
 10   7  10 9  
Aβ42 Conversion  --   Year 3  -- -- -- 
Clinical Followup 
After Conversion (Yr) 
 --   4  -- -- -- 
Clinical Status  
 
CN 
  
CN 
 
CN 
CDR 0.5, 
Yr 6; CDR 
1, Yr 9 
 
PiB Status 
 --   --  
Stable 
Positive 
Stable 
Positive 
Stable 
Positive 
Sex  F   F  F F F 
APOE ε Alleles 
 
3/3 
  
3/3 
 
3/4 3/3 3/4 
The cohort was split in to 6 bins by baseline age: 45-49 years, 50-54 years, 55-59 years, 60-64 years, 65-69 years, and 70-74 years. Within each 
age group, individuals were further separated by amyloid status:  stable Aβ42- (BL and Followup CSF Aβ42 values all above 1,041 pg/ml), Aβ42 
Converter (declining from CSF Aβ42 >1,041 pg/ml at BL to <1,041 pg/ml during Followup), and stable Aβ42+ (BL and Followup CSF Aβ42 
values all below 1,041 pg/ml).  
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Average LP interval and LP followup indicate the frequency and duration of LP followup from LP baseline.  
Clinical Followup in years accounts for years from LP baseline to the most recent clinical examination.   
Aβ42 Conversion indicates number of years after baseline LP conversion occurred, while Clinical Followup After Conversion indicates the 
number of years after exhibiting Aβ42 positivity converters had clinical followup information available.  
Clinical Status accounts for the latest clinical examination in the case of cognitively normal (CN) individuals while, for those who progress from 
CN to a CDR 0.5 or 1, the year of conversion is indicated.   
The letters A-JJ identify each individual allowing comparison between Table 4.1 and Figures 4.1-4.6. 
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Figure 4.1 Core CSF Biomarkers and CSF Aβ40 for Individuals from 45-49 Years Old at Baseline Lumbar Puncture 
Each graph represents a single individual from the ACS Case Study cohort, with each color representing a different biomarker (Red, Aβ42; 
Orange, Aβ40; Dark Blue, Tau; Light Blue, P-tau181; Purple Dash, Tau/Aβ42 Ratio). Time (Yr) indicates time between lumbar punctures (LP) with 
T0 indicating baseline LP. Each LP, represented by an open circle, is presented as baseline quintile at T0 followed by the absolute percent change 
from the baseline biomarker level. Left column, stable Aβ42-; middle column, Aβ42 converter; right column, stable Aβ42+. Black arrows indicate 
the time of Aβ42 transition from negative to positive during study follow up. 
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Figures 4.1 through 4.6 illustrate core and Aβ40 biomarkers on a within-person basis. The 
alphabetical labels in Table 4.1 correspond to each individual graph in Figures 4.1-4.6. The core 
biomarkers (CSF Aβ42, Tau, and P-tau181) and CSF Aβ40 are graphed on a single graph for each 
individual. Each figure encompasses a five-year age bin at baseline LP (Figure 4.1, 45-49 years 
old; Figure 4.2, 50-54 years old; Figure 4.3, 55-59 years old; Figure 4.4, 60-64 years old; 
Figure 4.5, 65-69 years old; and Figure 4.6, 70-74 years old), and within each figure the left 
column are stable Aβ42- individuals, the middle column are Aβ42 converters, and the right 
column are stable Aβ42+ individuals. There is a distinctly different biomarker profile for each 
Aβ42 classification, with stable Aβ42- individuals having lower Tau(s) at baseline, Quintile 1 or 
2 with the exception of individual “O”, and Tau/Aβ42 Ratios in the first quintile at BL exhibiting 
little change throughout follow up. Similarly, Aβ42 converters had low Tau(s) in Quintile 1 or 2 
at baseline but were more likely to increase over time than stable Aβ42- individuals throughout 
follow up. In contrast, many of the stable Aβ42+ individuals exhibited levels of Tau(s) and 
Tau/Aβ42 in Quintile 1-3 at baseline, though over time levels of Tau(s) and, to a greater extent, 
Tau/Aβ42 increased more than in either the stable Aβ42- or Aβ42 converters. CSF Aβ40 in most 
individuals was in the same quintile as Aβ42 and followed similar longitudinal trajectories, but 
was less consistent than the core biomarkers.  
Individuals in the center, Aβ42 converter columns of Figures 4.1-4.6 were marked with a black 
arrow indicating the LP at which their CSF Aβ42 status changed from – to +. None of these 
individuals or the Aβ42- individuals exhibited a CDR >0.5 at any time from baseline LP through 
the most recent clinical assessment; for the stable Aβ42- group, clinical follow up lasted between 
8 and 13 years from baseline LP and for the Aβ42 converter group, clinical follow up lasted 
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Figure 4.2 Core CSF Biomarkers and CSF Aβ40 for Individuals from 50-54 Years Old at Baseline Lumbar Puncture  
Each graph represents a single individual from the ACS Case Study cohort, with each color representing a different biomarker (Red, Aβ42; 
Orange, Aβ40; Dark Blue, Tau; Light Blue, P-tau181; Purple Dash, Tau/Aβ42 Ratio). Time (Yr) indicates time between lumbar punctures (LP) with 
T0 indicating baseline LP. Each LP, represented by an open circle, is presented as baseline quintile at T0 followed by the absolute percent change 
from the baseline biomarker level. Left column, stable Aβ42-; middle column, Aβ42 converter; right column, stable Aβ42+. Black arrows indicate 
time of Aβ42 transition from negative to positive. 
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between 7 and 13 years from baseline LP.  In contrast, 4 of 13 individuals in the Aβ42+ group 
(31%) were assigned a CDR of 0.5 or 1 at some point during clinical follow up from baseline LP, 
which lasted between 8 and 12 years.  Individual R (Figure 4.3) received a CDR 0.5 10 years 
after baseline LP; CSF Aβ42 was considered positive even at baseline and remained stable, while 
Tau and P-tau181 were in the second quintile but increasing over time. The Tau/Aβ42 Ratio began 
in the third quintile and increased substantially throughout follow up. Individual CC (Figure 4.5) 
received a CDR 0.5 at 4 years after baseline LP, which further progressed to a CDR 1 9 years 
after baseline LP. The CSF Aβ42 level was in the second quintile, and decreasing slightly while 
the Tau(s) and Tau/Aβ42 Ratio were increasing over time.  Individual HH (Figure 4.6) received 
a CDR 0.5 at 9 years after baseline LP, though this returned to a CDR 0 at 10 years.  The Tau(s) 
and Tau/Aβ42 Ratio patterns show an increase followed by a decrease between years 4 and 6 
after baseline LP while Aβ40 in individual HH is the only instance exhibiting a longitudinal 
increase in Aβ40 in the ACS Case Study cohort. Individual II (Figure 4.6) received a CDR 0.5 at 
7 years after baseline LP and a CDR 1 at 9 years after baseline. While the Tau(s) were only in 
the first Quintile at baseline and increasing slightly over time, the Tau/Aβ42 Ratio was in 
Quintile 2 at baseline and exhibited large increases longitudinally. 
Graphing individuals by baseline age bin, while informative, does not give a visual sense of how 
longitudinal biomarker changes may perform across a large age range within Aβ42-, Aβ42 
converter, and Aβ42+ groups. To better visualize this, Figure 4.7 was created to show biomarker 
changes across the entire middle-age range of the ACS cohort (45-74 years of age). While 
difficult to pinpoint biomarker behavior on a single-individual basis, this did better represent 
biomarker changes across nearly a 30-year span during middle-age. 
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Figure 4.3 Core CSF Biomarkers and CSF Aβ40 for Individuals from 55-59 Years Old at Baseline Lumbar Puncture 
Each graph represents a single individual from the ACS Case Study cohort, with each color representing a different biomarker (Red, Aβ42; 
Orange, Aβ40; Dark Blue, Tau; Light Blue, P-tau181; Purple Dash, Tau/Aβ42 Ratio). Time (Yr) indicates time between lumbar punctures (LP) with 
T0 indicating baseline LP. Each LP, represented by an open circle, is presented as baseline quintile at T0 followed by the absolute percent change 
from the baseline biomarker level. Left column, stable Aβ42-; middle column, Aβ42 converter; right column, stable Aβ42+. Black arrows indicate 
time of Aβ42 transition from negative to positive, red arrows indicate a Clinical Dementia Rating Score of 0.5.  
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Figure 4.4 Core CSF Biomarkers and CSF Aβ40 for Individuals from 60-64 Years Old at Baseline Lumbar Puncture 
Each graph represents a single individual from the ACS Case Study cohort, with each color representing a different biomarker (Red, Aβ42; 
Orange, Aβ40; Dark Blue, Tau; Light Blue, P-tau181; Purple Dash, Tau/Aβ42 Ratio). Time (Yr) indicates time between lumbar punctures (LP) with 
T0 indicating baseline LP. Each LP, represented by an open circle, is presented as baseline quintile at T0 followed by the absolute percent change 
from the baseline biomarker level. Left column, stable Aβ42-; middle column, Aβ42 converter; right column, stable Aβ42+. Black arrows indicate 
time of Aβ42 transition from negative to positive. 
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Figure 4.5 Core CSF Biomarkers and CSF Aβ40 for Individuals from 65-69 Years Old at Baseline Lumbar Puncture 
Each graph represents a single individual from the ACS Case Study cohort, with each color representing a different biomarker (Red, Aβ42; 
Orange, Aβ40; Dark Blue, Tau; Light Blue, P-tau181; Purple Dash, Tau/Aβ42 Ratio). Time (Yr) indicates time between lumbar punctures (LP) with 
T0 indicating baseline LP. Each LP, represented by an open circle, is presented as baseline quintile at T0 followed by the absolute percent change 
from the baseline biomarker level. Left column, stable Aβ42-; middle column, Aβ42 converter; right column, stable Aβ42+. Black arrows indicate 
time of Aβ42 transition from negative to positive, red arrows indicate a Clinical Dementia Rating (CDR) Score of 0.5, dark red indicate a CDR>1. 
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Figure 4.6 Core CSF Biomarkers and CSF Aβ40 for Individuals from 70-74 Years Old at Baseline Lumbar Puncture 
Each graph represents a single individual from the ACS Case Study cohort, with each color representing a different biomarker (Red, Aβ42; 
Orange, Aβ40; Dark Blue, Tau; Light Blue, P-tau181; Purple Dash, Tau/Aβ42 Ratio). Time (Yr) indicates time between lumbar punctures (LP) with 
T0 indicating baseline LP. Each LP, represented by an open circle, is presented as baseline quintile at T0 followed by the absolute percent change 
from the baseline biomarker level. Left column, stable Aβ42-; middle column, Aβ42 converter; right column, stable Aβ42+. Black arrows indicate 
time of Aβ42 transition from negative to positive, red arrows indicate a Clinical Dementia Rating (CDR) Score of 0.5, dark red indicate a CDR>1.
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Figure 4.7 Longitudinal Biomarker Change by Aβ42 classification, Core and Non-Core 
Biomarkers in the ACS Case Study Cohort 
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Longitudinal biomarker changes starting at baseline age. Left column, core biomarkers and Aβ40 (Red, 
Aβ42; Orange, Aβ40; Blue, Tau; Light blue, P-Tau181; Purple dash, Tau/Aβ42 Ratio), right column, non-
core biomarkers (Green, VILIP-1; Teal, YKL-40; Gold dash, Aβ42/Aβ40 Ratio).  
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4.1.3 Discussion 
When visualizing the ACS case study cohort using the graphing paradigm shown, it becomes 
clear that there are indeed differences on a within-person level that indicate the very earliest 
stages of AD pathology. Figures 4.1-4.6 show that levels of Aβ42, as expected, are 
comparatively higher (Quintile 2-5 at BL) in the Stable Aβ42- individuals than the Stable Aβ42+ 
individuals (Quintile 1-3 at BL), with Converters at intermediate levels (Quintile 2-3 at BL). 
Across the full age range of 45-74 years, Tau and Ptau181 in Stable Aβ42- individuals remained 
low and unchanging (Quintile 1), except the oldest member of the cohort who had Tau(s) levels 
in Quintile 2 at BL which remained unchanged at followup for 9 years. In the Converter group, 
levels of Tau and Ptau181, as well as the Tau/Aβ42 ratio, were in Quintile 1-2 at baseline and all 
but the two youngest showed increases over time. All individuals whose Tau/Aβ42 Ratio reached 
the third quintile, with the exception of individual Q, exhibited signs of cognitive decline.  
Analysis on an individual level in the ACS cohort indicates that, at least for the core CSF 
biomarkers, there is a clear difference over time in individuals who exhibit eventual clinical 
decline compared to those who do not. The greatest strength and the greatest weakness of the 
ACS cohort, as a whole, is the preclinical nature of the cohort – middle-aged, cognitively normal 
individuals recruited to the study because of their family history of AD. On one hand, this 
relatively young cohort is unique because individuals with an AD CSF profile are in the 
preclinical stage until cognitive status begins to change which provides a perspective on very 
early CSF biomarker changes in AD; on the other hand, because this is such a young cohort very 
few individuals have exhibited cognitive decline even after 6 or more years of clinical follow up. 
Assessing longitudinal biomarker change in these individuals is interesting, but ultimately does 
not provide additional information on the relationship between CSF biomarkers and disease 
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status until an individual begins to show signs of dementia. However, this case study is an 
interesting and, ultimately, a net gain in the identification of AD on a within-person basis. The 
biggest barrier to clinical translation is that the quintile data would not be informative without 
longitudinal data – these case study analyses do not provide a single-timepoint identification 
with the available data. 
Despite this, it remains clear that AD can be pinpointed even in individuals who remain 
cognitively normal for a number of years post-amyloid-biomarker positivity. Future work should 
focus on the biomarker trajectories of individuals who begin studies in the preclinical phase of 
disease and eventually progress to show cognitive decline. The combination of clinical follow up 
and CSF biomarkers alone will likely not be sufficient to account for environmental factors such 
as cognitive reserve, but investigation on a within-person basis on a large scale may elucidate 
trends in biomarker behavior that correspond to these environmental factors, thus rendering them 
easier to account for in studies of preclinical AD. 
4.2 Case Studies from the ADNI Cohort 
The ADNI cohort provided a unique perspective on within-person changes in CSF biomarkers 
due to the heterogeneous nature of the cohort. Individuals in the ADNI study may be cognitively 
normal, exhibit MCI, or have a diagnosis of AD at study entry. The longitudinal ADNI cohort in 
Chapter 3 also covered an extensive older age range, from 58 to 90 years old at baseline, 
compared with the ACS cohort. 
4.2.1 Methods 
The majority of the ADNI cohort had data from 3 or more LP’s, therefore the case study cohort 
was defined by the number of Aβ42 converters. As with the original analyses in Chapter 3, Aβ42 
status was defined by xMAP values. In the ADNI cohort, the cutoff value for Aβ42 has been  
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reported widely as 192 pg/ml, therefore individuals who transitioned from CSF Aβ42 >192 
pg/ml to <192 pg/ml were classified as Aβ42 converters; 9 total individuals met these criteria. 
The availability of both xMAP and Elecsys data aided in selecting 9 stable Aβ42- and 9 stable 
Aβ42+ individuals. The Elecsys assay provided a much larger working range (1,472 pg/ml) 
compared with the xMAP assay (300 pg/ml) of Aβ42 values in the ADNI cohort. The 9 
individuals with the highest Elecsys Aβ42 and lowest Elecsys Aβ42 values were chosen to 
represent stable Aβ42- and +, respectively, and compared with xMAP values to ensure that Aβ42 
status was consistent between the two assays. 
The graphing paradigm used for the ADNI cohort was identical to that used for the ACS cohort. 
Age matching was not possible because 9 of 27 individuals were either 77 or 78 years old at 
baseline, therefore the ADNI case studies are grouped by Aβ42 status in 3 groups. Additionally, 
the ADNI cohort did not have Aβ40 data available, so Figures 4.7-4.9 represent only the core 
CSF biomarkers Aβ42, Tau, P-tau181 and the Tau/Aβ42 ratio. Figure 4.10 represents the core 
CSF biomarkers and the non-core biomarkers VILIP-1, SNAP-25, Ng, and YKL-40. 
4.2.2 Results 
The case study cohort visualized in 3 groups representing Aβ42 status as the age distribution was 
not even enough to bin by baseline age. Table 4.2 contains demographic information on each 
participant. Of the 27 individuals comprising the case study cohort: 13 were female (48%), 5 had 
one APOE ε4 allele (19%%), 2 had two ε4 alleles (7%). After baseline LP, each of the 27 
individuals had between 2 and 9 years of follow up LP data with LP’s performed approximately 
every year, and between 2 and 9 years of clinical follow up. Of 27 individuals, 9 were diagnosed 
as having MCI at baseline (33%), and 2 were diagnosed with AD at baseline (7%).  
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Across the Aβ42 status groups, the Aβ42 converter group had 8 of 9 individuals diagnosed as 
cognitively normal at baseline, but 5 of those 8 exhibited cognitive decline which justified a 
diagnosis of MCI at some point during clinical followup (6-9 years). The individual diagnosed as 
having MCI at baseline showed no change over 8 years. The stable Aβ42- group had 3 MCI 
individuals. Of those, one showed no cognitive change over 8 years, one was diagnosed at a 
CDR 1 but reverted to CDR 0.5, and one reverted from CDR 0.5 to CDR 0. One CN individual 
was diagnosed at CDR 0.5 at followup but then reverted to CDR 0. The stable Aβ42+ group had 
five individuals diagnosed with MCI at baseline and 2 diagnosed with AD, of which 6 converted 
to CDR 1 or 2 during followup (2-6 years), and one MCI individual showed no change over 3 
years. Two individuals were cognitively normal at baseline, one progressed to CDR 0.5 and 
CDR 2 during 8 years of followup and one converted to CDR 0.5 at year 3 but reverted to CDR 0 
at year 4. Statistical analyses were not performed on this cohort for similar reasons as the ACS 
case study cohort, except that the ADNI study does not recruit based on family history of AD 
and has a much more varied cohort in terms of demographic variables such as education. 
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Table 4.2 Demographic Information on the 27 ADNI Case Study Cohort Individuals. 
 
n 9 
  
Stable Aβ42- A B C D E F G H I 
Avg. LP Interval, Yr 
(SD) 
2.4 (1.2) 1.6 (1.0) 1.0 (0.1) 1.5 (0.5) 1.5 (0.6) 1.7 (0.6) 1.6 (0.6) 1.4 (0.6) 1.6 (0.6) 
LP Followup (Yr) 7 5 3 5 6 5 8 7 8 
Clinical Followup (Yr) 7 8 7 6 7 8 8 7 8 
Diagnosis at BL CN CN CN CN CN MCI MCI CN MCI 
Clinical Followup 
No 
Change 
No 
Change 
CDR 0.5 
Yr 6 
No 
Change 
No 
Change 
No 
Change 
CDR 1 
Yr 2, 
Revert 
Yr 4 
CDR 0.5 
Yr 3, 
Revert 
Yr 7 
Revert 
Yr 3 
Age at BL (Yr) 70 79 76 62 90 74 83 72 86 
Sex M M F F F F F F M 
APOE ε4 Alleles (#) 1 0 0 0 0 0 0 0 0 
109 
 
Table 4.2 Cont. 
n 9         
Aβ42 Converters J K L M N O P Q R 
Avg. LP Interval, Yr 
(SD) 
1.6 (0.8) 1.5 (0.5) 3.0 (3.1) 1.3 (0.5) 1.2 (0.5) 1.5 (0.7) 1.5 (0.7) 1.3 (0.5) 1.4 (0.8) 
LP Followup (Yr) 8 9 6 5 5 3 6 8 7 
Clinical Followup (Yr) 8 9 6 6 8 9 7 8 8 
Aβ42 Conversion Yr 5 Yr 1 Yr 6 Yr 3 Yr 4 Yr 3 Yr 6 Yr 3 Yr 3 
Diagnosis at BL CN CN CN CN MCI CN CN CN CN 
Clinical Followup 
No 
Change 
CDR 0.5 
Yr 6 
No 
Change 
CDR 0.5 
Yr 3 
No 
Change 
CDR 0.5 
Yr 9 
CDR 0.5 
Yr 7 
No 
Change 
CDR 0.5 
Yr 8 
Age at BL (Yr) 78 77 72 78 79 82 77 78 77 
Sex F F F M M F M F F 
APOE ε4 Alleles (#) 0 0 0 0 0 0 0 0 o 
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Table 4.2 Cont. 
n 9 
  
Stable Aβ42+ S T U V W X Y Z AA 
Avg. LP Interval, Yr 
(SD) 
1.2 (0.6) 1.3 (0.5) 1.0 (0.0) 1.3 (0.6) 1.0 (0.0) 1.0 (0.1) 1.3 (0.6) 1.0 (0.1) 1.0 (0.1) 
LP Followup (Yr) 5 4 2 4 2 3 4 3 3 
Clinical Followup (Yr) 6 4 2 4 2 3 8 5 6 
Diagnosis at BL MCI MCI AD CN AD MCI CN MCI MCI 
Clinical Followup 
CDR 1  
Yr 3, 
CDR 2 
Yr 4 
CDR 2  
Yr 4 
CDR 1 
Yr 1, 
CDR 2 
Yr 2 
CDR 0.5 
Yr 3, 
Revert 
Yr 4 
CDR 1 
Yr 1 
No 
Change 
CDR 0.5 
Yr 7, 
CDR 2 
Yr 8 
CDR 1 
Yr 1, 
CDR 2 
Yr 4 
CDR 2 
Yr 6 
Age at BL (Yr) 70 71 69 76 68 73 77 77 78 
Sex M M M M F M M M M 
APOE ε4 Alleles (#) 2 2 0 0 1 1 1 1 1 
The cohort was split in to 3 bins by baseline amyloid status:  stable Aβ42- (BL and Followup CSF Aβ42 values all above 192 pg/ml [xMAP] or 
1,200 pg/ml [Elecsys]), Aβ42 Converter (declining from CSF Aβ42 >192 pg/ml at BL to <192 pg/ml during Followup), and stable Aβ42+ (BL and 
Followup CSF Aβ42 values all below 192 pg/ml [xMAP] or 1,200 pg/ml [Elecsys]).   
Average LP interval and LP followup indicate the frequency and duration of LP followup from LP baseline.  
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Clinical Followup in years accounts for years from LP baseline to the most recent clinical examination.   
Aβ42 Conversion indicates number of years after baseline LP conversion occurred, while Diagnosis at BL and Clinical Followup indicate the 
cognitive status (CN, MCI, or AD) and change in cognitive status for each individual during followup. 
The letters A-AA identify each individual allowing comparison between Table 4.2 and Figures 4.7-4.9. 
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Figure 4.8 Core CSF Biomarkers for Stable Aβ42- ADNI Participants
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Each graph represents a single individual from the ADNI Case Study cohort, with each color representing a different biomarker (Red, Aβ42; Dark 
Blue, Tau; Light Blue, P-tau181; Purple Dash, Tau/Aβ42 Ratio). Time (Yr) indicates time between lumbar punctures (LP) with T0 indicating 
baseline LP. Each LP, represented by an open circle, is presented as baseline quintile at T0 followed by the absolute percent change from the 
baseline biomarker level. A tan background indicates individuals diagnosed with MCI at baseline. Pink arrows indicate a Clinical Dementia Rating 
(CDR) Score of 0.5, red arrows indicate a CDR 1, dashed arrows indicate a CDR that reverted to a lower score at a later clinical followup.
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Figures 4.7 through 4.9 illustrate ADNI core CSF biomarkers on a within-person basis. The 
alphabetical labels in Table 4.2 correspond to each individual graph in Figures 4.7-4.9. The core 
biomarkers (CSF Aβ42, Tau, and P-tau181) and the Tau/Aβ42 ratio are graphed on a single graph 
for each individual. Each figure represents 9 individuals with differing Aβ42 statuses: Figure 
4.7, stable Aβ42-; Figure 4.8, Aβ42 Converters; Figure 4.9, stable Aβ42+. Biomarkers are more 
homogenous between Aβ42 classification groups than was seen in the ACS cohort. Stable Aβ42- 
individuals had lower Tau(s) at baseline, Quintile 1 or 2, and Tau/Aβ42 Ratios in the first 
quintile at BL, all exhibiting little change throughout follow up. Similarly, Aβ42 converters had 
low Tau(s) in Quintile 1 or 2 at baseline but were more likely to increase over time than stable 
Aβ42- individuals throughout follow up. Many of the stable Aβ42+ individuals exhibited levels 
of Tau(s) and Tau/Aβ42 in Quintile 1-2 at baseline and, unlike the ACS cohort, the levels of Tau, 
P-tau181 and the Tau/Aβ42 ratio changed less over time.  
The differential diagnoses of CN, MCI, and AD at baseline were coded by filling the 
corresponding graph background with tan (MCI) or pink (AD) to visually indicate individuals 
with evidence of cognitive decline at baseline. The stable Aβ42+ group had the largest number 
of impaired individuals at baseline. The stable Aβ42- group was next, but the majority of 
individuals that showed impairment or progression also reverted back to their baseline cognitive 
status over the course of the study. Interestingly, the Aβ42 converter group had the smallest 
number of both individuals with an MCI or AD diagnosis at BL, but did show a high rate of 
conversion from CN to a CDR 0.5. 
The Aβ42 converter group showed the most change in core biomarkers over time. Whereas the 
stable Aβ42- group remained stable throughout followup for all core biomarkers, the converter  
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Figure 4.9 Core CSF Biomarkers for Aβ42 Converter ADNI Participants 
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Each graph represents a single individual from the ADNI Case Study cohort, with each color representing a different biomarker (Red, Aβ42; Dark 
Blue, Tau; Light Blue, P-tau181; Purple Dash, Tau/Aβ42 Ratio). Time (Yr) indicates time between lumbar punctures (LP) with T0 indicating 
baseline LP. Each LP, represented by an open circle, is presented as baseline quintile at T0 followed by the absolute percent change from the 
baseline biomarker level. A tan background indicates individuals diagnosed with MCI at baseline. Pink arrows indicate a Clinical Dementia Rating 
(CDR) Score of 0.5 clinical followup. 
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Figure 4.10 Core CSF Biomarkers for stable Aβ42+ ADNI Participants
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Each graph represents a single individual from the ADNI Case Study cohort, with each color representing a different biomarker (Red, Aβ42; Dark 
Blue, Tau; Light Blue, P-tau181; Purple Dash, Tau/Aβ42 Ratio). Time (Yr) indicates time between lumbar punctures (LP) with T0 indicating 
baseline LP. Each LP, represented by an open circle, is presented as baseline quintile at T0 followed by the absolute percent change from the 
baseline biomarker level. A tan background indicates individuals diagnosed with MCI at baseline, a pink background indicates individuals 
diagnosed with AD at baseline. Pink arrows indicate a Clinical Dementia Rating (CDR) Score of 0.5 clinical followup, red arrows indicate a CDR 
1 diagnosis, and dark red arrows indicate a CDR 2 diagnosis. Dashed pink arrows indicate a reversion from CDR 0.5 to CDR 0. 
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group showed concomitant longitudinal changes in Aβ42, Tau, P-tau181 and the Tau/Aβ42 ratio. 
The stable Aβ42+ group did not show elevated levels of Tau, P-tau181 or the Tau/Aβ42 ratio – in 
fact, in many individuals such as T, U, or W exhibited longitudinal decreases in these 
biomarkers.  
As with the ACS case study cohort, it is difficult to visualize biomarker changes in relation to 
age. Figure 4.10 shows biomarker levels by baseline quintile and followup percent change 
across the entire age range of the ADNI case study cohort. The age range for the stable Aβ42- 
group covered the full age range from approximately 60-90 years of age at baseline for included 
individuals. The Aβ42 converter group was more compact, approximately 70-90 years and the 
stable Aβ42+ group was approximately 65-85 years at baseline. The stable Aβ42- exhibits 
relatively stable levels of all core biomarkers; the Aβ42 converter group exhibits decreasing CSF 
Aβ42 levels and increasing Tau, P-Tau181, and Tau/Aβ42 levels. The stable Aβ42+ group 
exhibits low Aβ42 levels and a mix of behavior for the Tau(s) biomarkers, including increasing 
over time, remaining relatively stable, and decreasing.  
4.2.3 Discussion 
The ADNI case study cohort is particularly interesting because many individuals included 
exhibited some form of cognitive impairment either at baseline or during clinical followup. This 
clinical data makes it a more conducive dataset for following changes through all stages of 
disease whereas the ACS cohort has greatest strength in the preclinical stage. A particular 
within-person characteristic that fits well with the longitudinal data presented in Chapter 3 – 
where significant decreases in markers of neuronal injury/death were seen in the AD group – are 
the relatively low and, in some cases, decreasing concentrations of the Tau(s) and Tau/Aβ42 
ratio in the stable Aβ42+ group. Unfortunately, as the preclinical stage of AD lasts between 
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Figure 4.11 Longitudinal Biomarker Change by Aβ42 classification, Core and Non-Core 
Biomarkers in the ADNI Case Study Cohort 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Longitudinal biomarker changes starting at baseline age. Left column, core biomarkers (Red, 
Aβ42; Blue, Tau; Light blue, P-Tau181; Purple dash, Tau/Aβ42 Ratio), right column, non-core 
biomarkers (Green, VILIP-1; Teal, YKL-40; Gold, SNAP-25; Orange, Ng).   
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10-20 years, there is an important cross-section of disease that is under-represented in the ADNI 
case study cohort: Aβ42 converters that go on to show signs of cognitive decline. A particular 
confounding factor is the use of both xMAP and Elecsys Aβ42 data – Chapter 5 briefly explores 
the analyte differences between the two platforms, particularly with respect to when an 
individual would be considered a “converter”, and the two assays do not agree in most of the 9 
Aβ42 converter cases in the ADNI dataset. This detail complicates the identification of the Aβ42 
conversion time point and, therefore, the downstream biomarkers of Tau(s) and the Tau/Aβ42 
ratio. The ADNI longitudinal cohort dataset was defined and analyzed before the Elecsys data 
became available, thus necessitating the retention of xMAP Aβ42 data because the study had 
been defined with it, regardless of the fact that the data was not truly longitudinally assayed. On 
the other hand, the Elecsys is a new platform for measuring AD biomarkers and does not have 
the same wealth of legacy data. Both concerns have been recognized in research facilities around 
the world, so the most thorough option seemed to be using both xMAP and Elecsys Aβ42 data 
when looking at case studies.  
Despite analytical differences, individuals J, K, O, Q, and R all exhibit strikingly similar core 
biomarker profiles to the ACS case study Aβ42 converter group. Individuals L and P appear to 
be in even earlier stages of preclinical disease, but further longitudinal followup is necessary to 
confirm these observations. Individuals M and N are notable due to unstable Aβ42 values – 
decreasing, then increasing – despite “N” having a baseline diagnosis of MCI. More individuals 
like these, with longer longitudinal followup, are necessary to get a clearer picture of disease 
progress in unstable Aβ42 cases. 
Perhaps the most striking visualization in the ADNI case study cohort comes from the stable 
Aβ42- group who, across a period of nearly 40 collective years, exhibit remarkably stable and 
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consistent core biomarker profiles that indicate the absence of AD. The Aβ42 converter and 
stable Aβ42+ groups covered a much smaller age range (70-90 years old and 65-85 years old, 
respectively) and show much more change over time than the stable Aβ42- group. In general, the 
core biomarkers of neuronal death/injury are increasing in the converter group while the stable 
Aβ42+ group exhibits higher levels of these markers at baseline, but variable longitudinal 
behavior. The non-core biomarkers of neuronal injury and inflammation were inconclusive 
across all three groups, similar to the ACS cohort. There is potential that these non-core 
biomarkers of neuronal injury or inflammation may be more useful after better understanding the 
mechanistic or risk-factor-based causes that result in the longitudinal change seen in AD. 
As with the ACS case study cohort, the ADNI case study cohort is too small to perform rigorous 
statistical analyses. 
4.3 Conclusions 
Visualizing multiple markers on a single graph, while not statistically rigorous, again points to 
the consistency of core biomarker changes that have been seen in both longitudinal and cross-
sectional CSF biomarker studies – low Aβ42, high Tau(s) and high Tau/Aβ42 ratio are indicators 
of future cognitive decline.  However, longitudinal studies such as the DIAN27 and the ADNI 
longitudinal cohort tell a slightly different story in that markers of neuronal injury/death may 
begin to decline after a certain point in disease.  The ACS and ADNI case study cohorts are of 
great interest because they provide a window in to the behavior of AD biomarkers as they relate 
to one another on an individual basis. Noting the distinct similarities between the Aβ42 converter 
groups, if nothing else, shows that despite obstacles with analytical aspects of these assays 
(Aβ42 assays in particular), biomarkers behave similarly enough to eventually combine data 
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from diverse and varied cohorts with CSF data to better understand and track disease progress on 
a within-person level as well as a group level.  
A number of considerations also spring from the apparent lack of association - or weak 
association in the case of the ACS case study cohort - between non-core biomarkers of neuronal 
injury/death and inflammation. Though it is important to note that group-level changes in these 
biomarkers were seen in both the ACS and ADNI cohorts, associated with either disease risk and 
amyloid status or diagnosis and amyloid status.  As CSF biomarkers were the only biomarker 
modality considered in this chapter, the addition of imaging biomarkers (e.g. longitudinal 
hippocampal volume) may pinpoint other aspects of disease that are more closely related to, for 
instance, the synaptic markers SNAP-25 or Ng. The current longitudinal datasets available are 
not large enough to allow such intricate analyses across all stages of disease. As stated earlier, 
preclinical longitudinal datasets have the drawback of tracking little cognitive change and 
datasets such as ADNI typically have very small AD groups due to the difficulty of retaining 
impaired individuals as part of a volunteer study. However, future work in assay development, 
continued longitudinal followup in these and similar studies, and more data from group-wise 
analyses should result in the sensitive and specific tracking of AD across all disease states.
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Chapter 5: Assay Platform and Cohort 
Comparison 
Portions of this chapter were published in the July 2015 issue of JAMA Neurology31.  
Some important pitfalls in AD biomarker investigation became apparent during the timeframe of 
the work covered in the current document. Analytical variability, particularly with the Aβ42 
peptide, has become a focus of investigation as the field attempts to solve 3 major problems 
hindering the translation of CSF biomarkers from research use to widespread clinical use: (1) 
high inter- and intra-lab variability, (2), analytical challenges within and between assay platforms 
and (3) lack of a certified reference material. While not the main focus of the current work, a 
number of assay comparisons were performed to assess agreement between different assay 
platforms on samples treated in an identical manner from collection, through processing, storage, 
and finally, analysis. 
5.1 Reasoning for Assay Comparison 
Studies like those covered in Chapter 2 and Chapter 3 are of paramount importance because 
groups such as the Alzheimer’s Association Quality Control (AAQC) Program, along with 
independent research labs, have discovered consistent undesirable characteristics when assessing 
CSF biomarkers – particularly Aβ42 – that may hinder diagnosis or prognosis in a transition to 
consistent clinical application.  
In 2013, the AAQC program reported consistency between participating laboratories in AD 
diagnosis, using cutoffs established prior to the formation of the program, but noted this was in 
spite of high measurement variability228. Some of the variability is due to inter-lab differences in 
assay technique and sample handling, but another setback was in assay variability. An important  
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guidance issued in the AAQC program report was that assay kit manufacturers, in particular 
those of enzyme-linked immunosorbent assays (ELISASs) and Multi-Analyte Profiling (xMAP) 
should consider it “critically important” to improve product quality and minimize lot-to-lot 
variability228 which, in an additional study, was considered a hindrance to applying biomarkers 
in a clinical setting229. Performing assay comparisons can help identify when an assay is not 
performing well, and can also serve as trials for new but promising assays. 
A more recent study that stemmed from the longitudinal ACS cohort found that one of the most 
commonly used assays worldwide (INNOTEST ELISA) exhibited significant upward drift in 
CSF Aβ42 over more than a decade of production230, and such assay drift has multiple 
implications for past and future data analysis. For example, individuals in the ACS cohort 
covered in Chapter 2 and Chapter 4 return for LP’s once every 3 years, if assays are run shortly 
after each LP, the upward drift may obscure biologically important changes in CSF Aβ42 levels, 
particularly if protein levels are close to the cutoff for amyloid positivity. A second implication is 
a moving cutoff for amyloid positivity over time; Aβ42 cutoffs have risen in conjunction with 
both assay drift and an improved INNOTEST ELISA, which improved variability but raised the 
absolute average value of Aβ42 substantially230. In this case, performing a single-lot analysis on 
samples that had been collected and analyzed over a period of ten years on different lots was 
what led to the investigation on assay drift.  
5.2 ACS Assay Comparisons 
5.2.1 INNOTEST Versus EUROIMMUN ELISA in the ACS Cohort 
As part of the design of the ACS longitudinal study (Chapter 2), the analysis of Aβ42, Aβ40, and 
Tau were performed simultaneously on the same set of samples. An experienced scientist 
performed “Improved” INNOTEST ELISA’s for Aβ42, Aβ40, Tau and P-Tau181 and 
126 
 
immediately after, the author performed EUROIMMUN ELISA’s for Aβ42, Aβ40, and Tau, as 
described in Chapter 2. All analyses were performed on the same set of samples, in parallel, to 
reduce variability in sample handling. Assay performance characteristics are reported in Table 
5.1. Compared to the previous version of the INNOTEST assays, the improved assays each 
contain a set of ready-to-use calibrator series, run validation control samples (calibrator in 
buffer), and harmonized buffer reagents.  The EUROIMMUN assays are considered second 
generation assays because they do not have matrix interference problems (i.e., they exhibit good 
dilutional linearity). The amount of CSF required for testing is lower in the EUROIMMUN 
assays, thereby reducing the issues with matrix interference179,231. So, in principle, the 
EUROIMMUN assay measures another fraction of the free, non-protein bound analyte in a 
sample, unlike many other Aβ42 ELISA’s which show poor dilutional linearity.  All ELISA kits 
passed in-house quality control measures including: 1) standard curve values having a CV <25% 
and no more than two standards either oversaturating or undersaturating using a Synergy 2 
Multi-Mode Reader (Bio-Tek Instruments, Inc.), 2) no more than one provided kit control and 
one internal pooled CSF control failing due to reading outside the provided range or having a CV 
>25% with the exception of one assay in which both internal CSF controls failed due to high CV 
– in this case, both kit controls passed, and 3) individual samples failed if there was a CV >25%. 
The Singulex kits passed in-house quality control measures including: 1) standard curves were 
assessed according to software provided by Singulex, 2) no more than 2 of 3 internal pooled CSF 
controls falling outside the range determined by all previous runs using the same lot number of 
kits and 3) samples failed if there was a CV >25%.  
Comparisons of CSF Aβ40, Aβ42, and total tau obtained with the 2 assays were positively 
correlated (Aβ40, n=412, Pearson r = 0.772 [95% CI, 0.730-0.808], P < .001; Aβ42, n=394,   
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Pearson r = 0.879 [95% CI, 0.855-0.900], P < .001; total tau, n = 410, Pearson r = 0.958 [95% 
CI, 0.949-0.965], P < .001). Although the absolute values for Aβ40 and Aβ42 differed between 
the assays (roughly 2- to 3-fold higher with EUROIMMUN compared with INNOTEST), 
absolute values for total tau were similar. Patterns of within-person biomarker changes over time 
were virtually identical between the 2 assays for Aβ42, total tau, and the total tau to Aβ42 ratio. 
However, baseline comparisons and longitudinal patterns for Aβ40 were slightly different 
between the assays and thus are difficult to interpret. Clinical observations were confirmed in 
both immunoassays for Aβ42 and total tau.  
More recent work has highlighted the same disparity in absolute concentration for Aβ42, as well 
as good correlation between multiple assays, for the INNOTEST and EUROIMMUN assays232. 
Head-to-head comparisons such as these are of paramount importance for studying Aβ42 (and, to 
a lesser extent Tau(s)) and allow for a focus on assay performance as many of the pre-analytical 
and analytical variables are controlled for, e.g. limited or no changes in kit lots, uniformity in 
assay conditions, or uniformity in sample handling across a single study233.   
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Table 5.1 Assay Performance Specifications as Provided by the Vendors 
 
 
 
 
 
 
 
 
 
 
 
 
Samples were analyzed for Aβ1-40, Aβ1-42, Tau, and P-tau181 using the “Improved” INNOTESTTM ELISA (Fujirebio Europe [formerly 
Innogenetics], Gent, Belgium). For comparison purposes, concentrations of Aβ1-40, Aβ1-42 and total tau were also measured using 
EUROIMMUN ELISAs (EUROIMMUN, Luebeck, Germany). For Aβ species, both assays utilize the same monoclonal antibodies, but they are 
obtained from a different process of culture, production, and purification. YKL-40 (also known as chitinase-3 like 1), an astrocyte-derived marker 
of gliosis/neuroinflammation, was measured with the MicroVue ELISA (Quidel, San Diego, CA). Visinin-like protein 1 (VILIP-1), a marker of 
neuronal injury, was measured using a two-site immunoassay implemented via a microparticle-based Erenna immunoassay system (Singulex, 
Alameda, CA). 1 performance characteristics as provided by the vendor. 2 actual performance characteristics in the current study. 
Vendor QUIDEL SINGULEX
Analyte Aß1-40 Aß1-42 Total tau Ptau181 Aß1-40 Aß1-42 Total tau YKL-40 VILIP-1
Technology
ELISA
Colorimetric
ELISA
Colorimetric
ELISA
Colorimetric
ELISA
Colorimetric
ELISA
Colorimetric
ELISA
Colorimetric
ELISA
Colorimetric
ELISA
Colorimetric
Single Molecule 
Counting (SMCTM)
Fluid Sample CSF CSF CSF CSF CSF CSF CSF CSF CSF
Capture Antibody 2G3 21F12 AT120 HT7 2G3 21F12 ADx 201 Not Available 3A8.1
Capture Antibody Epitope 35-40 37-42 218-224 159-163 Aßx-40 Aßx-42 Proline-rich region Not Available Not Available
Detection Antibody 3D6 3D6 HT7/BT2 AT270 3D6 3D6 ADx 215 Not Available Sheep 22
Detection Antibody Epitope 1-5 1-5 159-163/193-198 176-182 Aβ1-x Aß1-x N-terminus Not Available Multiple
Calibrator Concentration Range, 
pg/mL   (lot specific, for this study)
7.8 - 1000                 
(n=8)
62.5 - 4000                   
(n=6)
50 - 2500                 
(n=6)
15.6 - 1000                
(n=6)
54 - 711
(n=6)
83 - 1236
(n=6)
30 - 1050
(n=6)
20 - 300
(n=6)
3.9 - 3000
(n=10)
Limit of Detection (LOD), pg/mL, 
(range), number of runs
3.3                            
(0.7 - 4.2)                           
4 runs
65
(52-87)
7 runs
34
(25-47)
8 runs
13.4                                  
(11.4 - 14.9)                                 
4 runs
70                                
(58 - 85)                         
6 runs
7.5                          
(6.3 - 9.0)                              
6 runs
44.2                         
(41.1 - 46.8)                           
4 runs
5.4
Not available
Not available
1.4
(0.077-6.9)
16 runs
Sample Specifications
Sample Pre-dilution 1:100 No No No 1:21 No No 1:03 No
Volume Sample Per Well (µL) 75 25 25 75 15 15 25 20 15
Total Well Volume 100 100 100 100 115 115 125 120 200
Number of Replicate Wells 2 2 2 2 2 2 2 2 2
Sample Incubation
Time, hrs 14-18 1 14-18 14-18 3 3 3 1 2
Temperature 2-8°C 23-27°C 23-27°C 2-8°C 23-27°C 23-27°C 23-27°C 23-27°C 23-27°C
Reported Intra-Assay Variability1,                       
% CV, (range),  number of runs
2.8
(0.3 - 7.8)                                           
5 runs
4.6
(0.8 - 11.0)                       
3 runs
3.2
(0.0 - 13.2)                          
2 runs
1.7
(0.0 - 8.9)                            
4 runs
2.7                             
(2.4 - 3.1)                                      
3 runs
3.9                              
(2.3 - 6.2)                            
3 runs
5.0                               
(3.9 - 6.5)                       
4 runs
6
(5.6 - 6.6)
Not available
4.4                                
(3.1 - 7.0)                      
10 runs
Reported Inter-Assay Variability1,                             
%CV, (range), number of runs
4.4
(3.2 - 5.8)                              
4 runs
7.8
( 1.4 - 18.0)                         
3 runs
11.5
(3.8 - 42.8)                               
2 runs
11.4
(6.6 - 19.2)                         
4 runs
8.3                            
(7.3 - 9.3)                               
5 runs
5.6                              
(4.4 - 7.6)                    
7 runs
7.4                         
(6.1 - 9.3)                             
5 runs
6.7                                   
(6.0 - 7.0)                   
Not available
6.2                                  
(5.0 - 7.0)                         
1 run
Study Intra-Assay Variability2,                       
% CV, (range),  number of runs
2.7
(0.4 - 12.7)
12 runs
4.4
(0.2 - 13.7)
12 runs
2.0
(0.0 - 11.4)
12 runs
1.0
(0.1 - 4.6)
12 runs
2.3
(0.1 - 6.0)
12 runs
3.0
(0.1 - 9.7)
12 runs
5.42
(0.8 - 22.9)
12 runs
1.9
(0.1  -6.4)
12 runs
4.5
(0.0 - 20.8)
16 runs
Study Inter-Assay Variability2,                             
%CV, (range), number of runs
3.8
(0.0 - 24.6)
12 runs
4.3
(0.0 - 20.6)
12 runs
2.1
(0.0 - 14.8)
12 runs
2.2
(0.0 - 17.5)
12 runs
14
(0.1 - 13.7)
12 runs
4.1
(0.0 - 16.7)
12 runs
4.1
(0.0 - 24.2)
12 runs
3.7
(0.0 - 21.6)
12 runs
4.3
(0.0 - 24.8)
12 runs
Fujirebio (formerly Innogenetics) EUROIMMUN
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Figure 5.1 Group Longitudinal Change Over Spaghetti Plots of EUROIMMUN CSF Biomarkers During Middle-age. 
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Estimated slopes and within-person patterns for A) Aβ40, B) Aβ42, C) the Aβ42/Aβ40 ratio, D) tau, and E) tau/Aβ42 are shown in three age bins 
for APOE ε4-negative (top graph of each panel, n=108participants) and ε4-positive (bottom graph of each panel, n=61 participants) groups. 
Annual slopes have been extrapolated to 9 years, and each slope begins at the mean baseline biomarker value of each age bin. Blue, EARLY 
middle-age (45-54 years at baseline); Black, MID middle-age (55-64 years at baseline); Red, LATE middle-age (65-74 years at baseline). * slopes 
significantly different from 0 (p<0.05). +, slopes significantly different between APOE ε4 groups within a given age group (p<0.05). Trend, 
p=0.051-0.06. 
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While no judgements were made as to the quality of either the INNOTEST or EUROIMMUN 
ELISAs, this comparison was informative in that consistent results were found with both assays. 
The exception was Aβ40: the slopes in the APOE ε4 non carrier group were declining in the 
early- and mid-middle age groups. However, the EUROIMMUN data shows a significant decline 
in Aβ40 slope across all 6 groups. The INNOTEST data shows no change and perhaps even a 
slight increase in Aβ40 over time in the three APOE ε4 carrier groups, though not significant. 
Because assay comparison has largely focused on the problematic Aβ42 peptide, it is difficult to 
speculate the reasons behind this difference. However, recent data from Vanderstichele and 
colleagues may offer a potential explanation: despite both INNOTEST and EUROIMMUN using 
the same capture antibodies (21F12 for Aβ42 and 2G3 for Aβ40), and the same detection 
antibody (CD6) across all four assays, INNOTEST displays a dose-dependent difference in Aβ42 
levels that corresponds to Aβ40232. They speculate that this is due to Aβ40 interfering in the 
Aβ42 assay through CD6 binding, where higher levels of Aβ40 in the CSF result in a lower 
Aβ42 value. Because CD6 is a component of both the Aβ40 and Aβ42 assays there is some 
potential for interference in the Aβ40 assay, though Aβ40 is roughly ten times as abundant in 
CSF as Aβ42. It is additionally difficult to say how this interference is happening as the ELISA 
format goes through multiple washing steps before applying the detection antibody. Unless there 
is substantial binding of Aβ40 to the 21F12 antibody or oligomerization of Aβ40 on to Aβ42 that 
has bound to 21F12, there should be little to no interference as it is reported by Vanderstichele 
and colleagues. Interestingly, this interference is not seen with the EUROIMMUN assay. These 
questions are further support for the continued comparison of different assays and assay 
platforms as those used most frequently are not ready to transition in to clinical use at this time. 
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 5.2.2 xMAP Versus Elecsys Comparison in the ADNI Cohort 
Unlike the ACS cohort, assays for Aβ42, Tau, and P-Tau181 were not performed in-house in the 
ADNI cohort. Data for these analyses were downloaded from the ADNI, thus there is no way to 
compare specific performance characteristics of each assay. ADNI researchers analyze CSF 
samples on a rolling basis, though some longitudinal analyses have been completed. The ADNI 
study reported in Chapter 3 relied on two sets of xMAP data generated by re-analyzing 
longitudinal samples from an individual at the same time, rather than relying on data that was 
generated on the rolling basis. Unfortunately, not all samples were assayed in one longitudinal 
run and there is no way to determine which lot number of xMAP assay was used. Further, 
without access to the raw data, it is not possible to perform comparisons between the two sets of 
xMAP data to ensure continuity between assay lots. Fortunately, assay validation and assay 
comparisons are a major focus of numerous large studies, ADNI included, and data from the new 
Elecsys platform was released for Aβ42, Tau and P-Tau181 in early 2017. Correlations between 
xMAP and Elecsys data for Aβ42 and Tau were as expected – Tau was highly correlated 
(Pearson r = 0.948, p<0.001) and Aβ42 showed more variability but still correlated well between 
the two assay platforms (Pearson r = 0.884, p<0.001). Originally, P-tau181 was excluded from 
analysis due to clear variability between the two xMAP datasets. Typically, both Tau and P-
tau181 show very close correlation, as with the INNOTEST and EUROIMMUN comparisons 
above, but in this case xMAP and Elecsys P-tau181 did not correlate as well as would be expected 
(Pearson r = 0.743, p<0.001).  
Despite these close correlations, there were clear differences in diagnostic ability in individuals 
who converted from Aβ- at baseline LP to Aβ+ at a later LP. Figure 5.2 illustrates all nine 
individuals in the ADNI longitudinal cohort who converted from Aβ42- to Aβ42 positive as 
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defined by the cutoff of 192 pg/ml for the xMAP assay. This paradigm was used to classify 
individuals as amyloid + or – for the analyses in Chapter 3. A poster presentation in July 2017 
outlined potential cutoffs for amyloid positivity as defined by Elecsys values234. Three cutoffs 
were presented: 1,065 pg/ml when compared to xMAP Aβ42, 1,017 or 1,172 pg/ml when 
modeled by unweighted and weighted densities respectively, and 1,198 pg/ml when compared to 
amyloid imaging. The xMAP and Elecsys Aβ42 values showed good concordance, but better 
concordance was found when comparing to amyloid imaging. Mixture modeling identifies sub-
populations in a given sample and weighting takes in to account the distribution of each sub-
population in the overall population. The rich history of amyloid imaging and CSF biomarker 
analysis means that (1) concordance between amyloid imaging and CSF Aβ42 is high in most 
studies and (2) a general estimate for amyloid positivity in cognitively normal individuals can be 
established, therefore a cutoff of 1,200 pg/ml was chosen to indicate amyloid positivity using the 
Elecsys assay for the purposes of the current study.  
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Figure 5.2 ADNI Aβ42 Converter xMAP Versus Elecsys Positivity Comparison  
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Core CSF biomarkers, Tau/Aβ42 Ratio and MMSE score in the nine individuals in the ADNI longitudinal cohort that converted from Aβ42- to 
Aβ42+ at any LP after that baseline LP, as defined by xMAP Aβ42. Each graph represents a single individual, with T0 representing the baseline 
LP and representative baseline quintile for each biomarker. Follow up LP’s or MMSE tests are marked by open circles. Each colored line 
represents a different biomarker (Red, Elecsys Aβ42; Blue, Elecsys Tau; Light blue, Elecsys P-Tau181; Purple dash, Aβ42/Tau Ratio; Black, 
MMSE score). At the top of each graph, pink arrows indicate the time when an individuals’ CDR score changed from 0 to 0.5; black arrows 
indicate the time point that an individual would be considered Aβ42+ according to xMAP data; grey dashed arrows indicate the time point an 
individual would be considered Aβ42+ according to Elecsys data; grey dashed arrows with a star indicate an Elecsys value very close to the Aβ42 
cutoff of 1200 pg/ml. 
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Only one individual exhibited agreement between xMAP and Elecsys amyloid positivity – 
individual 61. Individual 210 was considered amyloid positive 6 years after baseline with the 
xMAP assay; with the Elecsys assay the CSF Aβ42 value was 1,271 pg/ml, very close to the 
1200 pg/ml cutoff. Individual 454, though showing decline in Aβ42 over time, did not exhibit 
amyloid positivity when using the Elecsys cutoff, even though xMAP Aβ42 values converted to 
positivity 3 years after baseline LP and a CDR score of 0.5 was given 9 years after baseline LP.  
The remaining 6 individuals would be classified as Aβ42+ one to five years earlier using Elecsys 
data than they would using xMAP data. Visually, the earlier positive classifications using 
Elecsys data fit better with the hypothesis of a long period of amyloid accumulation before 
cognitive symptoms appear and also match data from the ACS longitudinal cohort showing that 
amyloid changes are detected earlier than tau and cognitive changes. 
5.2.3 Conclusions 
Reductions in CSF Aβ42 over the time-course of AD are now a well-established phenomenon, 
but recent discoveries regarding the variability in measurement over time for this important 
biomarker have added an element in longitudinal analysis that is difficult to control for, much 
less anticipate. The increase in assay comparison studies, alongside the emergence of new assay 
platforms such as the Elecsys assays for Aβ42, Tau and P-tau181, is a barometer for the next 
important phase in AD research: the search for or development of reliable assays that can be used 
worldwide for the consistent measurement of Aβ42 from bodily fluids such as CSF. 
The ADNI dataset provides an interesting opportunity to compare a widely used assay – xMAP – 
and a new assay platform – Elecsys – in the same set of samples. The biggest caveat to the ADNI 
observations above is that they cannot, at this time, be statistically validated due to the very small 
group of only nine individuals. However, these data do again showcase the necessity for 
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biomarker comparison across multiple assays and assay platforms in the effort to find an assay 
(or assays) that perform most sensitively and most specifically in identifying AD on a within-
individual basis. 
There is a delicate balance between adequate assay testing and the depletion of precious stores of 
CSF from cohorts such as the ACS and ADNI, which necessitates careful consideration of 
appropriate assay platforms and study design. The development and adoption of stable 
measurement techniques for Aβ42 and other AD biomarkers will likely contribute greatly to 
defining the within-person changes that will allow biomarker-based diagnosis and prognosis on 
an individual basis. 
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Chapter 6: Conclusions and Discussion 
The development in CSF biomarkers of AD has progressed rapidly over the last decade. From 
the development of core biomarkers of disease through the identification and study of important 
non-core biomarkers, the field as a whole is learning important lessons about AD progression 
and about the difficulties involved in measuring biomarkers in a slow-developing disease where 
the organ of interest is not easily accessible. The current work is a step toward developing CSF 
biomarker profiles that may eventually provide, over the full course of the disease, diagnostic 
and prognostic applicability in conjunction with neuroimaging and psychometric analysis. The 
results reported in this document, alongside other work in the field, indicate that the diagnostic 
and prognostic paradigm for AD will likely require multi-factorial, longitudinal, assessment in 
order to pinpoint disease on a within-person basis. They also provide support for viewing AD as 
a continuum as outlined by Aisen et al3.  
The aim of the works presented here were primarily to define the behavior or CSF biomarkers in 
large, independent cohorts during the preclinical and early symptomatic stages of AD. In 
agreement with data from the DIAN cohort, changes in core CSF biomarkers of AD begin to 
differentiate individuals at higher risk of developing the disease than those at lower risk, as 
defined by APOE ε4 allele carriage in the ACS cohort, as early as 45 years of age. In many 
cases, these changes occurred earlier in ε4 carriers than non-carriers, though the rates of change 
did not differ between the two groups. In mid middle-age, core markers of neuronal injury and 
death, as well as non-core markers of neuronal injury and neuroinflammation in the ε4 carrier 
group increased at a faster rate than mid middle-age non-carriers, but this rate of change was not 
different between late or mid middle-aged carriers or late middle-aged non-carriers, indicating 
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that regardless of the age of disease onset, it progresses at roughly the same rate across 
individuals, when defined by biomarker status.  
Further investigation in the ACS cohort – though of an n too small to perform statistical analyses 
– indicated that PiB positivity developed only after CSF Aβ42 levels were reduced. This perhaps 
was most plainly indicated by two individuals with stable low CSF Aβ42 who were PiB 
negative. Interestingly, CSF Tau, VILIP-1, and YKL-40 were increasing slightly or at mid-to-
high concentrations compared to other individuals at similar ages, which suggests these 
individuals were in the beginning stages of amyloid deposition in the brain. Further follow-up 
with these individuals would be particularly interesting to confirm that indeed, this may be 
evidence of the very earliest stages of preclinical disease. 
These visual associations with PiB imaging, alongside an association with cognitive changes in 
late middle-age are an indication that the utilization of multiple modalities may lead to a more 
accurate representation of the full continuum of disease. The ACS cohort provides an incredibly 
important glimpse of CSF changes during preclinical AD, from very early longitudinal decreases 
in CSF Aβ42, followed by longitudinal increases in CSF markers of neuronal injury or death 
alongside the development of PiB positivity in mid middle-age, followed lastly by evidence of 
cognitive changes in the oldest age group studied. A larger n, paired with continued follow-up of 
this group of study participants has the potential to allow analysis of biomarker trajectories 
throughout the continuum of early disease. 
In contrast, the ADNI cohort provided the ability to study CSF biomarkers across the spectrum 
of cognitive impairment that physicians currently use to define AD in research and clinical 
settings. Only the core CSF biomarkers Aβ42, Tau, and P-tau showed longitudinal change in the 
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preclinical, cognitively normal amyloid negative and/or amyloid positive groups, mirroring 
changes seen in the ACS cohort. The non-core markers VILIP-1 and YKL-40 did not exhibit 
changes during this period, unlike the changes seen in the ACS cohort. However, the core 
biomarkers and non-core markers indicative of neuronal dysfunction (either neuronal injury, 
death, or synaptic injury) showed longitudinal decreases during the early symptomatic stages of 
disease with the exception of CSF Tau. Again based on data from the DIAN cohort, longitudinal 
decreases in CSF biomarkers of neuronal dysfunction were not unexpected64. However, the work 
published here supports these findings in a large, independent cohort of individuals with sporadic 
AD, providing further evidence that the pathologic disease processes of AD are indeed the same 
in both ADAD and sporadic AD, regardless of differing etiology.  
These data have important implications for clinical trials looking to enroll individuals during 
preclinical AD. For instance, a trial aiming to capture individuals across the spectrum of changes 
that occur during preclinical AD may enroll participants with only low CSF Aβ42, with low CSF 
Aβ42 and who are amyloid imaging positive, or who are CSF or amyloid imaging with evidence 
of high or increasing markers of neuronal dysfunction. Such separation may provide 
opportunities to test anti-amyloid therapeutics at varying states of disease prior to cognitive 
impairment to best pinpoint when during preclinical disease these agents are most efficacious. It 
may also provide a platform for testing alternative therapeutic agents such as anti-tau or secretase 
inhibiting drugs to determine if/when they are efficacious at preventing amyloid or tau 
accumulation or neuronal death. Further reasoning for determining in-depth biomarker 
trajectories over the full course of AD is apparent in the ADNI data. In many cases, reduction in 
a biomarker that is elevated during disease would be seen as an indicator of therapeutic efficacy 
in a clinical trial. However, if the core and non-core biomarkers are indeed decreasing 
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longitudinally during the early symptomatic stages of AD (individuals with a CDR score of 0.5 
to 1), a reduction in, for instance, Tau or VILIP-1 might be indicative of the natural course of 
disease rather than therapeutic target engagement or treatment efficacy. This is particularly 
important in clinical trials enrolling individuals with mild cognitive impairments, where a 
reduction in markers of neuronal injury might well be considered an indicator of treatment 
downstream treatment efficacy, even with anti-amyloid therapeutics.  
As mentioned in Chapter 1, the hypothetical models of biomarker change that have thus far been 
proposed were invariably represented as sigmoidal curves. Much work remains to allow cross-
study comparisons of biomarkers in a way that would render modeling changes in the ACS and 
ADNI groups together a possibility. However, the pictures of core AD CSF biomarkers 
developed in the ACS, ADNI, DIAN and other studies are largely in agreement in terms of 
direction of change (increasing or decreasing) over the course of the disease. If the non-core CSF 
biomarkers are considered similarly, the ACS and ADNI data may also indicate how these 
biomarkers change, as a whole, over the course of disease. Figure 6.1 outlines what the 
biomarker trajectories of CSF Aβ42, Tau, Ptau, VILIP-1, SNAP-25, Ng, and YKL-40 might look 
like as further data from longitudinal studies is added to our knowledge base. Current constraints 
do not allow for the ACS and ADNI data to be formally compared to one another, but for the 
purposes of visualizing biomarker change based on disease state, the ACS and ADNI data are 
considered on the same curve for each individual biomarker. The ACS data likely shows a more 
complete picture of preclinical AD as the CN Aβ- and Aβ+ groups were small. However, without 
enough longitudinal follow-up to show individuals progressing from cognitively normal and 
biomarker positive through clinically recognizable cognitive impairments, it is currently only 
possible to speculate which individuals might be in the very earliest stages of disease 
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(hypothesized to exhibit only CSF amyloid changes). Therefore the hypothetical curves do not 
extend through the full range of “preclinical AD” as labeled in Figure 6.1. Further, as SNAP-25 
and Ng were only assessed in the ADNI cohort, the hypothetical curve (shown in lavender) 
begins later in the “preclinical AD” range than the other CSF biomarkers. The inflection points 
where markers of neuronal dysfunction hit a peak and then fall between the “MCI” and “AD” 
labels are hypothesized to occur in the ADNI group designated as MCI Aβ+, individuals who 
most likely are exhibiting impairment due to AD. Data from Chapter 3 indicates that these 
markers do not significantly change during MCI, potentially due to either a plateau once 
biomarker concentrations are at their maximum, followed by the decline seen in the AD group, 
or due to the slope of biomarker change being in effect washed out by individuals on one side of 
the inflection increasing longitudinal and individuals on the other side decreasing. Further 
research will be needed to develop these curves more fully. 
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Figure 6.1 Hypothetical Model of Combined ACS and ADNI CSF Biomarker Trajectories 
Hypothetical trajectories of CSF biomarkers based on data from both the ACS and ADNI datasets 
combined. The x-axis indicates disease state as it progresses from Preclinical AD, through MCI, through 
AD; vertical dashed lines indicate, roughly, the transition from one disease state to the next. The y-axis 
indicates direction of longitudinal change, which can be interpreted as upward change corresponding to 
significant increases in biomarkers over time, downward change corresponding to significant decreases 
over time, and plateaus or inflection points corresponding to no significant change over time in the 
respective diagnostic groups. Each line indicates a single CSF biomarker trajectory: Red, Aβ42; Dark 
Blue, Tau; Light Blue, Ptau; Purple, VILIP-1; and Orange, YKL-40; Lavender represents both SNAP-25 
and Ng as both biomarkers performed similarly in the ADNI cohort.  
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Biomarker research in AD is still only just beginning. The data generated by this project will be 
used moving forward for a number of projects: 1) analyzing VILIP-1 and YKL-40 across both 
the ACS and ADNI datasets to assess whether the two cohorts might be viably combined, thus 
increasing the n for at least two non-core biomarkers to 317 individuals; 2) assessing further 
promising non-core biomarkers in these populations such as NfL; 3) exploring further statistical 
analyses based on the addition of neuroimaging biomarkers or different classification schemes. 
The wealth of data offered by these studies allows for a multitude of avenues of investigation. In 
particular, the data presented lends itself well to investigation using groups defined by the 
proposed A/T/N classification from the NIA-AA. Grouping by APOE allele risk factor or by 
amyloid positivity only as defined by CSF Aβ42 may obscure longitudinal changes occurring in 
the later preclinical or MCI stages of AD. For instance, grouping individuals by CSF Aβ42 status 
only may not accurately capture differences in the rates of longitudinal change in biomarkers of 
neuronal dysfunction that could occur in an individual who is amyloid positive only, compared 
with an individual who is amyloid positive and tau positive. There is much left to learn from 
these studies. 
By far, one of the biggest limitations of the current studies is the low n; despite both the ACS and 
ADNI being the largest longitudinal studies of AD reported to date, they are still quite small in 
terms of statistical power. However, these studies may be used to perform power calculations in 
further cohorts, allowing judicial allocation of precious CSF for testing at a time when enough 
samples have been collected. Another limitation was brought to the forefront in Chapter 5: assay 
variability. Particularly with CSF Aβ42, the reproducibility and comparability of Aβ42 when 
measured in labs around the world is not at a level that receives confidence from regulatory 
agencies as a validated diagnostic, prognostic, or theragnostic tool – though in Europe the 
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measurement of core CSF biomarkers is more widely approved and more common than in the 
United States. Additionally, non-core biomarkers may be especially valuable in tracking 
downstream indicators of therapeutic efficacy in clinical trials. However, further longitudinal 
validation is needed on each of the biomarkers reported here, as well as development of other 
promising biomarkers, to bring the level of confidence in such markers on par with the core 
biomarkers.  
Large longitudinal studies such as the ACS and ADNI require rigorous planning, protocol 
adherence, abundant funding, and, most importantly, dedicated populations of volunteers willing 
to undergo a gamut of testing modalities on a regular basis. Despite being active for nearly two 
decades, the ACS is only now at a point to assess longitudinal CSF data from enough 
participants to allow rigorous statistical analysis. The ADNI study is just over a decade old 
though, as a study designed with the validation of AD biomarkers in mind, much more data has 
been collected and on a shorter time-scale than the ACS. Data gained through both cross-
sectional and longitudinal data on these and other large, diverse cohorts is essential to the 
forward movement in understanding the full course of AD. Hopefully, these data will allow 
development of statistically validated trajectories of biomarkers throughout the course of disease, 
allowing clinical trials to accurately assess biomarker changes in relation to therapeutic agents 
and eventually allowing physicians to reliably diagnose individuals with AD at any stage and 
offer a prognosis or, someday, the appropriate treatment at the best possible junction. 
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Appendix 
A.1 Appendix Data and Figures for Chapter 3 
A.1.1 Assay Details 
VILIP-1  
Mouse anti-human VILIP-1 and sheep anti-human VILIP-1 were used to develop a sandwich 
ELISA using an Erenna instrument (Singulex). Assay reagents include biotinylated mouse anti-
human VILIP-1, clone 3A8.1 “capture” antibody, bound to streptavidin-coated magnetic micro 
particles and Invitrogen Alexa Fluor 647 dye labeling of sheep anti-human VILIP1. Additional 
materials purchased from Singulex include 10X Wash Buffer (02-0001-01), Elution Buffer (02-
0297-xx) and elution step neutralization Buffer C (02-0298-00). 
Prior to the assay all samples were centrifuged (11,000 g x 3 minutes) to remove particulates. All 
assay steps were performed at room temperature unless otherwise indicated. A calibration curve 
was prepared using dilutions of recombinant human VILIP-1 ranging from 3.9 to 3000pg/mL in 
assay buffer (prepared daily for the assay and filtered before use contained per liter) containing 
10 mm TRIS, 150 mm NaCl, pH = 8.1, supplemented with 0.1% each of  Triton X (Sigma T-
9284), and Sodium Azide, also with 1 gram BSA (Sigma A-7030), as well as 2 gram Equitech-
Bio mouse IgG (SLM66) (2 mg/mL) and 2 mM CaCl2 (Sigma 21115), with each concentration 
assayed in triplicate. 15 μL standards or CSF sample were combined with 135ul assay buffer and 
50μL antibody coated micro particles. The assay plate was incubated for two hours on a plate 
shaker set to 525 revolutions per minute. Micro particles were then magnetically separated and 
washed one time using an Agilent (Santa Clara, CA) Bravo Automated Liquid Handling 
Platform using Singulex Wash Buffer. Fluorescent dye labeled detection antibody (20μL per 
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well) was added and incubated for one hour. After washing the magnetic micro-particles five 
times, 20μL per well of Singulex Elution Buffer was added for 10 minutes to separate detection 
antibody from the micro-particles. Eluted antibodies were then transferred with the Bravo 
instrument to a clean 384 well plate for reading in the Erenna® immunoassay system. 
SNAP-25 
Mouse anti-human SNAP-25 antibodies were used for development of a sandwich ELISA using 
an Erenna instrument (Singulex). Assay reagents included a preparation of the monoclonal 
capture antibody 6H07-2C12 for binding to Invitrogen (Carlsbad, CA) MyOne magnetic micro-
particles and Invitrogen Alexa fluor dye labeling of monoclonal antibody 9E11, using Singulex 
labeling kits (capture antibody labeling kit 03-0077-xx and detection antibody labeling kit 03-
0076-02). Additional materials purchased from Singulex include 10X Wash Buffer (02-0001-
01), Elution Buffer (02-0297-xx) and elution step neutralization Buffer C (02-0298-00). 
Prior to the assay all samples were centrifuged (11,000 g x 3 minutes) to remove particulates. All 
assay steps were performed at room temperature unless otherwise indicated. A calibration curve 
was prepared using dilutions of recombinant human SNAP25 (CSI15602) from Cell Science, Inc 
(Seattle, WA) ranging from 0.078 to 90pg/mL in Thermo Scientific, Inc (Rockford IL) Blocker 
Casein in TBS plus 0.1% Tween-20 from Sigma-Aldrich, Inc (St Louis MO) and with each 
concentration assayed in triplicate. 100μL standards or CSF diluted 4-fold were combined with 
100μL antibody coated micro particles diluted in Blocker Casein in TBS plus 1% Tween-20. The 
assay plate was incubated for two hours on a plate shaker set to 525 revolutions per minute. 
Micro-particles were then magnetically separated and washed one time using an Agilent (Santa 
Clara, CA) Bravo Automated Liquid Handling Platform using Singulex wash buffer. Fluorescent 
dye labeled detection antibody diluted in Blocker Casein in TBS plus 1% Tween-20 (20μL per 
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well) was added and incubated for one hour. After washing the magnetic micro-particles five 
times, 20μL per well of Singulex Elution Buffer was added for 10 minutes to separate detection 
antibody from the micro particles. Eluted antibodies were then transferred with the Bravo 
instrument to a clean 384 well plate for reading in the Erenna® immunoassay system. 
Ng 
Two epitope-specific rabbit anti-human NGRN antibodies were used for development of an 
ELISA using an Erenna instrument (Singulex). Assay reagents included a preparation of a C-
terminal specific antibody (P-4793) for binding to Invitrogen (Carlsbad, CA) MyOne magnetic 
micro-particles and Invitrogen Alexa fluor dye labeling of N-terminal specific antibody (P-4794) 
using Singulex labeling kits (capture antibody labeling kit 03-0077-xx and detection antibody 
labeling kit 03-0076-02). Additional materials purchased from Singulex include 10X Wash 
Buffer (02-0001-01), and custom Elution Buffer (02-0002-01). 
Prior to the assay all samples were centrifuged (11,000 g x 3 minutes) to remove particulates. All 
assay steps were performed at room temperature unless otherwise indicated. A calibration curve 
was prepared using dilutions of synthetic full-length NGRN purchased from AAPPTec, (Louisville 
KY), ranging from 1.75 to 3000pg/mL in standard diluent (TBS, 2 mg/ml rabbit IgG from 
Equitech-Bio [Kerrville, TX] plus 0.1% Tween-20), with each concentration assayed in 
triplicate. 50μL standards or CSF diluted 10-fold were combined with 100μL antibody coated 
micro-particles diluted in assay buffer (TBS, rabbit IgG plus 1% Tween-20). The assay plate was 
incubated for two hours on a plate shaker set to 525 revolutions per minute. Micro-particles were 
then magnetically separated and washed one time using an Agilent (Santa Clara, CA) Bravo 
Automated Liquid Handling Platform using Singulex Wash Buffer.  Fluorescent dye labeled 
detection antibody diluted in assay buffer (20μL per well) was added and incubated for one hour. 
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After washing the magnetic micro-particles 5 times, 20μL per well of Singulex custom Elution 
Buffer (PN 02-0002-03) was added for 30 minutes to separate detection antibody from the 
micro-particles. Eluted antibodies were then transferred with the Bravo instrument to a clean 384 
well plate for reading in the Erenna® immunoassay system. 
YKL-40 
YKL-40 was measured using the MicroVue YKL-40 ELISA assay (Quidel, San Diego, CA). 
Prior to the assay, all samples were lightly vortexed for 5 seconds. All assay steps were 
performed at room temperature unless otherwise noted. The complete standard curve of YKL-40 
purified from osteosarcoma MG-63 cells is provided with the assay kit, and each standard and 
sample was assayed in duplicate. All CSF samples were diluted 1:2 in Standard A (0 ng/ml) on 
an ice cold pre-plate before transferring 20μl to the coated ELISA plate. After adding 100μl 
capture solution, the plate was incubated for 60 minutes followed by washing 4 times with 250μl 
wash buffer. Enzyme conjugate (100μl) was prepared prior to beginning the assay and added to 
the assay plate, followed by a 60 minute incubation. The substrate solution was prepared during 
this step to ensure dissolution of the substrate tablet. After another wash (four times with 250μl 
wash buffer), 100μl substrate was added to the assay plate followed by a 60 minute incubation. 
Finally, 100μl stop solution was added to the assay plate, and samples were read at an optical 
density of 405nm and analyzed with a linear regression curve-fit. 
A.1.2 Assay Quality Control 
All samples (each from the same freeze/thaw cycle) were run in triplicate for VILIP-1, SNAP-25 
and Ng and in duplicate for YKL-40, all using a single assay lot number. Importantly, within-
person longitudinal samples were run on the same assay plate to reduce inter- and intra-plate 
variability. Quality control (QC) for VILIP-1, SNAP-25 and Ng included analysis of three 
internal standard CSF pools run on each assay plate. For YKL-40, two internal standard CSF 
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pools were run on each plate. QC mean and tolerance limits for VILIP-1, SNAP-25 and Ng were 
established by computing the average of at least 15 values collected over at least four runs prior 
to running ADNI samples. Tolerance limits were defined at ± two standard deviations (2SD) and 
± three standard deviations (3SD) from the mean. QC mean and tolerance limits for YKL-40 
were determined by the kit manufacturer. For VILIP-1, SNAP-25 and Ng plates with two or 
more QC sample values greater than 2SD from the mean were reanalyzed. For YKL-40, plates 
with two or more internal pooled controls and/or kit-provided controls falling outside the 2SD 
limit were reanalyzed. In addition, any individual sample with a coefficient of variation (% CV) 
greater than 25% was reanalyzed. Samples that failed QC were refrozen and stored at -80°C for 
at least 48 hours before being reanalyzed. When samples were reanalyzed due to QC failure, all 
within-person longitudinal samples were reanalyzed as well, on the same freeze/thaw cycle. Due 
to the availability of only a single 500uL aliquot of ADNI CSF, workflows defined that VILIP-1, 
SNAP-25 and Ng were to be run on the first freeze/thaw cycle, while YKL-40 (and any required 
reruns for VILIP-1) was run on the second freeze/thaw cycle. Internal QC experiments 
previously revealed <10% loss of YKL-40 over four freeze/thaw cycles (unpublished 
observations). Any samples that required repeat SNAP-25 or Ng measurements were performed 
on the third freeze/thaw cycle samples. Due to protein loss from multiple freeze/thaw cycles, 
SNAP-25 reruns did not pass QC; therefore, any samples that failed QC from the first 
freeze/thaw were removed from the SNAP-25 dataset. In total, 21 of 587 (3.4%) samples failed 
initial QC for VILIP-1, 1 of 587 (0.2%) for SNAP-25, 126 of 587 (21.5%) for Ng, and 73 of 587 
(12.4%) for YKL-40. 
A.1.3 Statistical results adjusting for sex, APOE ε4 status, education and 
baseline age 
Elecsys® tTau 
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When adjusting for sex, females had significantly higher levels of tTau at baseline (p=0.008), but 
such adjustment had no effect on longitudinal change. Adjusting for sex resulted in the loss of 
significant increase in the CN groups and a gain of significance of a longitudinal decrease in the 
AD+ group (p=0.02). Between-group comparisons were identical to the unadjusted model at 
baseline and longitudinally. Adjusting for education had no significant effects on baseline or 
longitudinal tTau or between-group comparisons, but the between group differences no longer 
reached statistical significance, likely due to inadequate statistical power. Adjusting for baseline 
age significantly affected the MCI+ group at baseline, lower in older individuals (p=0.04), but 
had no effect on longitudinal or between-group comparisons. The MCI+ group remained 
significantly higher at baseline than the CN- group (p=0.04). Adjusting for total ventricular 
volume significantly affected tTau in the MCI+ group at baseline (p=0.007), but did not 
influence longitudinal change or between-group comparisons. Adjusting for APOE ε4 status had 
no effect on baseline or longitudinal tTau patterns. 
Elecsys® pTau 
Adjusting for education and baseline age had no significant effect on baseline or longitudinal 
pTau values or between-group comparisons. However, the between-group differences seen in the 
unadjusted model no longer achieved statistical significance, nor did the longitudinal changes in 
the CN+ and AD+ groups, likely due to inadequate statistical power. Adjusting for sex showed 
that females had significantly elevated baseline pTau (p=0.01), but it did not change any 
longitudinal or between-group comparison findings compared to the unadjusted model. 
Adjusting for APOE ε4 status negated the significantly elevated baseline in the CN+ compared to 
the CN- group (p=0.07), but otherwise the results were the same as in the unadjusted model. 
Adjusting for total ventricular volume significantly affected pTau in the MCI+ group at baseline 
(p<0.001), but did not influence longitudinal change or between-group comparisons. 
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VILIP-1 
Adjusting for education had no significant effect on baseline or longitudinal VILIP-1 or 
between-group differences, but the between-group differences observed in the unadjusted model 
no longer achieved statistical significance, likely due to inadequate statistical power. Adjusting 
for baseline age had a significant effect in the MCI+ group at baseline (higher levels with older 
age, p<0.01) but did not change the group differences between MCI+ and the MCI- and CN- 
groups. Adjusting for APOE ε4 status or sex had a significant effect on baseline VILIP-1 (ε4+ 
and female individuals were higher at baseline (both p<0.03)). The significant between-group 
comparisons at baseline were lost in the ε4 model. In the sex model, all aspects remained 
identical to the unadjusted model except that the MCI+ was now significantly higher than the 
CN+ group at baseline (p=0.03). Adjusting for total ventricular volume had a significant effect 
on baseline in the MCI+ group (p<0.0001), but not longitudinally. Between-group comparisons 
at baseline were lost in the AD+ compared with both CN- and MCI- groups as well as 
longitudinal comparisons in the AD+ compared with the CN-, CN+, and MCI- groups. 
SNAP-25 
Adjusting for APOE ε4 status had a significant effect on baseline SNAP-25 (higher in ε4+ 
individuals, p<0.0001) In addition, baseline differences between the MCI+ and the CN groups is 
lost, as is the significant longitudinal decrease in the AD+ group. Adjusting for baseline age and 
education had no significant effect on baseline or longitudinal SNAP-25 or between-group 
comparisons, but the between-group differences seen in the unadjusted model no longer reached 
significance, likely due to inadequate statistical power. Adjusting for sex had no effect on 
baseline or longitudinal SNAP-25 patterns. Adjusting for total ventricular volume significantly 
affected baseline SNAP-25 (p=0.02), but not longitudinal patterns. The baseline difference 
between the AD+ and CN+ groups was lost. 
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Ng 
Adjusting for APOE ε4 status had no effect on baseline or longitudinal Ng; however, the MCI+ 
group at baseline was no longer higher than the MCI- and CN- groups (p=0.1 and p=0.057). 
Adjusting for sex had a significant effect on baseline Ng (higher in females, p=0.03), but did not 
have a significant effect on longitudinal Ng. Between group comparisons were identical to the 
unadjusted model except the MCI+ group now also showed significant decreases over time 
(p=0.04). Adjusting for baseline age and education had no significant effect on baseline or 
longitudinal Ng or between-group comparisons, but the between-group differences observed in 
the unadjusted model no longer reached significance, likely due to inadequate statistical power. 
Adjusting for total ventricular volume significantly affected baseline Ng (<0.0001), but not 
longitudinal patterns. The baseline difference between the AD+ and CN+ groups was lost as 
were longitudinal differences between the AD+ and CN-, CN+, and MCI- groups. 
YKL-40 
Adjusting for sex impacted many of the baseline and longitudinal patterns of YKL-40 among the 
groups. In general females showed higher levels of baseline YKL-40 compared to males 
(p=0.003). Baseline levels of YKL-40 were still significantly higher in the AD+ compared to the 
MCI- group (p=0.04), but was now also higher in the AD+ compared to the CN- group (p=0.03), 
as well as the MCI+ compared to the MCI- (p=0.005) and both CN groups (p=0.03 for CN+, 
p=0.001 for CN-). Longitudinally, YKL-40 levels no longer increased significantly in the MCI+ 
group, but instead now decreased in the AD+ group (p=0.003). Adjusting for baseline age and 
education had minimal effect on baseline or longitudinal patterns of YKL-40, but the between-
group differences seen in the unadjusted model no longer reached significance, potentially due to 
high variability and inadequate statistical power. Adjusting for APOE ε4 status had no significant 
effect on baseline or longitudinal YKL-40, but the difference at baseline between the AD+ and 
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MCI- groups was no longer significant (p=0.08). Adjusting for total ventricular volume had a 
significant effect on longitudinal YKL-40 (p<0.001), but not on baseline levels, and the 
difference at baseline between the AD+ and MCI- groups was no longer significant (p=0.22). 
Elecsys® Aβ42 
Adjusting for APOE ε4 status affected baseline Aβ42 levels right at the statistical significance 
level (i.e., ε4+ had lower Aβ42, p=0.05), but did not influence longitudinal change or between-
group comparisons. Adjusting for sex only impacted the longitudinal decline in the AD+ group 
(i.e., losing significance, now p=0.08). Adjusting for baseline age eliminated the statistical 
significance of decline in both the AD+ and CN- groups. In addition, most between-group 
comparisons at baseline lost significance, except that the AD+ group was still lower than the CN- 
group at the statistical significance level (p=0.05). Adjusting for total ventricular volume affected 
baseline levels and longitudinal change in the MCI- group (p=0.05 and p=0.01, respectively) but 
not between-group comparisons. 
Adjusting for education had a significant effect on baseline Aβ42 in the CN+ group (p=0.006), 
with more education associated with a higher baseline Aβ42. Longitudinally, more education had 
a significant impact in the MCI- group which showed significant yearly increases in Aβ42. The 
significant longitudinal decline in the AD+ and CN- groups seen in the unadjusted model was 
lost. The significant difference at baseline between the MCI+ and MCI- groups was also lost, but 
the MCI+ group now had significantly lower Aβ42 than the CN+ group (p=0.03), possibly 
driven by the significant effect of education on the CN+ group. 
MMSE  
Adjusting for education had no effect on baseline or longitudinal MMSE, though all between-
group comparisons at baseline lost significance. In this model, longitudinal MMSE in the AD+ 
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and MCI+ groups still decreased at a significant rate (both p<0.04), but were not significantly 
different from each other.  
Adjusting for baseline age had no effect on baseline MMSE, but did significantly affect 
longitudinal change in the AD+ group (slowed the decline) (p=0.05); however, the AD+ and 
MCI+ groups still decreased at a significant rate (both p<0.03). Adjusting for APOE ε4 status 
and sex had no effect on baseline or longitudinal MMSE or between-group comparisons, and the 
significant results were identical to those in the unadjusted model. 
ADAS11 and ADAS13 
Adjusting for education had no effect on baseline or longitudinal ADAS11; however, it did affect 
the between-group comparisons, with only the difference between the MCI+ and CN+ groups 
remaining significant (p=0.05). In this model, the AD+ group was still significantly increasing 
longitudinally (p=0.0035). Adjusting for baseline age had a significant effect on the slope in the 
AD+ and MCI+ groups (slowed the rate of increase) (both p<.02), but both groups retained the 
significant longitudinal increases observed in the unadjusted model (both p<0.003). The between 
group effects seen at baseline in the unadjusted model were absent, though the AD+ group still 
increased longitudinally at a faster rate than the MCI+ group (p=0.05). Adjusting for APOE ε4 
status and sex had no effect on baseline or longitudinal ADAS11 and yielded results identical to 
the unadjusted model. 
Adjusting for education had no effect on baseline or longitudinal ADAS13, but affected 
between-group comparisons similarly to ADAS11, with the MCI+ group being elevated 
compared to both CN groups (both p<0.04). In this model, the AD+ group was not significantly 
increasing longitudinally (p=0.07). Adjusting for baseline age showed similar results to those 
seen in ADAS11; however, the AD+ group was no longer increasing at a faster rate than the 
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MCI+ group (now p=0.13). Adjusting for APOE ε4 status did not affect baseline or longitudinal 
ADAS13, except that no significant difference was observed between the MCI+ and MCI- 
groups (p=0.09). Adjusting for sex significantly affected the longitudinal change in ADAS13, 
with females showing a faster increase (decline in performance)(p=0.03). Between-group 
comparisons at baseline remained identical to the unadjusted model. The longitudinal increase in 
the CN+ group was no longer significant (p=0.06), but between-group differences remained 
identical to the unadjusted model.  
HP Volume 
Adjusting for baseline age had no significant effect on baseline or longitudinal HP volume or 
between-group comparisons, but the slopes and between-group differences observed in the 
unadjusted model no longer reached significance, likely due to inadequate statistical power. The 
model adjusted for sex showed a significant effect on baseline HP volume, with females having a 
smaller volume (p=0.006). The significant differences at baseline between the AD+ and both 
MCI groups were lost (p=0.08 for MCI-, p=0.06 for MCI+), and longitudinally the AD+ group 
was no longer decreasing at a faster rate than the MCI- group (p=0.06). Adjusting for APOE ε4 
status had no effect on baseline or longitudinal HP volume, but the longitudinal between-group 
differences were lost for the AD+ and MCI- groups, the CN+ and CN- groups, and the MCI+ and 
MCI- groups (all p=0.2). 
EC Thickness 
Adjusting for baseline age affected EC thickness the same way it did HP volume. Adjusting for 
sex had no effect on baseline or longitudinal EC thickness, and between-group comparisons 
remained identical to the unadjusted model. Adjusting for APOE ε4 status had a significant effect 
on longitudinal change, with ε4+ individuals thinning more rapidly (p=0.03), and the CN- group 
now also significantly declining (p=0.005). Longitudinally the AD+ group was thinning 
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significantly faster than the CN- group (p=0.0007), but the MCI- versus CN+ between-group 
difference was no longer significant when adjusting for APOE ε4 status, nor were the 
longitudinal between-group differences for the AD+ and MCI- groups or the MCI+ and MCI- 
groups.  
Figure A.1 Spaghetti plots of longitudinal change in CSF biomarkers. 
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Supplemental Figure 1 (continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Within-person longitudinal changes for tTau (A), pTau (B), VILIP-1 (C), SNAP-25 (D), Ng (E), YKL-40 
(F), and Aβ42 (G). Dashed lines indicate Aβ42-negative (Aβ-) individuals. Solid lines indicate Aβ42-
positive (Aβ+) individuals. Each biomarker is shown according to diagnostic group: left column, 
cognitively normal at baseline (n=56); middle column, MCI at baseline (n=79); right column, AD at 
baseline (n=17). 
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Figure A.2 Spaghetti plots of longitudinal change in cognition 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Within-person longitudinal changes in performance on ADAS-Cog 11 (A), ADAS-Cog 13 (B), and 
MMSE (C). Dashed lines indicate Aβ42-negative (Aβ-) individuals. Solid lines indicate Aβ42-positive 
(Aβ+) individuals. Each biomarker is shown according to diagnostic group: left column, cognitively 
normal at baseline (n=56); middle column, MCI at baseline (n=79); right column, AD at baseline (n=17). 
MMSE, 30 is the best possible score. ADAS-Cog 11/13, lower score is better performance, with 70 as the 
worst possible score. 
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Figure A.3 Spaghetti plots of longitudinal change in MRI measures.  
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Within-person longitudinal changes for total Entorhinal Cortical Thickness (A) and total Hippocampal 
Volume (B). Dashed lines indicate Aβ42-negative (Aβ-) individuals. Solid lines indicate Aβ42-positive 
(Aβ+) individuals. Each biomarker is shown according to diagnostic group: left column, cognitively 
normal at baseline (n=56); middle column, MCI at baseline (n=79); right column, AD at baseline (n=17). 
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Table A.1 Spearman R Correlation Matrix for CSF Biomarkers 
 
Bold, significant correlations (at least p<0.008) 
anot significantly correlated 
 
Abbreviations: Aβ42, AlzBio3 Aβ42; VILIP-1, visinin-like protein 1; SNAP-25, synaptosomal associated 
protein-25;Ng, neurogranin;  E-Aβ42, Elecsys Aβ42; E-tTau, Elecsys tTau; E-pTau, Elecsys pTau181 
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A.2.1 ACS Data 
This work was supported by grants P01AG026276, 5P30 NS048056, and 5P30 NS048056 from 
the National Institutes of Health, the Barnes-Jewish Hospital Foundation, the Fred Simmons and 
Olga Mohan fund, and a grant from Eli Lilly and Co. 
A.2.2 ADNI Data 
Data used in preparation of Chapters 3-6 this work were obtained from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within 
the ADNI contributed to the design and implementation of ADNI and/or provided data but did 
not participate in analysis or writing of this report. A complete listing of ADNI investigators can 
be found at: http://adni.loni.usc.edu/wp-
content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf 
Aβ42 VILIP-1 SNAP-25 Ng YKL-40 E-Aβ42 E-tTau
Aβ42
VILIP-1 -0.235
SNAP-25 -0.413 0.72
Ng -0.22 0.849 0.619
YKL-40 -0.121a 0.311 0.307 0.422
E-Aβ42 0.868 -0.131a -0.240 -0.154a 0.007a
E-tTau -0.416 0.798 0.688 0.853 0.389 -0.214
E-pTau -0.512 0.744 0.668 0.803 0.346 -0.324 0.975
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